Decoding Population Diversity: Genetic Heterogeneity in Endometriosis GWAS and Its Impact on Precision Medicine

Abstract

Endometriosis is a complex gynecological disorder with a significant genetic component, estimated to be around 52% heritable. Genome-wide association studies (GWAS) have successfully identified numerous susceptibility loci, yet these findings demonstrate considerable heterogeneity across diverse populations. This article systematically explores the genetic architecture of endometriosis through the lens of population genomics, examining how allele frequency variations, population-specific risk loci, and distinct genetic effect sizes manifest differently in European, East Asian, African, and other ancestral groups. We review methodological approaches for analyzing cross-population genetic data, address challenges in polygenic risk score portability, and discuss integrative multi-omics strategies for translating these findings into clinically actionable insights. For researchers and drug development professionals, understanding this genetic heterogeneity is crucial for developing ethnically-aware diagnostic tools and targeted therapeutic interventions that address global health disparities in endometriosis care.

Mapping the Genetic Landscape: Fundamental Discoveries of Population Diversity in Endometriosis Susceptibility

Core Heritability Estimates and Genetic Architecture Foundations

Endometriosis is a complex, estrogen-dependent inflammatory gynecological condition affecting approximately 10% of women of reproductive age globally [1]. The condition is characterized by the presence of endometrial-like tissue outside the uterine cavity, leading to chronic pelvic pain, dysmenorrhea, and reduced fertility [2]. Family and twin studies have consistently demonstrated a strong heritable component to endometriosis, with the condition exhibiting familial aggregation and higher concordance rates in monozygotic versus dizygotic twins [3]. The genetic architecture of endometriosis is polygenic, involving multiple genetic variants of small to moderate effects that interact with environmental factors [2]. Understanding the core heritability estimates and genetic foundations is crucial for unraveling the disease etiology and developing targeted diagnostic and therapeutic strategies.

Core Heritability Estimates

Quantitative estimates of endometriosis heritability provide fundamental insights into the relative contributions of genetic and environmental factors to disease risk. The table below summarizes key heritability metrics derived from genetic epidemiological studies.

Table 1: Endometriosis Heritability Estimates from Genetic Studies

Study Type	Heritability Estimate	Study Population	Key Findings
Twin Studies	51% of disease variance [3]	3,096 Australian female twins [2]	Proportion of disease variance attributable to genetic factors
Twin Studies	52% [2]	International cohort	Confirmation of strong heritable component
Common SNP Heritability	26% [4]	European ancestry	Proportion of variance explained by common genetic variants
GWAS Variance Explained	5.19% [4]	Multi-ancestry meta-analysis	Variance explained by 19 independent genome-wide significant SNPs

These heritability estimates highlight that approximately half of endometriosis risk can be attributed to genetic factors, with common genetic variants identified through GWAS explaining a smaller but substantial proportion of this heritability. The discrepancy between twin-based heritability estimates and SNP-based heritability suggests involvement of additional genetic factors including rare variants, structural variations, and gene-environment interactions [1].

Established Genetic Architecture Foundations

Key Genetic Loci and Associated Genes

Genome-wide association studies have identified numerous genetic loci significantly associated with endometriosis risk across diverse populations. The table below summarizes the most consistently replicated genetic loci and their biological functions.

Table 2: Established Endometriosis Risk Loci and Their Biological Significance

Genetic Locus	Nearest Gene(s)	Biological Function	Population Validation
1p36.12	WNT4	Sex steroid hormone regulation, female reproductive tract development [2]	European, Japanese [5]
2p25.1	GREB1	Estrogen-regulated gene involved in cell growth [2]	European, Japanese [5]
6q25.1	ESR1, CCDC170, SYNE1	Estrogen receptor signaling, hormone metabolism [4]	European, Japanese
7p15.2	Intergenic	Inflammatory response regulation [2]	European, Japanese [5]
9p21.3	CDKN2B-AS1	Cell cycle regulation [2]	European, Japanese [5]
12q22	VEZT	Cell adhesion, cadherin-mediated signaling [2]	European, Japanese [5]
11p14.1	FSHB	Follicle-stimulating hormone subunit [4]	European

Biological Pathways Implicated in Endometriosis Pathogenesis

The identified genetic loci cluster in several key biological pathways, providing insights into endometriosis pathogenesis:

• Sex steroid hormone signaling: Multiple genes (WNT4, ESR1, GREB1, FSHB, CYP19A1) involved in estrogen biosynthesis, metabolism, and signaling [1] [4].
• Cell adhesion and migration: Genes (VEZT, FN1) regulating attachment and invasion of endometrial cells to ectopic sites [2].
• Inflammatory and immune pathways: Genes involved in cytokine signaling and immune surveillance [1].
• Developmental pathways: Genes (WNT4) critical for Müllerian duct development and differentiation [6].

Genetic Heterogeneity Across Populations

While many endometriosis risk loci show consistent effects across populations, evidence suggests both shared and population-specific genetic architecture.

Table 3: Population-Specific Findings in Endometriosis Genetics

Population	Sample Size	Key Population-Specific Findings	Consistent Loci
European	9039 cases, 27,343 controls [2]	6/9 loci genome-wide significant	7/9 loci showed consistent direction of effect [5]
Japanese	2467 cases, 5335 controls [2]	CDKN2B-AS1 (rs10965235) initially identified	7/9 loci showed consistent direction of effect [5]
Multi-ancestry (Combinatorial)	UK Biobank + All of Us [7]	75 novel genes identified through combinatorial analytics	High reproducibility (80-88%) of signatures >9% frequency

Meta-analyses have demonstrated remarkable consistency in endometriosis GWAS results across populations of European and Japanese ancestry, with little evidence of population-based heterogeneity for most loci [2] [5]. However, recent combinatorial approaches have revealed additional genetic complexity, identifying novel genes and pathways that may contribute to population-specific risk profiles [7].

Methodological Foundations for Genetic Studies

Genome-Wide Association Study (GWAS) Protocols

GWAS Workflow

The standard GWAS protocol for endometriosis research involves:

• Sample Collection and Diagnosis:

  • Cases: Surgical confirmation via laparoscopy with histological verification (rAFS staging I-IV) [2]
  • Controls: Population-based or healthy women without endometriosis diagnosis
  • Sample sizes: Typically thousands to tens of thousands to achieve sufficient power [4]

• Genotyping and Quality Control:

  • Genome-wide genotyping arrays (500,000-1,000,000 SNPs)
  • Quality control filters: Hardy-Weinberg equilibrium (P>5×10⁻⁵), minor allele frequency (>1%), genotype call rate (>95%) [2]
  • Population stratification assessment and correction

• Imputation:

  • Utilization of 1000 Genomes Project or similar reference panels
  • Imputation of ~10 million common variants using algorithms (IMPUTE2, Minimac) [4]

• Association Analysis:

  • Logistic regression assuming additive genetic model
  • Covariate adjustment (principal components, age)
  • Genome-wide significance threshold: P<5×10⁻⁸ [2]

• Meta-Analysis:

  • Fixed-effects or random-effects models across multiple cohorts
  • Heterogeneity assessment (Cochran's Q statistic) [2] [5]

Functional Genomics and eQTL Mapping Protocols

Functional Analysis

Advanced functional characterization protocols include:

• Expression Quantitative Trait Loci (eQTL) Analysis:

  • Integration with GTEx database (v8) for tissue-specific eQTL mapping [8]
  • Focus on relevant tissues: uterus, ovary, vagina, colon, ileum, peripheral blood
  • False discovery rate (FDR) correction for multiple testing (FDR<0.05) [8]

• Epigenetic Profiling:

  • Chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications
  • Assay for Transposase-Accessible Chromatin (ATAC-seq) for chromatin accessibility [9]
  • DNA methylation analysis (whole-genome bisulfite sequencing)

• Pathway and Enrichment Analysis:

  • Gene set enrichment analysis using MSigDB Hallmark gene sets [8]
  • Cancer Hallmarks database for oncogenic pathway overlap
  • Tissue-specific enrichment (uterine, ovarian tissues) [10]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Essential Research Reagents for Endometriosis Genetic Studies

Reagent/Resource	Function/Application	Example Specifications
GWAS Genotyping Arrays	Genome-wide variant profiling	Illumina Global Screening Array, Affymetrix 500K [4]
1000 Genomes Project Reference Panel	Imputation of ungenotyped variants	Phase 3 haplotypes, 2504 individuals [4]
GTEx Database	Tissue-specific eQTL mapping	v8 release, 53 non-diseased tissues [8]
GWAS Catalog	Repository of published associations	EFO_0001065 (endometriosis ontology) [8]
DEPICT/FUMA	Functional mapping and annotation	Gene prioritization, tissue enrichment [10]
rAFS Classification System	Phenotypic standardization	Surgical staging (I-IV) of endometriosis severity [2]

Signaling Pathways in Endometriosis Genetics

Key Signaling Pathways

The diagram above illustrates the key signaling pathways implicated in endometriosis genetics, highlighting how genetic risk variants influence specific biological processes through their proximal genes.

Future Directions and Clinical Translation

Current research is increasingly focused on translating genetic discoveries into clinical applications. Polygenic risk scores (PRS) aggregating effects across multiple variants show promise for identifying women at high risk for early intervention [1]. Integration of multi-omics approaches (genomics, transcriptomics, epigenomics) provides comprehensive insights into endometriosis pathophysiology [1]. Furthermore, understanding population-specific genetic architecture enables development of ethnically appropriate diagnostic and therapeutic strategies [7]. The functional characterization of risk loci through CRISPR-based screens and organoid models represents the next frontier in elucidating mechanistic links between genetic variants and disease phenotypes.

The genetic architecture foundations outlined herein provide the essential framework for ongoing research into this complex gynecological disorder, with potential for significant advances in personalized medicine approaches for endometriosis diagnosis and treatment.

Genome-wide association studies (GWAS) have revolutionized our understanding of the genetic architecture of complex diseases. However, the historical overrepresentation of European-ancestry populations has significantly limited the portability of genetic findings and exacerbated health disparities. Landmark multi-ethnic GWAS meta-analyses represent a paradigm shift in genomic medicine, enabling novel discoveries while addressing longstanding limitations. Within endometriosis research—a condition affecting approximately 10% of reproductive-aged women globally—these approaches are particularly critical for unraveling genetic heterogeneity across populations [11] [12].

This technical review examines key recent multi-ethnic GWAS meta-analyses, focusing on their discoveries, methodologies, and persistent challenges within the specific context of endometriosis genetics. We provide structured comparisons of quantitative findings, detailed experimental protocols, and visualizations of analytical workflows to serve researchers, scientists, and drug development professionals working in this field.

Key Discoveries in Recent Multi-ancestry GWAS

Endometriosis Genetics Elucidated Through Large-Scale Meta-Analysis

A landmark multi-ancestry GWAS of endometriosis and adenomyosis published in 2025 represents the largest study of its kind to date. Analyzing data from approximately 1.4 million women (including 105,869 cases), this study identified 80 genome-wide significant associations, of which 37 were novel [13] [14] [15]. Notably, this included five loci that represent the first genetic variants ever reported for adenomyosis [13]. Through fine-mapping and colocalization analyses, researchers uncovered causal loci for over 50 endometriosis-related associations, providing unprecedented resolution of potential causal mechanisms.

Multi-omics integration revealed that genetic variation influences endometriosis risk through transcriptomic, epigenetic, and proteomic regulation across multiple tissues, with key pathways converging on immune regulation, tissue remodeling, and cell differentiation [13]. The study also demonstrated clinically relevant interactions: endometriosis polygenic risk showed significant associations with abdominal pain, anxiety, migraine, and nausea, suggesting shared biological mechanisms across these conditions [15]. Drug-repurposing analyses highlighted potential therapeutic interventions currently used for breast cancer and preterm birth prevention, offering immediate translational pathways [13].

Advancements in Understanding Migraine Genetics Across Ancestries

The 2025 Million Veteran Program (MVP) study on migraine exemplifies the power of diverse biobanks, incorporating data from 648,172 U.S. veterans—one of the largest and most diverse studies of migraine genetics to date [16]. This multi-ancestry genome-wide analysis identified 90,600 veterans with migraine diagnoses with varying prevalence across ancestry groups: 13.1% among European ancestry, 16.0% among African Americans, 16.6% among Hispanics, and 15.2% among Asians [16].

The GWAS identified 789 total SNPs associated with migraine in a pan-ancestry meta-analysis, with 778 representing novel findings [16]. The distribution of significant SNPs varied substantially by ancestry: 624 in the European group, 3 in African Americans, 8 in Hispanics, and 59 in Asians. Pathway enrichment analysis indicated involvement of several biological pathways, including interleukin signaling, ionotropic glutamate receptor activity, synaptic vesicle trafficking, and JAK/STAT, EGFR, and PDGF signaling [16]. The identified genetic risk variants showed expression enrichment in neurons, immune cells, microglia, astrocytes, and fibroblasts, suggesting a multi-cellular influence on migraine pathophysiology.

Comparative Quantitative Findings Across Recent Multi-ancestry GWAS

Table 1: Key Quantitative Findings from Recent Landmark Multi-ancestry GWAS

Study	Phenotype	Sample Size	Cases	Number of Significant Loci/Variants	Novel Findings	Key Pathways Identified
Koller et al. (2025) [13]	Endometriosis & Adenomyosis	~1.4 million women	105,869	80 loci	37 novel loci, 5 first adenomyosis loci	Immune regulation, tissue remodeling, cell differentiation
MVP Migraine Study (2025) [16]	Migraine	648,172 veterans	90,600	789 SNPs (778 novel)	778 novel SNPs	Interleukin signaling, glutamate receptor activity, JAK/STAT signaling
Facial Morphology Study (2025) [17]	Facial Features	21,336 individuals (Europeans & East Asians)	N/A	253 SNPs across 188 loci	64 SNPs at 62 novel loci	Craniofacial development, evolutionary conserved pathways

Methodological Approaches in Multi-ancestry GWAS

Core Experimental Protocols and Analytical Workflows

Multi-ancestry GWAS meta-analyses employ sophisticated statistical genetics approaches to maximize discovery while accounting for ancestral diversity. The foundational protocol involves:

Stage 1: Cohort-Specific Genome-Wide Analysis

• Individual-level genotype data from participating cohorts undergo rigorous quality control including filters for call rate, Hardy-Weinberg equilibrium, and imputation quality [18].
• Ancestry determination performed using genetic principal components analysis projected onto reference panels (e.g., 1000 Genomes) [16].
• Within each ancestry group within cohorts, trait association analyses are conducted using linear or logistic regression models adjusted for principal components, age, and other study-specific covariates [17].

Stage 2: Ancestry-Specific Meta-Analysis

• Summary statistics from cohorts are aggregated within ancestral groups using fixed-effects or random-effects models in tools like METAL or GWAMA [18].
• Heterogeneity between cohorts is quantified using I² statistics, with genomic control applied to correct for residual population stratification [17].

Stage 3: Cross-Ancestry Meta-Analysis

• Trans-ancestry meta-analysis combines summary statistics across ancestry groups using methods that account for differing linkage disequilibrium patterns, such as MR-MEGA or RE2 approaches [17].
• Fine-mapping of association signals is performed using trans-ancestry methods to improve resolution of causal variants [13].

Stage 4: Functional Annotation and Validation

• Colocalization analyses integrate molecular QTL data (e.g., eQTLs, pQTLs) from diverse populations to link associations to target genes [19].
• Heritability and genetic correlation analyses quantify shared genetic architecture across ancestries and traits [13].
• Polygenic risk scores are developed and validated across ancestry groups, with assessment of portability metrics [17].

Diagram 1: Multi-ancestry GWAS Meta-analysis Workflow. This four-stage approach enables genetic discovery across diverse populations while accounting for ancestry-specific differences in allele frequencies and linkage disequilibrium patterns.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 2: Key Research Reagents and Computational Tools for Multi-ancestry GWAS

Resource Category	Specific Tools/Databases	Primary Function	Application in Endometriosis Research
Biobanks & Cohort Resources	UK Biobank, Million Veteran Program, All of Us, FinnGen	Provide large-scale genetic and phenotypic data from diverse populations	Enabled discovery of 37 novel endometriosis loci in multi-ancestry meta-analysis [13] [15]
Analysis Pipelines	METAL, GWAMA, MR-MEGA, REGENIE	Perform meta-analysis across cohorts and ancestries	Combined data from ~1.4 million women across multiple biobanks [13]
Functional Genomics Databases	GTEx v8, eQTL Catalog, PharmGKB	Provide tissue-specific gene expression and regulation data	Identified endometriosis risk genes regulated in uterus, ovary, and immune tissues [19]
Variant Annotation Tools	Ensembl VEP, ANNOVAR, FUMA	Functional consequence prediction of non-coding variants	Annotated 465 endometriosis-associated GWAS variants [19]
Pathway Analysis Resources	MSigDB, Cancer Hallmarks, KEGG	Biological pathway enrichment analysis	Revealed immune and tissue remodeling pathways in endometriosis [13] [19]

Limitations and Challenges in Current Approaches

Persistent Ancestry-Based Representation Gaps

Despite advances, significant disparities in ancestral representation persist. In the landmark endometriosis GWAS, while the overall sample size approached 1.4 million individuals, the proportion of non-European participants remains substantially lower [13]. This limitation is echoed in the MVP migraine study, where despite inclusion of diverse participants, the number of significant discoveries varied dramatically by ancestry: 624 SNPs in Europeans compared to only 3 in African Americans [16]. These disparities directly impact the transferability of findings and perpetuate health inequities.

The functional characterization of endometriosis-associated variants further highlights these limitations. A 2025 study examining regulatory effects of endometriosis variants across six tissues (uterus, ovary, vagina, colon, ileum, and blood) relied predominantly on GTEx data derived from European-ancestry individuals [19]. This constraint potentially masks ancestry-specific regulatory mechanisms that could be critical for understanding disease etiology across populations.

Methodological Complexities in Cross-Ancestry Analysis

Cross-ancestry genetic analyses face several methodological challenges that impact result interpretation:

Differential Linkage Disequilibrium (LD) Patterns

• Variation in LD structure across populations complicates fine-mapping efforts and causal variant identification [17].
• Differences in allele frequencies can lead to effect size heterogeneity that is difficult to distinguish from technical artifacts [12].

Ancestry-Specific Genetic Effects

• The Iranian endometriosis study demonstrated population-specific genetic architecture, with different variants showing significance compared to European and East Asian populations [12].
• Gene-environment interactions, such as those between ancient regulatory variants and modern environmental pollutants, may drive ancestry-specific disease risk [11].

Polygenic Risk Score Portability

• Limited transferability of polygenic risk scores across ancestries remains a significant clinical translation challenge [17].
• Current prediction models explain substantially less phenotypic variance in underrepresented populations, limiting clinical utility [16].

Diagram 2: Key Limitations in Current Multi-ancestry GWAS. Three major challenge areas persist despite methodological advances, impacting the discovery and translational potential of genetic findings across diverse populations.

Landmark multi-ethnic GWAS meta-analyses have substantially advanced our understanding of complex traits like endometriosis, revealing dozens of novel genetic loci and elucidating key biological pathways. The integration of diverse cohorts has enabled more powerful discovery while highlighting the extensive genetic heterogeneity across populations. However, significant challenges remain in achieving equitable representation, refining cross-ancestry analytical methods, and ensuring clinical translation benefits all populations equally.

For endometriosis research specifically, future directions should include: (1) purposeful recruitment of underrepresented populations to address ancestry-based disparities; (2) development of advanced statistical methods that better account for population structure and gene-environment interactions; and (3) integration of multi-omics data from diverse tissues to illuminate ancestry-specific regulatory mechanisms. Addressing these priorities will be essential for realizing the full potential of multi-ethnic GWAS in reducing health disparities and advancing precision medicine for all populations.

Differential Allele Frequencies Across Continental Populations

Endometriosis, a complex, estrogen-dependent inflammatory disorder affecting approximately 10% of reproductive-aged women globally, demonstrates a strong genetic predisposition with an estimated heritability of around 52% [2] [11]. Despite increasing genomic insights, the genetic architecture of endometriosis exhibits marked heterogeneity across human populations. Genome-wide association studies (GWAS) have identified numerous susceptibility loci; however, the replication of these associations across diverse ethnic groups has been inconsistent, complicating the interpretation of disease mechanisms and the development of universally effective diagnostics and therapies [12] [20]. This heterogeneity arises from a complex interplay of demographic history, population-specific selective pressures, and variation in linkage disequilibrium patterns.

The differential distribution of allele frequencies of endometriosis-associated single nucleotide polymorphisms (SNPs) across continental populations is not merely a statistical curiosity but a fundamental aspect of the disease's etiology. Research indicates that the genetic underpinnings of endometriosis, particularly early-stage disease, remain poorly understood, limiting opportunities for timely diagnosis and intervention [11]. The genetic risk landscape is further complicated by interactions with environmental factors, such as endocrine-disrupting chemicals (EDCs), which may modulate genetic susceptibility in population-specific ways [11]. Understanding these patterns is therefore critical for advancing personalized medicine approaches and ensuring equitable application of genetic discoveries across all population groups.

Methodological Framework for Allele Frequency Analysis

The analysis of allele frequency differences requires a clear understanding of the allele frequency spectrum (AFS), which is the distribution of allele frequencies of a given set of loci (often SNPs) in a population or sample [21]. The AFS is typically represented as a histogram where each entry records the total number of loci with the corresponding derived allele frequency, providing a powerful summary of population genetic variation. For endometriosis research, the primary data sources include:

• The 1000 Genomes Project: Provides a comprehensive resource of genetic variation from multiple geographically dispersed populations, serving as a reference for population-specific allele frequencies [22].
• GWAS Catalog: Curates published genome-wide significant associations, providing a standardized resource for endometriosis-associated variants [19].
• Bio-repositories and Population Cohorts: Resources like the Personalized Medicine Research Project (PMRP) offer population-based allele frequencies for disease-associated polymorphisms, enabling stratification by self-reported race and region of ancestry [23].

The integration of these data sources allows researchers to contextualize endometriosis GWAS findings within global patterns of human genetic diversity.

Analytical Approaches and Statistical Considerations

Robust statistical methods are essential for identifying consistent allele frequency differences between populations. The Cochran-Mantel-Haenszel (CMH) test has been widely used to test for consistent allele frequency differences across biological replicates or population strata [24]. However, simulations reveal that the CMH-test performs poorly with high false positive rates when underlying assumptions are violated, particularly when heterogeneity in allele frequency differences is confounded with main effects [24].

Generalized Linear Models (GLMs) with quasibinomial error structure offer a superior alternative, as they do not confound heterogeneity and main effects and allow for correction for multiple testing by standard procedures [24]. These models can effectively account for pseudoreplication inherent in pool-seq experimental designs where single chromosomes are "counted" multiple times.

For functional characterization of population-specific variants, integration with expression Quantitative Trait Loci (eQTL) data from resources like the GTEx database enables exploration of tissue-specific regulatory effects, providing mechanistic insights into how population-specific variants might influence disease risk [19].

Table 1: Key Data Resources for Population Genetic Studies in Endometriosis

Resource	Primary Use	Key Features	Limitations
1000 Genomes Project	Reference allele frequencies	Multidimensional representation of human genetic diversity; 5 major population groups	Limited sample size for some populations
GWAS Catalog	Variant-disease associations	Curated genome-wide significant associations	Incomplete functional annotation
GTEx Portal	Functional annotation	Tissue-specific eQTL data across 6 relevant tissues	Based on healthy tissues
Demetra Application Database	Endometriosis-specific SNPs	Classification of SNPs by association strength	Limited to previously reported variants

Global Patterns of Endometriosis-Associated Allele Frequencies

Continental Variation in Risk Loci

A global population genomic analysis of endometriosis revealed striking differences in the distribution of risk alleles across five major population groups: Europeans, Africans, Americans, East Asians, and South Asians [22]. The analysis identified 296 and 6 common genetic targets of SNPs with low allele frequencies (≤0.1) and high allele frequencies (>0.9), respectively, with marked differences between the population groups [22]. This population-based heterogeneity in the disease genomic 'grammar' (DGG) of endometriosis suggests that the genetic architecture of the disease has been shaped by the demographic history of human populations.

The serial founder effect, which occurred as human populations expanded from Africa, resulted in a continuous loss of genetic diversity proportional to the geographic distance from the African homeland [22]. This pattern is evident in the distribution of endometriosis risk alleles, with African populations maintaining extremely high genetic diversity relative to out-of-Africa populations [22]. For example, hunter-gatherer groups such as the Khoisan, Hadza, Sandawe, and Forest Pygmies show remarkable genetic diversity that is not observed in non-African populations.

Meta-analyses of GWAS datasets have confirmed remarkable consistency in endometriosis genetic associations across studies of European and Japanese ancestry, with little evidence of population-based heterogeneity for the majority of loci [2]. Specifically, seven out of nine loci showed consistent directions of effect across studies and populations, with six remaining genome-wide significant in meta-analysis [2]. However, two independent inter-genic loci (rs4141819 and rs6734792 on chromosome 2) showed significant evidence of heterogeneity across datasets, highlighting population-specific effects at specific loci [2].

Population Attributable Risk and Clinical Implications

The differential distribution of allele frequencies has direct implications for the population attributable risk (PAR) of endometriosis across ethnic groups. Studies have reported a nine-fold increase in the risk of developing endometriosis among women from the East Asian population compared with European or American women populations [22]. This elevated risk cannot be fully explained by differences in healthcare access or diagnostic practices, suggesting a genuine biological difference in susceptibility.

The differential effect sizes of risk alleles across populations further complicate risk prediction models. Eight of the nine loci identified in GWAS meta-analyses had stronger effect sizes among Stage III/IV cases, implying that they are likely implicated in the development of moderate to severe, or ovarian, disease [2]. This pattern of effect size modification by disease stage may vary across populations, contributing to differences in disease presentation and progression.

Table 2: Representative Endometriosis Risk Loci with Population Frequency Differences

Locus/SNP	Nearest Gene	European Frequency	East Asian Frequency	African Frequency	Functional Role
rs7521902	WNT4	0.71	0.68	0.82	Developmental pathways
rs10859871	VEZT	0.47	0.52	0.61	Cell adhesion
rs13394619	GREB1	0.36	0.41	0.29	Hormonal response
rs12700667	Intergenic (7p15.2)	0.27	0.31	0.19	Regulatory function
rs1537377	CDKN2B-AS1	0.53	0.49	0.61	Cell cycle regulation

Note: Allele frequencies are approximate and based on published literature [2] [20].

Experimental Approaches and Research Workflows

Protocol for Population-Stratified Allele Frequency Analysis

Objective: To identify and validate population-specific differences in allele frequencies of endometriosis-associated SNPs.

Materials and Reagents:

• DNA Samples: From biorepositories with appropriate ethical approval (e.g., 1000 Genomes Project, PMRP cohort)
• Genotyping Platforms: Array-based or sequencing-based genotyping methods
• Bioinformatic Tools: PLINK for basic association analysis, R for statistical modeling, STRUCTURE or ADMIXTURE for ancestry estimation
• Reference Data: HapMap or 1000 Genomes Project for imputation and ancestry inference

Procedure:

• Sample Selection and Quality Control: Select population-based samples with detailed ethnicity information. Apply strict quality control filters: call rate >98%, Hardy-Weinberg equilibrium p > 1×10⁻⁶, and minor allele frequency >0.01.
• Genotype Imputation: Use reference panels from the 1000 Genomes Project to impute genotypes to a standard set of variants, accounting for population-specific haplotype structure.
• Population Stratification Assessment: Perform principal component analysis (PCA) or similar methods to identify and control for population substructure.
• Allele Frequency Estimation: Calculate allele frequencies for each SNP of interest within each population group.
• Statistical Testing for Frequency Differences: Implement GLMs with quasibinomial error structure to test for consistent allele frequency differences while accounting for heterogeneity between subpopulations [24].
• Multiple Testing Correction: Apply false discovery rate (FDR) correction using the Benjamini-Hochberg procedure to account for the large number of statistical tests performed.

This workflow enables robust identification of population-specific allele frequency differences while minimizing false positives due to population structure or technical artifacts.

Functional Validation of Population-Specific Variants

Objective: To characterize the functional consequences of population-specific endometriosis risk variants.

Materials and Reagents:

• eQTL Data: From GTEx portal for relevant tissues (uterus, ovary, vagina, colon, ileum, peripheral blood)
• Epigenetic Annotations: ENCODE data on chromatin accessibility, histone modifications
• Luciferase Reporter Vectors: For enhancer activity assays
• Cell Culture Models: Endometrial stromal cells, epithelial organoids

Procedure:

• Integration with Functional Genomics Data: Cross-reference endometriosis-associated variants with tissue-specific eQTL data from GTEx to identify regulatory variants [19].
• Variant Effect Prediction: Use Ensembl Variant Effect Predictor (VEP) to annotate variants with functional consequences.
• In Silico Prioritization: Prioritize variants based on regulatory potential, evolutionary conservation, and overlap with functional genomic elements.
• Experimental Validation: For top candidates, perform luciferase reporter assays in relevant cell types to test for allele-specific effects on gene regulation.
• Pathway Analysis: Use MSigDB Hallmark gene sets and similar resources to identify biological pathways enriched for population-specific risk variants.

This integrated approach moves beyond statistical associations to provide mechanistic insights into how population-specific variants contribute to endometriosis risk.

Diagram 1: Analytical workflow for population-stratified allele frequency studies. The process begins with sample collection and proceeds through quality control, statistical analysis, and functional validation.

Table 3: Essential Research Reagents and Resources for Population Genetic Studies of Endometriosis

Category	Specific Resource	Application	Key Features
Genotyping Platforms	Illumina Global Screening Array	Cost-effective genotyping	Designed for multi-ethnic populations
Sequencing Technologies	Whole Genome Sequencing (WGS)	Comprehensive variant discovery	Identifies population-specific variants
Bioinformatic Tools	PLINK, EIGENSOFT	Quality control and population structure analysis	Handles large-scale genomic data
Reference Databases	1000 Genomes Project, gnomAD	Population allele frequency reference	Diverse population representation
Functional Annotation	GTEx Portal, ENCODE	Regulatory element annotation	Tissue-specific functional data
Statistical Packages	R/Bioconductor, STRUCTURE	Advanced statistical modeling	Specialized for genetic data

Tissue-Specific Regulatory Mechanisms Across Populations

Differential Gene Regulation in Relevant Tissues

Integrative analyses combining GWAS findings with eQTL data reveal tissue-specific regulatory profiles for endometriosis-associated variants. A comprehensive study examining six physiologically relevant tissues (peripheral blood, sigmoid colon, ileum, ovary, uterus, and vagina) found distinct patterns of gene regulation across these tissues [19]. In the colon, ileum, and peripheral blood, immune and epithelial signaling genes predominated, whereas reproductive tissues showed enrichment of genes involved in hormonal response, tissue remodeling, and adhesion [19].

This tissue specificity has important implications for understanding population differences in endometriosis susceptibility. If a risk variant acts as an eQTL in a tissue-specific manner, and its frequency varies across populations, it could contribute to population differences in disease risk or presentation. Key regulators such as MICB, CLDN23, and GATA4 were consistently linked to hallmark pathways, including immune evasion, angiogenesis, and proliferative signaling across populations [19].

Ancient Genetic Contributions to Modern Disease Risk

Recent evidence suggests that ancient hominin introgression may contribute to modern endometriosis risk. Regulatory variants derived from Neandertal and Denisovan genomes have been identified in genes such as IL-6, CNR1, and IDO1, with these variants showing significant enrichment in endometriosis cohorts [11]. For example, co-localized IL-6 variants rs2069840 and rs34880821—located at a Neandertal-derived methylation site—demonstrated strong linkage disequilibrium and potential immune dysregulation [11].

The distribution of these archaic variants varies dramatically across modern human populations, reflecting the diverse patterns of interbreeding between modern humans and archaic hominins as they migrated out of Africa. This differential distribution represents another layer of population-specific genetic risk that must be considered in endometriosis genetics research.

Diagram 2: Tissue-specific regulatory mechanisms and ancient genetic contributions to endometriosis risk. GWAS variants show tissue-specific eQTL effects, while archaic variants contribute to risk through altered biological pathways.

Implications for Drug Development and Personalized Medicine

The heterogeneity of allele frequencies across populations has profound implications for drug development and personalized medicine approaches in endometriosis. Population-specific genetic backgrounds can influence drug metabolism, efficacy, and adverse event profiles, potentially leading to variable treatment responses across ethnic groups.

Pharmacogenomic studies have revealed that many polymorphisms in drug metabolism enzymes and transporters show significant frequency differences across populations [23]. For example, stratification of Caucasian populations by self-reported region of origin revealed 19 polymorphisms that were significantly different between individuals of different origins, with five showing p-values of 0.0001 or less [23]. This fine-scale population structure must be considered when designing clinical trials and developing targeted therapies for endometriosis.

The development of polygenic risk scores (PRS) for endometriosis is particularly vulnerable to population-specific allele frequency differences. PRS developed in one population typically show reduced performance when applied to other populations, due to differences in allele frequencies, LD patterns, and effect sizes. This transferability problem highlights the need for diverse recruitment in genetic studies and the development of population-specific PRS models.

The comprehensive analysis of differential allele frequencies across continental populations reveals the complex genetic architecture of endometriosis and underscores the importance of considering population context in genetic studies. The remarkable consistency of some loci across populations, contrasted with the population specificity of others, suggests that while core biological pathways may be shared, their genetic regulation and modulation may vary across human groups.

Future research must prioritize the inclusion of diverse populations in endometriosis genetic studies to ensure equitable advancement of knowledge and clinical applications. This will require:

• Expanded Biobanking Initiatives in underrepresented populations to address the current bias in genomic databases.
• Advanced Statistical Methods that can better account for population structure and admixture in association studies.
• Functional Genomics Studies in diverse cell models to characterize the mechanistic consequences of population-specific variants.
• Integration of Environmental Factors to understand gene-environment interactions across different populations.

Addressing these challenges will advance our understanding of endometriosis pathogenesis and pave the way for truly personalized approaches to diagnosis, treatment, and prevention that are effective across all population groups.

Population-Specific Risk Loci and Ancestry-Informed Genetic Signals

Endometriosis is a common, heritable gynecological disorder affecting 6–10% of women of reproductive age and is a major cause of infertility and pelvic pain [25]. Its etiology involves complex interactions between multiple genetic and environmental risk factors, with twin studies estimating its heritability at 0.47–0.51 and common SNP-based heritability at approximately 0.26 [25]. Genome-wide association studies (GWAS) have substantially advanced our understanding of endometriosis genetics, yet a critical challenge remains: the limited transferability of findings across diverse ancestral populations. Most large-scale GWAS have predominantly focused on European ancestry cohorts, creating significant gaps in our understanding of the genetic architecture of endometriosis in other populations.

This technical guide examines the current landscape of population-specific risk loci and ancestry-informed genetic signals in endometriosis research. We synthesize evidence from major genetic studies, highlight population-specific discoveries, and provide methodological frameworks for conducting inclusive genetic research that acknowledges the fundamental role of genetic heterogeneity across human populations. Understanding these population-specific dimensions is essential for developing comprehensive risk prediction models and targeted therapeutic interventions that benefit all patient groups.

Established Endometriosis Risk Loci Across Populations

European Ancestry Risk Profile

Large-scale meta-analyses in European populations have identified numerous genome-wide significant loci for endometriosis. A landmark meta-analysis of 11 GWAS datasets, totaling 17,045 cases and 191,596 controls of predominantly European ancestry (∼93%), identified five novel loci significantly associated with endometriosis risk (P<5×10⁻⁸) [25]. These implicated genes include FN1, CCDC170, ESR1, SYNE1, and FSHB—many involved in sex steroid hormone pathways—bringing the total number of independent SNPs robustly associated with endometriosis in European populations to 19, collectively explaining up to 5.19% of variance in endometriosis susceptibility [25].

Table 1: Key Endometriosis Risk Loci Identified in European Ancestry Populations

Locus	Candidate Gene	SNP	Odds Ratio	P-value	Functional Pathway
1p36.12	WNT4	rs12037376	1.16 (1.12-1.19)	8.87×10⁻¹⁷	Sex steroid hormone signaling
2p25.1	GREB1	rs11674184	1.13 (1.10-1.15)	2.67×10⁻²⁶	Estrogen regulation
6p22.3	ID4	rs7739264	1.14 (1.11-1.17)	3.65×10⁻¹⁶	Transcriptional repression
7p15.2	-	rs12700667	1.20 (1.14-1.26)	4.69×10⁻¹²	Developmental processes
9p21.3	CDKN2B-AS1	rs1537377	1.13 (1.10-1.16)	1.06×10⁻¹³	Cell cycle regulation
12q22	VEZT	rs10859871	1.17 (1.14-1.20)	1.51×10⁻²²	Cell adhesion
14q24.2	ESR1	rs71575922	0.92 (0.90-0.94)	1.11×10⁻³¹	Estrogen receptor signaling

Conditional analysis of the ESR1 locus revealed two secondary association signals, highlighting the complexity of genetic regulation at this hormonally relevant locus [25]. Notably, effect sizes were generally larger when analyses were restricted to moderate-to-severe (Stage III/IV) endometriosis cases, consistent with previous observations of greater genetic loading in more severe disease presentations [25].

Japanese Ancestry Risk Profile

The genetic landscape of endometriosis in East Asian populations, particularly Japanese women, demonstrates both shared and distinct risk loci compared to European populations. The first GWAS for endometriosis conducted in Japanese ancestry women identified rs10965235 in CDKN2BAS on chromosome 9p21.3 as a significant risk locus [25]. This variant was not polymorphic in European populations, representing an early example of a population-specific genetic risk factor for endometriosis.

Subsequent multi-ethnic meta-analyses that incorporated Japanese datasets confirmed that while several risk loci are shared across ancestries, their effect sizes and allele frequencies often differ substantially [25]. For instance, the risk allele frequency of rs12037376 in WNT4 is 0.17 in European populations but 0.58 in Japanese populations, despite similar effect sizes (OR≈1.16) [25]. These differences in allele frequency contribute to varying population-attributable risks and have implications for the predictive power of polygenic risk scores across populations.

Table 2: Comparison of Select Risk Allele Frequencies Across Populations

SNP	Locus	European RAF	Japanese RAF	Odds Ratio	Shared or Population-Specific
rs10965235	CDKN2BAS (9p21.3)	Not polymorphic	0.19-0.23	1.40-1.50	Japanese-specific
rs12037376	WNT4 (1p36.12)	0.17	0.58	1.16	Shared, different frequencies
rs1537377	CDKN2B-AS1 (9p21.3)	0.46	0.38	1.13	Shared, different frequencies
rs10859871	VEZT (12q22)	0.63	0.49	1.17	Shared, different frequencies

Methodological Framework for Cross-Population Genetic Analysis

Genome-Wide Association Studies in Diverse Cohorts

Conducting robust GWAS in diverse populations requires careful consideration of several methodological aspects:

Cohort Selection and Ascertainment:

• Prioritize population-based recruitment to minimize ascertainment bias
• Ensure sufficient sample size to detect loci with moderate effect sizes (power >80%)
• Collect detailed demographic and clinical data to enable sub-phenotype analyses
• For endometriosis, utilize surgical confirmation (rAFS staging) when possible to reduce heterogeneity

Genotyping and Imputation:

• Use high-density genotyping arrays with content optimized for diverse populations
• Perform imputation using population-appropriate reference panels (1000 Genomes Project, gnomAD, population-specific references)
• Apply stringent quality control filters (call rate >98%, HWE P>1×10⁻⁶, MAF>0.01)
• Account for population stratification using principal components analysis or genetic relationship matrices

Association Analysis:

• Implement appropriate statistical models (logistic regression for case-control designs)
• Include relevant covariates (age, BMI, genetic principal components)
• Apply genome-wide significance threshold (P<5×10⁻⁸)
• Conduct conditional analysis to identify independent signals at associated loci

Trans-ancestry Meta-analysis Approaches

Trans-ancestry meta-analysis combines data from multiple ancestral groups to enhance power for locus discovery and fine-mapping:

Fixed-Effects vs. Random-Effects Models:

• Fixed-effect models assume the same effect size across populations
• Random-effects models (e.g., RE2) allow for heterogeneity and can be more powerful when heterogeneity exists [25]
• Han-Eskin random-effects model specifically increases power under heterogeneity while controlling false positives

Implementation Workflow:

• Perform ancestry-specific GWAS with standardized quality control
• Apply genomic control within each cohort to account for residual stratification
• Meta-analyze using inverse-variance weighted methods
• Assess heterogeneity using Cochran's Q statistic or I²
• Interpret trans-ancestry signals in biological context

Figure 1: Trans-ancestry Genetic Analysis Workflow

Functional Annotation and Fine-mapping

Prioritizing causal variants and genes from association signals requires comprehensive functional annotation:

Expression Quantitative Trait Locus (eQTL) Analysis:

• Map endometriosis-associated variants to gene expression effects in relevant tissues (uterus, ovary, vagina, colon, ileum, blood) [19]
• Identify colocalization between GWAS signals and eQTL signals
• Assess tissue specificity of regulatory effects

Chromatin Interaction Mapping:

• Utilize Hi-C and promoter capture Hi-C data from endometrium and ovarian cells
• Identify long-range regulatory interactions connecting non-coding variants to candidate genes
• Prioritize genes based on chromatin interaction profiles rather than simple proximity

Fine-mapping Credible Sets:

• Use statistical fine-mapping methods (e.g., FINEMAP, SUSIE) to identify 95% credible sets of causal variants
• Leverage trans-ancestry data to improve fine-mapping resolution due to differences in LD patterns
• Integrate functional genomic annotations to prioritize likely causal variants within credible sets

Beyond SNPs: Structural Variants and Rare Genetic Contributions

Copy Number Variants in Endometriosis

While most endometriosis GWAS have focused on single nucleotide polymorphisms, copy number variants (CNVs) represent another important source of genetic variation. CNVs account for more genetic variation in the genome (0.5-1%) than SNPs (0.1%) and have been implicated in various complex diseases [26].

A genome-wide survey of CNVs in endometriosis included 2,126 surgically confirmed cases and 17,974 population controls of European ancestry [26]. After applying stringent quality filters to reduce false positives, researchers identified an average of 1.92 CNVs per individual with an average size of 142.3 kb [26]. While no differences in global CNV burden were detected between cases and controls, several specific CNV regions showed nominal association with endometriosis risk:

Table 3: Copy Number Variants Associated with Endometriosis Risk

Genomic Location	Candidate Gene	Variant Type	P-value	Odds Ratio	Frequency in Cases vs Controls
8p22	SGCZ	Deletion	7.3×10⁻⁴	8.5 (2.3-31.7)	0.8% vs 0.1%
10p12.31	MALRD1	Deletion	5.6×10⁻⁴	14.1 (2.7-90.9)	0.6% vs 0.04%
11q14.1	-	Deletion	5.7×10⁻⁴	33.8 (3.3-1651)	0.3% vs 0.01%
7q36.2	DPP6	SNP in CNV region	0.0045	-	-
9q33.1	ASTN2	SNP in CNV region	0.0002	-	-

Collectively, these CNV loci were detected in 6.9% of affected women compared to 2.1% in the general population, suggesting that rare CNVs contribute to endometriosis susceptibility in a subset of patients [26]. The genes implicated in these CNV regions include SGCZ, which encodes sarcoglycan zeta, a component of the dystrophin-glycoprotein complex, and MALRD1, which encodes MAM and LDL receptor class A domain containing 1, potentially involved in cellular adhesion and signaling pathways relevant to endometriosis pathogenesis.

Family-Based Studies and Rare Variants

Family-based studies provide an alternative approach to identifying rare variants with larger effect sizes. Sequencing of 32 families with multiple affected women (3 or more cases per family) revealed a significant association between rare variants in the NPSR1 gene and stage III/IV endometriosis [27]. The NPSR1 gene encodes neuropeptide S receptor 1, which is involved in inflammation and pain signaling pathways.

Functional validation in cellular assays and mouse models demonstrated that inhibition of NPSR1 reduced inflammation and abdominal pain, suggesting this receptor as a potential target for non-hormonal therapeutics for endometriosis [27]. This finding highlights how family-based designs can complement large-scale GWAS by identifying rare variants that might be missed in population-based association studies.

Functional Validation and Mechanistic Insights

Experimental Protocols for Functional Validation

Expression Quantitative Trait Locus (eQTL) Analysis:

• Extract RNA and genotype from endometriosis lesions and eutopic endometrium
• Perform RNA sequencing and whole-genome sequencing
• Conduct matrix eQTL analysis with appropriate covariates (age, menstrual phase, batch effects)
• Validate findings in independent cohorts and diverse populations
• Integrate with public datasets (GTEx, Endometriosis eQTL browser)

Mendelian Randomization for Causal Inference: Mendelian randomization (MR) uses genetic variants as instrumental variables to assess causal relationships between risk factors and diseases. Recent MR analyses have revealed causal relationships between endometriosis and ovarian cancer risk [28].

Protocol for Two-Sample Mendelian Randomization:

• Select independent genetic instruments (P<5×10⁻⁸, r²<0.001) associated with the exposure
• Calculate F-statistic to assess instrument strength (F>10 indicates strong instruments)
• Obtain association estimates for instruments with the outcome from independent datasets
• Perform inverse-variance weighted MR as primary analysis
• Conduct sensitivity analyses (MR-Egger, weighted median, MR-PRESSO)
• Test for directional pleiotropy using MR-Egger intercept and MR-PRESSO global test

Application of this approach demonstrated that genetically proxied endometriosis significantly increases risks of overall ovarian cancer [OR=1.18], high-grade serous [OR=1.12], clear cell [OR=1.87], and endometrioid carcinomas [OR=1.48] [28].

In Vitro and In Vivo Functional Studies:

• Develop patient-derived endometriosis cell cultures
• Implement CRISPR/Cas9 genome editing to introduce risk variants
• Assess cellular phenotypes (proliferation, invasion, hormone response)
• Validate findings in mouse models of endometriosis
• Test therapeutic compounds targeting identified pathways

Tissue-Specific Regulatory Mechanisms

Comprehensive analysis of endometriosis-associated variants using eQTL data from six physiologically relevant tissues (uterus, ovary, vagina, sigmoid colon, ileum, and peripheral blood) revealed tissue-specific regulatory profiles [19]. In reproductive tissues, eQTL-associated genes were enriched for functions in hormonal response, tissue remodeling, and adhesion, whereas in intestinal tissues and blood, immune and epithelial signaling genes predominated [19].

Key regulatory genes identified include:

• MICB: MHC class I polypeptide-related sequence B, involved in immune recognition
• CLDN23: Claudin-23, component of tight junctions
• GATA4: GATA binding protein 4, transcription factor involved in steroidogenesis

These findings highlight the importance of considering tissue context when interpreting the functional consequences of genetic risk variants and suggest that endometriosis risk variants may exert their effects through disruption of different biological processes in various anatomical locations.

Figure 2: Tissue-Specific Regulatory Effects of Endometriosis Risk Variants

Clinical Translation and Therapeutic Implications

Drug Target Prioritization

Integration of endometriosis GWAS findings with genomic and functional data has enabled prioritization of promising therapeutic targets:

RSPO3 (R-spondin 3):

• Identified through Mendelian randomization analysis of plasma proteins [29]
• Encodes a secreted activator of Wnt/β-catenin signaling
• Shows elevated expression in endometriosis patients validated by ELISA and RT-qPCR
• Represents a novel candidate for targeted therapy development

NPSR1 (Neuropeptide S Receptor 1):

• Identified through family-based sequencing of severe endometriosis cases [27]
• Inhibition reduces inflammation and abdominal pain in mouse models
• Potential target for non-hormonal treatment

ESR1 (Estrogen Receptor 1):

• Contains multiple independent endometriosis risk signals [25]
• Well-established role in endometriosis pathophysiology
• Existing SERMs and aromatase inhibitors partially effective

Polygenic Risk Scores and Clinical Stratification

Polygenic risk scores (PRS) aggregate the effects of many genetic variants to estimate an individual's genetic susceptibility to endometriosis. However, current PRS models developed in European populations show reduced predictive accuracy in non-European populations due to differences in allele frequencies, LD patterns, and potentially causal variants.

Considerations for Ancestry-Informed PRS:

• Develop ancestry-specific PRS using population-specific GWAS summary statistics
• Implement cross-population PRS methods that account for genetic architecture differences
• Integrate PRS with clinical risk factors for improved prediction
• Validate PRS performance in diverse clinical cohorts before implementation

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagents for Endometriosis Genetic Studies

Reagent/Resource	Specifications	Application	Key Considerations
GWAS Arrays	Illumina Global Screening Array, Infinium Asian Screening Array	Genotyping of common variants	Population-specific content optimization
Whole Genome Sequencing	30x coverage, PCR-free library prep	Rare variant discovery, structural variants	Sufficient depth for accurate variant calling
Reference Panels	1000 Genomes, gnomAD, population-specific panels	Imputation, frequency estimation	Match ancestral background of study population
eQTL Resources	GTEx v8, endometriosis-specific eQTL maps	Functional annotation of risk loci	Tissue relevance to endometriosis pathogenesis
Cell Models	Primary endometriotic stromal cells, immortalized lines	Functional validation of risk genes	Maintain phenotypic properties in culture
Animal Models	Mouse model of endometriosis, non-human primates	In vivo functional studies	Species differences in reproductive biology

The landscape of population-specific risk loci and ancestry-informed genetic signals in endometriosis is rapidly evolving. While substantial progress has been made in identifying genetic risk factors, particularly in European and East Asian populations, significant gaps remain in other ancestral groups, including African, Hispanic, and Indigenous populations.

Future research priorities should include:

• Diversifying Genetic Studies: Intentional inclusion of underrepresented populations in endometriosis genetics research
• Integrating Multi-omics Data: Combining genomic, transcriptomic, epigenomic, and proteomic data to elucidate functional mechanisms
• Developing Ancestry-Aware Tools: Creating polygenic risk scores and diagnostic algorithms that perform equitably across populations
• Translating Genetic Discoveries: Advancing therapeutic development based on genetically validated targets

Addressing these priorities will require global collaboration, standardized phenotyping, shared resources, and commitment to inclusive science. By embracing genetic heterogeneity across populations, the research community can develop more comprehensive models of endometriosis pathogenesis and more equitable approaches to risk prediction and treatment.

The Impact of Evolutionary History and Ancient Hominin Introgression

Endometriosis, a chronic, estrogen-driven inflammatory disorder affecting approximately 10% of reproductive-aged women globally, represents a significant challenge in gynecological health [1] [30]. Despite increasing genomic insights, particularly for advanced-stage disease, the genetic underpinnings of early-stage endometriosis remain poorly understood, limiting opportunities for timely diagnosis and intervention [30]. The conventional approach to understanding endometriosis genetics has primarily focused on genome-wide association studies (GWAS) that identify common single nucleotide polymorphisms (SNPs) associated with disease risk in modern populations [1] [2]. However, these studies have revealed substantial genetic heterogeneity across different populations and ethnicities, suggesting that population-specific genetic architectures contribute to differential disease susceptibility and presentation [1] [22].

The emerging paradigm in endometriosis research explores the intersection between modern environmental pollutants and ancient genetic regulatory variants, proposing that gene-environment interactions may exacerbate disease risk [30]. This perspective reframes our understanding of endometriosis susceptibility by considering how ancestral genetic contributions, preserved through thousands of years of human evolution, interact with contemporary environmental factors to modulate disease pathways. Recent evidence suggests that regulatory variants derived from ancient hominin introgression—specifically from Neandertals and Denisovans—may play a previously unrecognized role in shaping the genetic landscape of endometriosis [30] [31]. This integrative approach not only identifies new potential biomarkers for early-stage detection but also provides a novel framework for understanding the population-specific heterogeneity observed in endometriosis GWAS.

Genetic Heterogeneity in Endometriosis Across Populations

Evidence from Genome-Wide Association Studies

GWAS have been instrumental in identifying genetic variations associated with endometriosis, revealing specific loci that contribute to disease risk. Recent large-scale studies have provided substantial insights into the genetic architecture of endometriosis, identifying numerous genetic loci associated with the disease [1]. A meta-analysis of four GWAS and four replication studies including 11,506 cases and 32,678 controls demonstrated remarkable consistency in endometriosis GWAS results across studies, with little evidence of population-based heterogeneity for the majority of identified loci [2]. This analysis confirmed six genome-wide significant loci (rs12700667 on 7p15.2, rs7521902 near WNT4, rs10859871 near VEZT, rs1537377 near CDKN2B-AS1, rs7739264 near ID4, and rs13394619 in GREB1) that showed consistent directions of effect across datasets and populations [2].

Despite these consistent findings, deeper analysis reveals significant population-specific variations in endometriosis genetic risk. A global population genomic analysis studying five major population groups (Europeans, Africans, Americans, East Asians, and South Asians) found marked differences in the disease genomic "grammar" of endometriosis [22]. This study analyzed allele frequencies of endometriosis-related SNPs and classified them into low and high allele frequency categories, revealing 296 and 6 common genetic targets with low and high allele frequencies, respectively, across populations. However, the distribution of these genetic targets varied significantly between population groups, with the African population showing the most diverse genetic targets in its susceptible groups of allele frequency [22].

Table 1: Population-Specific Genetic Heterogeneity in Endometriosis

Population Group	Key Genetic Findings	Notable Risk Alleles	Heritability Estimates
European	27 genetic loci associated at genome-wide significance; 13 novel loci identified	WNT4, GREB1, FN1, CDKN2B-AS1	~51% from twin studies
East Asian	9-fold increased risk compared to European populations; distinct susceptibility profile	CDKN2B-AS1 (rs10965235)	Higher prevalence rates
African	Most diverse genetic targets; unique allele frequency patterns	Population-specific variants under investigation	Limited studies available
Mixed Ancestry	Effect sizes vary by population background; heterogeneity in some loci	rs4141819, rs6734792 on chromosome 2	Varies by genetic background

The Founder Effect and Global Migration Patterns

The observed genetic heterogeneity in endometriosis risk across populations can be partially explained by human evolutionary history and migration patterns. Genetic and paleoanthropological evidence indicates that approximately 45,000 to 60,000 years ago, a significant demographic and geographic expansion began in Africa that rapidly brought human presence to almost all habitable areas of the earth [22]. This expansion was accompanied by a continuous loss of genetic diversity—a result of what is known as the "serial founder effect" [22]. It is generally assumed that a bottleneck occurred as a small group(s) with an effective population size of only approximately 2,000 individuals migrated from the African continent to the Near East [22].

During this great expansion, there was an uninterrupted and considerable reduction in genetic diversity proportional to the geographic distance from the African homeland, as indicated by the motif of average heterozygosities of contemporary populations [22]. However, genomes from substructured populations retain a numerous amount of unique variants. As a result of the relatively profound substructure within the African continent, genetic variation in Africa varies considerably from region to region. Groups such as the Khoisan, Hadza, Sandawe, and Forest Pygmies have been shown to maintain extremely high genetic diversity, relative to out-of-Africa populations, as evidenced by studies on autosomal DNA polymorphism patterns in present-day African hunter-gatherers [22]. This complex evolutionary history has created a diverse genetic backdrop against which endometriosis risk variants have evolved, contributing to the heterogeneity observed in modern GWAS.

Ancient Hominin Introgression and Endometriosis Susceptibility

Methodology for Identifying Introgressed Variants

The investigation of ancient hominin introgression in endometriosis susceptibility requires specialized genomic approaches. A 2025 study conducted a dual-phase literature review to identify genes implicated in endometriosis pathophysiology and endocrine-disrupting chemical (EDC) sensitivity [30]. Five genes (IL-6, CNR1, IDO1, TACR3, and KISS1R) were selected based on tissue expression, pathway involvement, and EDC reactivity. Whole-genome sequencing (WGS) data from the Genomics England 100,000 Genomes Project were analysed in nineteen females with clinically confirmed endometriosis [30].

Variant enrichment, co-localisation, and linkage disequilibrium analyses were conducted, and functional impact was evaluated using public regulatory databases. The specific methodology included:

• Variant Identification: Extraction of all variants within the target genes from the WGS data.
• Enrichment Analysis: Comparison of variant frequencies in the endometriosis cohort versus matched controls and the general Genomics England population.
• Ancestral Origin Assessment: Evaluation of the phylogenetic origin of identified variants through comparison with ancient hominin genomes (Neandertal and Denisovan).
• Functional Annotation: Mapping of variants to regulatory regions and assessment of potential impact on gene expression and function.
• Gene-Environment Interaction Analysis: Examination of overlap between identified variants and EDC-responsive regulatory regions.

Table 2: Key Experimental Methods for Studying Ancient Introgression in Endometriosis

Methodological Approach	Technical Specifications	Application in Endometriosis Research
Whole-Genome Sequencing	Illumina platforms; 30x coverage; GRCh38 reference	Comprehensive variant discovery in coding and non-coding regions
Variant Enrichment Analysis	Fisher's exact test with multiple testing correction	Identification of variants overrepresented in endometriosis cases
Linkage Disequilibrium Mapping	r² calculation; haplotype reconstruction	Determination of variant co-inheritance patterns
Phylogenetic Comparison	Comparison to Neandertal/Denisovan reference genomes	Assignment of ancestral origin to identified risk variants
Regulatory Element Annotation	ENCODE; Roadmap Epigenomics; FANTOM5	Functional characterization of non-coding variants
Gene-Environment Interaction	Overlap analysis with EDC-responsive regions	Assessment of potential gene-environment interplay

Key Findings on Neandertal and Denisovan Derived Variants

The investigation into ancient hominin introgression revealed six regulatory variants that were significantly enriched in the endometriosis cohort compared to matched controls and the general Genomics England population [30]. Notably, co-localized IL-6 variants rs2069840 and rs34880821—located at a Neandertal-derived methylation site—demonstrated strong linkage disequilibrium and potential immune dysregulation [30]. The IL-6 gene encodes interleukin-6, a pro-inflammatory cytokine implicated in endometriosis pathophysiology through its role in inflammation, immune response modulation, and potential influence on estrogen production.

Variants in CNR1 and IDO1, some of Denisovan origin, also showed significant associations with endometriosis susceptibility [30]. CNR1 encodes the cannabinoid receptor 1, involved in pain modulation and inflammatory responses, both relevant to endometriosis symptoms. IDO1 encodes indoleamine 2,3-dioxygenase 1, an enzyme involved in tryptophan metabolism and immune tolerance, potentially contributing to the immune dysregulation observed in endometriosis. Several of these variants overlapped with EDC-responsive regulatory regions, suggesting that gene-environment interactions may exacerbate endometriosis risk [30].

These findings propose a novel perspective of endometriosis susceptibility, in which ancient regulatory variants and contemporary environmental exposures converge to modulate immune and inflammatory responses [30]. The preservation of these archaic genetic elements in modern human populations suggests they may have conferred selective advantages in ancient environments, potentially related to enhanced immune responses to pathogens or environmental challenges. However, in the context of modern environmental exposures, these same genetic variants may contribute to increased susceptibility to chronic inflammatory conditions such as endometriosis.

Functional Mechanisms of Introgressed Variants in Endometriosis Pathophysiology

Impact on Immune Dysregulation and Inflammatory Pathways

The introgressed variants identified in endometriosis susceptibility appear to predominantly affect immune regulation and inflammatory pathways, which are central to endometriosis pathophysiology. The IL-6 variants of Neandertal origin potentially alter the expression or regulation of this key inflammatory cytokine [30]. IL-6 is known to be elevated in the peritoneal fluid of women with endometriosis and contributes to the proliferation and survival of endometriotic lesions, angiogenesis, and pain sensitization.

The diagram below illustrates the proposed mechanism through which ancient hominin introgressed variants contribute to endometriosis pathophysiology:

The Denisovan-derived variants in CNR1 may alter endocannabinoid signaling, which plays a role in pain perception, uterine function, and inflammation. Similarly, variants in IDO1 could affect immune tolerance mechanisms, potentially contributing to the survival of ectopic endometrial tissue in the peritoneal cavity by evading immune surveillance [30]. These findings align with the understanding of endometriosis as an immune-related disorder with significant inflammatory components.

Gene-Environment Interactions with Modern Pollutants

A crucial aspect of the ancient introgression model for endometriosis susceptibility involves its interaction with modern environmental exposures. Several of the identified archaic variants overlap with endocrine-disrupting chemical (EDC)-responsive regulatory regions [30]. EDCs are environmental pollutants that can interfere with hormone signaling and immune function, and have been implicated in endometriosis risk.

The convergence of ancient genetic variants and modern environmental exposures creates a "double-hit" scenario where individuals carrying introgressed variants may be more susceptible to the effects of contemporary environmental pollutants. This interaction potentially explains the increasing prevalence and early onset of endometriosis in industrialized populations, where EDC exposure is widespread. The diagram below illustrates the experimental workflow for investigating these gene-environment interactions:

Research Reagents and Methodological Toolkit

Table 3: Essential Research Reagents for Investigating Ancient Introgression in Endometriosis

Research Reagent/Category	Specific Examples	Research Application
Genomic Sequencing Technologies	Illumina NovaSeq; PacBio SMRT; Oxford Nanopore	Comprehensive variant discovery including structural variants
Reference Genomes	GRCh38; Altai Neandertal; Denisovan	Phylogenetic comparison and ancestral origin assignment
Epigenomic Databases	ENCODE; Roadmap Epigenomics; FANTOM5	Functional annotation of non-coding regulatory variants
Endometriosis Model Systems	Stromal cell cultures; organoids; mouse models	Functional validation of identified risk variants
Environmental Exposure Assays	EDC screening; transcriptomic response profiling	Assessment of gene-environment interactions
Bioinformatics Tools	SAI Python package; PLINK; ADMIXTOOLS	Population genetics and introgression analysis

Discussion and Future Directions

Implications for Understanding Endometriosis Heterogeneity

The discovery of ancient hominin introgression contributing to endometriosis susceptibility provides a novel framework for understanding the genetic heterogeneity observed in endometriosis GWAS across different populations. The distribution of Neandertal and Denisovan ancestry varies significantly among modern human populations, with the highest levels of Neandertal ancestry found in non-African populations and Denisovan ancestry primarily present in Oceanian and East Asian populations [31]. This differential distribution of archaic ancestry may contribute to the population-specific genetic risk profiles observed in endometriosis.

The integration of ancient introgression maps with endometriosis GWAS findings can help explain why certain genetic risk factors show such divergent frequencies across populations. For instance, variants that originated in archaic hominins and were adaptive in ancient environments may have become maladaptive in the context of modern environmental exposures, contributing to disease risk in specific populations where these variants are present at higher frequencies.

Therapeutic Implications and Personalized Medicine Approaches

Understanding the role of ancient introgression in endometriosis pathogenesis opens new avenues for therapeutic development. The identified genes and pathways—particularly IL-6, CNR1, and IDO1—represent potential targets for pharmacological intervention. Additionally, the recognition of population-specific risk variants derived from archaic ancestry highlights the importance of considering genetic background in treatment approaches and clinical trial design.

Future research directions should include:

• Expanded genomic studies in diverse populations to better characterize archaic introgression contributions to endometriosis risk across different genetic backgrounds.
• Functional studies using CRISPR-based approaches to validate the mechanistic impact of introgressed variants on gene regulation and cellular function in relevant tissue types.
• Longitudinal studies examining how gene-environment interactions between archaic variants and modern pollutants influence disease onset and progression.
• Development of integrated risk prediction models that incorporate both modern genetic risk factors and ancient introgressed variants.

The investigation of ancient hominin introgression in endometriosis represents a paradigm shift in our understanding of this complex disease, connecting deep evolutionary history with modern environmental challenges to explain both disease susceptibility and its heterogeneous presentation across global populations.

Advanced Analytical Frameworks: Methods for Deciphering Cross-Population Genetic Data

Genome-Wide Association Study Designs for Diverse Cohorts

Endometriosis, a common estrogen-driven inflammatory condition, affects approximately 10% of reproductive-aged women globally, yet its genetic architecture remains incompletely characterized, particularly across diverse populations [11] [32]. This complex gynecological disorder, characterized by endometrial-like tissue growing outside the uterus, demonstrates substantial heritability estimates of approximately 50% based on twin studies [2] [3], highlighting the crucial role of genetic factors in its etiology. Genome-wide association studies (GWAS) have emerged as powerful hypothesis-free tools for identifying common genetic variants contributing to endometriosis susceptibility, with recent large-scale efforts identifying 42 significant genomic loci [33].

Despite these advances, a critical limitation persists: the overwhelming predominance of European-ancestry participants in GWAS, creating a pronounced representation gap in genomic databases [34]. This disparity has profound implications for both biological understanding and health equity. Research indicates that women of color experience longer diagnostic delays and undergo more invasive surgical procedures for endometriosis, outcomes potentially exacerbated by genetic research that fails to capture their unique susceptibility profiles [34]. The historical focus on European populations has constrained our understanding of endometriosis pathophysiology across human genetic diversity and limited the development of universally effective diagnostic and therapeutic approaches.

This technical guide examines GWAS study designs that incorporate diverse cohorts, addressing methodological considerations, analytical challenges, and practical implementation strategies to advance the field of endometriosis genetics beyond its current constraints.

Current Landscape of Endometriosis GWAS

Established Genetic Architecture

Endometriosis GWAS conducted over the past decade have identified numerous susceptibility loci, revealing key biological pathways involved in disease pathogenesis. Early GWAS meta-analyses demonstrated remarkable consistency across populations, with six loci maintaining genome-wide significance (P < 5 × 10⁻⁸) across studies: 7p15.2 (rs12700667), 1p36.12 (WNT4), 12q22 (VEZT), 9p21.3 (CDKN2B-AS1), 2p14, and 6p21.31 (ID4) [2]. More recent large-scale meta-analyses have substantially expanded this catalog, identifying 42 genome-wide significant loci comprising 49 distinct association signals that collectively explain approximately 5% of disease variance [33].

The biological pathways implicated by these associations include:

• Sex steroid hormone signaling (ESR1, CYP19A1, FSHB)
• Wnt signaling pathway (WNT4)
• Cell proliferation and differentiation (GREB1)
• Inflammatory processes (IL-6-related pathways) [35] [32]

Table 1: Key Endometriosis Susceptibility Loci Identified Through GWAS

Locus	Nearest Gene(s)	Population Identified	Potential Biological Function
1p36.12	WNT4, CDC42	European, Japanese, Taiwanese-Han	Reproductive development, hormone signaling
6q25.1	ESR1, CCDC170	European, Japanese	Estrogen receptor signaling
7p15.2	Intergenic	European	Transcriptional regulation
9p21.3	CDKN2B-AS1	Japanese	Cell cycle regulation
12q22	VEZT	European	Cell adhesion
2p14	Intergenic	European	Unknown
6p21.31	ID4	European	Transcription factor
5q31.1	C5orf66/C5orf66-AS2	Taiwanese-Han	Long non-coding RNA

Limitations of Existing Studies

The substantial progress in endometriosis genetics has been constrained by significant limitations in population diversity. Currently available GWAS data predominantly represent women of European ancestry, with limited representation of other ancestral groups [34] [36]. This European-centric focus has several consequences:

• Reduced portability of polygenic risk scores across populations
• Incomplete characterization of the allelic spectrum underlying endometriosis susceptibility
• Perpetuation of health disparities in diagnosis and treatment
• Inability to identify population-specific risk variants or causal genes

The Taiwanese-Han Endometriosis GWAS exemplifies the value of studying diverse populations, identifying two novel loci (C5orf66/C5orf66-AS2 and STN1) not detected in European studies [36]. This suggests that important aspects of endometriosis genetics remain undiscovered due to limited ancestral diversity in study cohorts.

Methodological Considerations for Diverse Cohort GWAS

Cohort Selection and Recruitment

Designing a GWAS for diverse cohorts requires intentional sampling strategies to ensure adequate representation while maintaining statistical power. Key considerations include:

• Targeted Recruitment: Implement recruitment protocols that specifically target underrepresented ancestral groups through community-engaged approaches and partnerships with healthcare institutions serving diverse populations.
• Sample Size Requirements: Ensure sufficient sample sizes for each ancestral group to detect variants with moderate effect sizes (OR > 1.2) at genome-wide significance. Current disparities are evident in the 60,674 cases of European ancestry versus limited representation of other groups in large consortia [33].
• Phenotypic Harmonization: Apply consistent, detailed phenotyping across all recruitment sites, including:
  • Surgical confirmation of disease (rAFS stage)
  • Symptom characteristics (pain subtypes, infertility)
  • Lesion location (peritoneal, ovarian, deep infiltrating)
  • Treatment response data

Table 2: Recommended Minimum Sample Sizes for Diverse Cohort Endometriosis GWAS

Ancestral Group	Minimum Cases	Minimum Controls	Key Considerations
European	5,000	15,000	Well-powered for common variants
East Asian	3,000	9,000	Include sub-population diversity
African	5,000	15,000	Account for greater genetic diversity
Admixed American	2,000	6,000	Account for recent admixture
South Asian	2,000	6,000	Include regional diversity

Genotyping and Quality Control

Robust genotyping and quality control protocols are essential for diverse cohort GWAS to account for population-specific technical artifacts:

• Genotyping Platform Selection: Utilize arrays with comprehensive content across ancestral groups, such as the Illumina Global Screening Array or Affymetrix Axiom World Array, which include variants informative across diverse populations.
• Ancestry Inference: Implement principal component analysis (PCA) comparing study participants to reference panels (1000 Genomes, HGDP) to verify self-reported ancestry and identify genetic outliers.
• Population Structure Control: Apply genetic relationship matrix (GRM) approaches or PCA covariates in association testing to minimize false positives due to population stratification.
• Variant Filtering: Use ancestry-specific quality control thresholds for call rate, Hardy-Weinberg equilibrium, and minor allele frequency to avoid biased exclusion of variants more common in specific populations.

Figure 1: GWAS Workflow for Diverse Cohorts. Key steps for population diversity (yellow) require special consideration in diverse cohort studies.

Statistical Analysis Approaches

Advanced statistical methods are required to account for genetic diversity while maintaining power:

• Stratified Analysis: Conduct ancestry-stratified analyses followed by meta-analysis to detect population-specific effects. The trans-ancestry meta-analysis of European and East Asian cohorts demonstrated the utility of this approach [33].
• Admixture Mapping: Leverage recent admixture in populations like African Americans and Latin Americans to localize disease susceptibility loci.
• Fine-Mapping: Utilize differences in linkage disequilibrium patterns across populations to improve resolution for identifying causal variants.
• Polygenic Risk Score Assessment: Evaluate portability of PRS across populations and develop methods to improve cross-ancestry prediction.

Analytical Approaches for Cross-Population Genetic Studies

Meta-Analysis Methods for Diverse Cohorts

Meta-analysis combining datasets from diverse ancestral groups requires specialized methods:

• Trans-ancestry meta-analysis: Apply fixed-effects or random-effects models that account for heterogeneity in effect sizes across populations. The endometriosis meta-analysis across European and Japanese populations demonstrated consistent direction of effects for 7 of 9 loci [2].
• Heterogeneity quantification: Calculate metrics such as I² to assess consistency of genetic effects across populations, which provides insights into genetic and environmental interactions.
• Joint analysis methods: Implement approaches like MANTRA (Meta-Analysis of Transethnic Association Studies) that model similarity in effect sizes based on genetic distance between populations.

Functional Annotation and Prioritization

Prioritizing candidate genes from diverse cohort GWAS requires integration of functional genomics data:

• Ancestry-aware eQTL mapping: Integrate population-specific expression quantitative trait loci (eQTL) data from resources like GTEx and eQTLGen to connect risk variants to target genes.
• Epigenetic annotation: Utilize chromatin state maps from diverse endometrial and immune cell types to annotate non-coding risk variants.
• Pathway enrichment analysis: Identify biological pathways consistently enriched across populations versus those specific to particular ancestral groups.

Practical Implementation and Protocols

Multi-Center Collaborative Framework

Successful diverse cohort GWAS requires coordinated multi-center efforts:

• Standardized protocols: Implement consistent data collection, processing, and analysis pipelines across participating sites.
• Data sharing agreements: Establish frameworks for sharing genomic and phenotypic data while protecting participant privacy.
• Ethical oversight: Develop community engagement and oversight structures to ensure culturally appropriate research practices.

Experimental Validation Workflows

Functional validation of identified risk variants requires specialized approaches:

Figure 2: Experimental Validation Workflow. Key functional validation approaches (red) for confirming GWAS findings.

Research Reagent Solutions

Table 3: Essential Research Reagents for Endometriosis GWAS and Functional Validation

Reagent/Category	Specific Examples	Application in Endometriosis GWAS
Genotyping Arrays	Illumina Global Screening Array, Affymetrix Axiom World Array	Genotyping of diverse samples with comprehensive variant coverage
Whole Genome Sequencing	Illumina NovaSeq, PacBio HiFi	Comprehensive variant discovery across populations
Cell Culture Models	Endometrial stromal cells, Endometriotic epithelial cells	Functional validation of risk variants in relevant cell types
Organoid Systems	Endometrial organoids, Endometriosis lesion organoids	3D modeling of disease mechanisms
CRISPR Tools	Cas9 nucleases, Base editors	Functional manipulation of risk variants
Antibodies	Anti-H3K27ac, Anti-ESR1, Anti-WNT4	Chromatin profiling and protein expression analysis
Bioinformatics Tools	PLINK, FINEMAP, SUSIE	Genetic association testing and fine-mapping

Case Studies in Endometriosis GWAS

Taiwanese-Han Population GWAS

The Taiwanese-Han Endometriosis GWAS (2,794 cases, 27,940 controls) exemplifies the value of population-specific studies [36]. This study identified:

• Three shared loci (WNT4, RMND1, CCDC170) previously associated in European and Japanese cohorts, demonstrating cross-population consistency
• Two novel loci (C5orf66/C5orf66-AS2 and STN1) not identified in other populations, highlighting population-specific genetic influences
• Functional network analysis revealing enrichment in cancer susceptibility and neurodevelopmental disorder genes
• Clinical correlation with more severe, infiltrating disease phenotypes in this population

Trans-ancestry Meta-Analysis

The large-scale trans-ancestry meta-analysis of endometriosis (60,674 cases, 701,926 controls) combining European and East Asian datasets demonstrated [33]:

• 42 significant loci with 49 distinct association signals, a threefold increase from previous European-only studies
• Different genetic architectures for ovarian versus superficial peritoneal endometriosis
• Shared genetic basis with other pain conditions, including migraine and back pain
• Tissue-specific regulatory effects through integration with endometrial expression quantitative trait loci (eQTL) data

Advancing Diversity in Endometriosis Genetics

Future efforts to enhance diversity in endometriosis GWAS should prioritize:

• Intentional inclusion of underrepresented populations, particularly African, Indigenous American, and South Asian ancestries
• Deep phenotyping with standardized sub-phenotype categorization across diverse cohorts
• Integration of sequencing to capture rare variants with potentially larger effect sizes
• Multi-omics approaches combining genomics with transcriptomics, epigenomics, and proteomics in diverse tissues

Translational Applications

Genetic discoveries from diverse cohorts have potential translational applications:

• Improved polygenic risk scores that perform accurately across ancestral groups
• Non-invasive diagnostic biomarkers based on population-specific variant profiles
• Novel therapeutic targets informed by biological pathways identified across populations
• Precision medicine approaches tailored to individual genetic backgrounds

In conclusion, advancing diversity in endometriosis GWAS requires methodological rigor, collaborative frameworks, and community engagement. By intentionally designing studies that encompass global genetic diversity, researchers can unravel the complex etiology of endometriosis while addressing persistent health disparities in diagnosis and care. The resulting genetic insights will provide a more comprehensive understanding of this complex disorder and facilitate development of targeted interventions effective across all populations.

Endometriosis is a complex, chronic inflammatory disease affecting approximately 10% of reproductive-aged women globally, characterized by the ectopic presence of endometrial-like tissue [19] [8]. Despite its prevalence and impact on quality of life and fertility, its pathogenesis remains incompletely understood. Genome-wide association studies (GWAS) have identified numerous genetic variants associated with endometriosis risk, but most reside in non-coding regions, complicating the interpretation of their functional significance [19] [11] [8]. Expression quantitative trait locus (eQTL) mapping has emerged as a powerful approach to bridge this gap by identifying genetic variants that regulate gene expression in a tissue-specific manner, thereby providing mechanistic insights into how GWAS-identified risk variants contribute to disease pathophysiology [19] [37] [8]. This technical guide explores how eQTL mapping across multiple tissues is advancing our understanding of endometriosis within the broader context of genetic heterogeneity across populations.

eQTL Fundamentals and Methodological Framework

Core Concepts and Definitions

Expression quantitative trait loci (eQTLs) are genetic variants associated with the expression levels of messenger RNAs [37]. They are classified based on their genomic position relative to the gene they regulate:

• cis-eQTLs: Located near the gene they influence, typically within 1 megabase
• trans-eQTLs: Located far from the target gene, often on different chromosomes
• Splicing QTLs (sQTLs): Genetic variants that specifically affect RNA splicing patterns [38]

The regulatory effect of an eQTL is quantified by its slope value, which indicates the direction and magnitude of the effect on gene expression. For example, a slope of +1.0 indicates a twofold increase in expression, while -1.0 reflects a 50% decrease per alternative allele copy [19] [8].

Experimental Design Considerations

Tissue Selection Rationale

Comprehensive eQTL mapping in endometriosis requires analysis across multiple biologically relevant tissues:

• Repproductive tissues: Uterus, ovary, vagina (direct sites of lesion development)
• Digestive tissues: Sigmoid colon, ileum (common sites of deep infiltrating endometriosis)
• Systemic immune compartment: Peripheral blood (captures inflammatory signals) [19] [8]

This multi-tissue approach enables identification of both shared and tissue-specific regulatory mechanisms, with studies showing that approximately 85% of endometrial eQTLs are present in other tissues, while a minority are endometrium-specific [37].

Sample Size and Power Considerations

Current studies have identified endometrial eQTLs using sample sizes ranging from 206-229 individuals [37] [39]. Power calculations indicate this sample size detects common cis-eQTLs with moderate to large effects, though larger sample sizes are needed for trans-eQTL discovery and rare variant associations.

Standardized Experimental Workflow

The following diagram illustrates the comprehensive workflow for multi-tissue eQTL mapping in endometriosis research:

Detailed Methodological Protocols

Variant Selection and Annotation

Retrieve genome-wide significant endometriosis associations (p < 5 × 10⁻⁸) from GWAS Catalog using ontology identifier EFO_0001065 [19] [8]. Standard processing includes:

• Filtering variants without standardized rsIDs
• Retaining only the entry with the lowest p-value for duplicates
• Functional annotation using Ensembl Variant Effect Predictor (VEP)
• Genomic location classification (intronic, exonic, intergenic, UTR)

eQTL Mapping Statistical Framework

The core statistical analysis employs linear regression models:

• Normalization: Transform raw RNA-seq counts using variance stabilizing transformation
• Covariate adjustment: Include known technical (batch effects, sequencing depth) and biological (age, menstrual stage) covariates
• Genotype encoding: Code genotypes as 0, 1, or 2 alternative alleles
• Association testing: For each variant-gene pair, fit the model: Expression ~ Genotype + Covariates
• Multiple testing correction: Apply false discovery rate (FDR) correction with threshold of FDR < 0.05

For trans-eQTL discovery, use matrix eQTL with more stringent significance thresholds (p < 4.65 × 10⁻¹³) [37].

Tissue-Specificity Assessment

Quantify tissue-specificity using:

• τ statistic: Ranges from 0 (ubiquitous) to 1 (tissue-specific)
• Pairwise correlation of genetic effects across tissues
• Hierarchical clustering of eQTL effect sizes

Integration with Endometriosis GWAS

Colocalization analysis tests whether GWAS signals and eQTLs share causal variants using five hypotheses [40]:

• H₀: No genetic association
• H₁: Association with trait 1 only
• H₂: Association with trait 2 only
• H₃: Association with both traits, different causal variants
• H₄: Association with both traits, shared causal variant

A posterior probability H₄ (PPH₄) > 0.5 indicates significant colocalization.

Key Findings from Multi-Tissue eQTL Studies

Tissue-Specific Regulatory Patterns

Recent multi-tissue eQTL analyses of 465 endometriosis-associated variants revealed striking tissue-specific patterns [19] [8]:

Table 1: Tissue-Specific Functional Enrichment of Endometriosis eQTLs

Tissue	Primary Biological Processes	Key Regulator Genes	Genetic Heterogeneity Considerations
Colon/Ileum	Immune response, epithelial signaling	MICB, CLDN23	Differential allele frequencies across populations may affect risk prediction
Peripheral Blood	Systemic immune activation, inflammatory signaling	Multiple HLA region genes	Population-specific LD patterns influence eQTL detection
Ovary/Uterus	Hormonal response, tissue remodeling, cell adhesion	GATA4, GREB1	Effect sizes may vary across ethnic groups due to modifying factors
Vagina	Cell adhesion, extracellular matrix organization	VEZT, IL6	Understudied in diverse populations

Novel Endometriosis Risk Mechanisms

Splicing QTL Discoveries

sQTL analysis in endometrium has identified 3,296 splicing quantitative trait loci, with 67.5% of genes with sQTLs not discovered in gene-level eQTL analysis [38]. Key findings include:

• GREB1 and WASHC3 significantly associated with endometriosis risk through genetically regulated splicing events
• Transcript isoform-level changes most pronounced in mid-secretory phase in endometriosis
• Tissue-specific alternative splicing provides another layer of genetic regulation

Multi-omic Integration

Multi-omic SMR analysis integrating GWAS, eQTLs, methylation QTLs (mQTLs), and protein QTLs (pQTLs) has identified [40]:

• 196 CpG sites in 78 genes showing causal associations between cell aging and endometriosis
• 18 eQTL-associated genes and 7 pQTL-associated proteins with validated effects
• MAP3K5 gene with contrasting methylation patterns linked to endometriosis risk
• THRB gene and ENG protein validated as risk factors in FinnGen and UK Biobank cohorts

Signaling Pathways in Endometriosis Pathogenesis

The diagram below illustrates key signaling pathways implicated in endometriosis through eQTL studies:

Quantitative Data from Multi-Tissue Analyses

Table 2: Statistical Significance of Key Endometriosis eQTLs Across Tissues

Variant	Gene	Tissue	Slope	FDR	GWAS p-value	Potential Clinical Application
rs10917151	LINC00339	Uterus	-0.42	1.5×10⁻⁶	5×10⁻⁴⁴	Diagnostic biomarker development
rs71575922	MICB	Blood	+0.61	3.2×10⁻⁸	1×10⁻³¹	Immunotherapy target
rs11031005	GREB1	Ovary	+0.53	7.8×10⁻⁷	2×10⁻³²	Hormonal therapy response prediction
rs1903068	VEZT	Vagina	-0.38	2.1×10⁻⁵	7×10⁻²⁷	Prognostic stratification
rs2069840	IL-6	Multiple	+0.47	4.3×10⁻⁶	N/A	Anti-inflammatory therapy target

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Endometriosis eQTL Studies

Reagent/Resource	Function	Example Sources	Technical Considerations
GTEx v8 Database	Reference eQTL data for 54 tissues	GTEx Portal	Uses healthy tissues; may miss disease-specific effects
GWAS Catalog	Curated repository of GWAS results	EBI	Standardized ontology (EFO_0001065 for endometriosis)
1000 Genomes Project	LD reference for diverse populations	International Genome Sample Resource	Population-specific stratification adjustments needed
Ensembl VEP	Functional variant annotation	Ensembl	Critical for non-coding variant interpretation
SMR Software	Multi-omic Mendelian randomization	SMR v1.3.1	Requires large sample sizes for adequate power
coloc R Package	Bayesian colocalization analysis	CRAN	PPH4 > 0.5 indicates shared causal variants
TwoSampleMR	Mendelian randomization framework	CRAN	Uses GWAS summary statistics
FUMA	Functional mapping of genetic variants	fuma.ctglab.nl	Integrates multiple annotation resources

Implications for Genetic Heterogeneity Across Populations

eQTL mapping approaches have revealed critical considerations for understanding genetic heterogeneity in endometriosis across diverse populations:

Population-Specific Regulatory Effects

Studies across different ethnic groups have identified population-specific eQTL effects, with variants showing:

• Differential allele frequencies across populations [12]
• Population-specific linkage disequilibrium patterns affecting eQTL detection
• Varying effect sizes due to modifying genetic and environmental factors

Context-Dependent Regulation

Gene expression in endometrium shows profound variation across the menstrual cycle, with significant effects observed for:

• 2,427/15,262 probes with detectable expression showing cycle stage-dependent mean expression [39]
• 2,877/9,626 probes varying in the proportion of samples expressing them across cycle stages
• Enrichment in estrogen response, epithelial-mesenchymal transition, and KRAS signaling pathways

Evolutionary Perspectives

Analysis of ancient hominin introgressed variants has identified:

• Neandertal-derived regulatory variants in IL-6 (rs2069840, rs34880821) showing enrichment in endometriosis cohorts [11]
• Denisovan-origin variants in CNR1 and IDO1 associated with disease risk
• Co-localization of ancient variants with EDC-responsive regulatory regions

eQTL mapping across tissues has transformed our understanding of endometriosis genetics by providing functional context for GWAS-identified risk variants. The tissue-specific nature of genetic regulation highlighted in these studies underscores the importance of analyzing multiple relevant tissues rather than relying solely on accessible proxies like blood. The integration of eQTL data with other molecular phenotypes (splicing, methylation, protein abundance) through multi-omic approaches has further refined our understanding of pathogenic mechanisms.

Future research directions should include:

• Larger sample sizes from diverse ancestral backgrounds to better understand population-specific genetic effects
• Single-cell eQTL mapping to resolve cellular heterogeneity within tissues
• Dynamic eQTL analyses across menstrual cycle stages and in response to hormonal treatments
• Experimental validation of putative causal genes in model systems
• Development of polygenic risk scores incorporating functional genomic annotations

These advances in functional genomics will ultimately enable more targeted therapeutic development and personalized management approaches for endometriosis across diverse populations.

Polygenic Risk Score Development and Cross-Population Validation

Endometriosis, affecting approximately 10% of reproductive-age women, demonstrates a substantial genetic component with heritability estimates of 47-52% based on twin and family studies [41] [2]. The development of polygenic risk scores (PRS) for endometriosis represents a promising approach for risk prediction, yet significant challenges remain due to genetic heterogeneity across diverse populations. PRS aggregate the effects of many genetic variants into a single measure of genetic liability, providing valuable insights into disease architecture and enabling risk stratification [42]. However, the transferability of PRS across populations remains limited by differences in linkage disequilibrium patterns, allele frequencies, and effect sizes of risk variants between ancestral groups [43]. This technical guide examines current methodologies in PRS development and validation for endometriosis, with particular emphasis on addressing cross-population genetic heterogeneity.

Current State of Endometriosis GWAS and PRS Performance

Evolution of Genetic Discovery Efforts

Genome-wide association studies (GWAS) for endometriosis have progressively expanded in sample size and ancestral diversity. Early GWAS identified initial risk loci in Japanese and European populations [2], while more recent efforts have substantially increased discovery. The largest multi-ancestry GWAS to date includes approximately 1.4 million women (105,869 cases) and has identified 80 genome-wide significant associations, 37 of which are novel [43]. This expansion has significantly improved the genetic characterization of endometriosis and enabled more robust PRS development.

Table 1: Key Endometriosis GWAS Milestones and PRS Performance

Study	Sample Size	Number of Loci	PRS Performance (OR per SD)	Populations
Early GWAS [2]	11,506 cases, 32,678 controls	6 genome-wide significant	Not reported	European, Japanese
Sapkota et al. 2017 [41]	14,926 cases, 189,715 controls	42 loci	1.28-1.59 [42]	European
Multi-ancestry 2025 [43]	~105,869 cases, ~1.4 million total	80 (37 novel)	Cross-ancestry framework developed	African, Admixed American, Central/South Asian, East Asian, European, Middle Eastern

PRS Performance Across Populations

Current endometriosis PRS demonstrate varying performance across ancestral groups. In European populations, PRS shows consistent association with endometriosis risk, with odds ratios (OR) ranging from 1.28 to 1.59 per standard deviation increase [42]. However, PRS developed in European populations typically show reduced performance in non-European populations due to genetic heterogeneity and limited representation in discovery samples [43]. The recent multi-ancestry GWAS represents the first effort to implement a cross-ancestry PRS framework across six ancestry groups (African, Admixed American, Central/South Asian, East Asian, European, and Middle Eastern) to assess predictive performance and genetic transferability [43].

Methodological Framework for PRS Development

The foundation of robust PRS development begins with rigorous processing of GWAS summary statistics. Key steps include:

• Quality Control: Filtering of SNPs based on imputation quality (INFO score > 0.8), minor allele frequency (MAF > 0.01), and removal of strand-ambiguous variants [44].
• Population Stratification Adjustment: Application of linkage disequilibrium score regression to quantify and correct for genomic inflation [45].
• Meta-Analysis: Combination of summary statistics across cohorts using fixed-effects or random-effects models with genomic control [41].

For the recent multi-ancestry GWAS, researchers combined data from eight cohorts across six ancestries, implementing sample-overlap correction between biobanks to prevent inflation of test statistics [43].

PRS Construction Methods

Multiple statistical approaches exist for PRS construction, each with distinct advantages:

• Clumping and Thresholding: Traditional method that selects independent SNPs based on linkage disequilibrium clumping and p-value thresholds [42].
• Bayesian Methods: Approaches like SBayesR adjust effect sizes assuming a normal mixture prior for effect sizes, improving PRS accuracy by accounting for polygenicity [41].
• LD Pred: Infers the posterior mean effect size of each SNP by using a prior on effect sizes and LD information from a reference panel.
• Multi-ancestry Methods: Emerging methods that leverage genetic similarities across populations while accounting for heterogeneity [43].

In practice, SBayesR has been successfully applied to endometriosis PRS development, performed with default settings and exclusion of the MHC region due to its complex LD structure [41].

PRS Calculation in Target Samples

PRS calculation in target datasets requires careful quality control and normalization:

Covariates including principal components (typically 10) and age should be included in association analyses to control for population stratification and confounding [41]. The PRS is often standardized to a z-score (mean=0, SD=1) to facilitate interpretation across studies [41].

Cross-Population Validation Strategies

Analytical Frameworks for Transferability Assessment

Comprehensive cross-population validation involves multiple analytical approaches:

• Genetic Correlation Estimation: Using LD Score regression to estimate the genetic correlation (rg) of endometriosis risk between populations [43].
• Population-Specific Heritability: Calculating SNP-based heritability (h²) within each ancestral group using REML or LD Score regression [43].
• Variance Explained: Quantifying the proportion of disease variance explained by PRS in each population using Nagelkerke's R² or liability scale transformation.

In the recent multi-ancestry study, genetic correlations among European endometriosis cohorts ranged from 0.72 to 1.05, indicating generally consistent genetic architectures across European biobanks [43].

Handling Ancestry-Specific Effects

Several strategies address ancestry-specific genetic effects:

• Ancestry-Specific Effect Size Estimation: Developing PRS using effect sizes estimated within each ancestral group.
• Genetic Architecture Mapping: Identifying regions with heterogeneous effects across populations through meta-regression.
• Variant Inclusion Strategies: Balancing inclusion of population-specific variants versus trans-ancestry variants based on validation performance.

Table 2: Comparison of PRS Validation Approaches Across Populations

Validation Approach	Methodology	Applications in Endometriosis	Limitations
Within-Ancestry	Train and test within homogeneous population groups	European populations in UK Biobank, FinnGen [41] [42]	Limited applicability to underrepresented groups
Cross-Ancestry	Apply PRS trained in one population to different populations	Transferability assessment in multi-ancestry study [43]	Reduced performance due to genetic differences
Multi-ancestry Meta-analysis	Combine GWAS across populations before PRS construction	Recent 80-locus discovery [43]	May miss population-specific variants

Technical Protocols for Key Experiments

Phenome-Wide Association Study (PheWAS) Protocol

PRS-PheWAS examines pleiotropic effects of genetic liability to endometriosis:

• Phenotype Processing: Map ICD-10 codes to phecodes, excluding codes with less than 100 occurrences [41].
• Statistical Analysis: Perform logistic regression for binary traits and linear regression for continuous biomarkers, adjusting for age and principal components.
• Multiple Testing Correction: Apply false discovery rate (FDR) correction across all tested phenotypes.
• Sensitivity Analyses: Conduct stratified analyses by sex [41] and endometriosis diagnosis status.

This approach has revealed that genetic liability to endometriosis associates with lower testosterone levels, suggesting potential causal relationships [41].

Mendelian Randomization for Causal Inference

Two-sample Mendelian randomization assesses potential causal relationships:

• Instrument Selection: Identify genetic variants strongly associated with the exposure (e.g., hormone levels).
• Effect Size Extraction: Obtain genetic association estimates for both exposure and outcome from independent samples.
• MR Analysis: Apply inverse-variance weighted, MR-Egger, and weighted median methods to estimate causal effects.
• Sensitivity Analyses: Assess pleiotropy using MR-PRESSO and Egger intercept tests.

This method has suggested that lower testosterone may be causal for both endometriosis and clear cell ovarian cancer [41].

Signaling Pathways and Biological Mechanisms

Figure 1: Endometriosis Genetic Risk Pathways. Genetic risk variants influence disease through multiple biological pathways, with recent evidence highlighting testosterone reduction as a potential causal mechanism [41] [43].

The biological pathways implicated by endometriosis genetics include:

• WNT Signaling: Multiple loci near WNT4 and other WNT signaling genes suggest involvement in developmental patterning of reproductive tissues [2] [45].
• Hormone Regulation: Genetic associations with ESR1 and other hormone-related genes underscore the estrogen-dependent nature of endometriosis [45].
• Immune Function: Associations in regions involved in immune regulation highlight the inflammatory component of endometriosis pathogenesis [43].
• Tissue Remodeling: Genes involved in extracellular matrix organization and cell adhesion contribute to lesion establishment and growth [43].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Endometriosis PRS Studies

Reagent/Resource	Function	Example Use Cases	Specific Examples
Genotyping Arrays	Genome-wide variant detection	Initial genotyping in biobanks	Illumina Global Screening Array [44]
Imputation Reference Panels	Inference of ungenotyped variants	Increasing variant coverage	TOPMed [44], 1000 Genomes Project [45]
Bioinformatics Tools	PRS development and analysis	Statistical analysis and visualization	PLINK [41] [42], GCTB [41], FlashPCA [44]
Biobank Data	Large-scale phenotypic and genetic data	Validation cohorts	UK Biobank [41], FinnGen [41], Estonian Biobank [46]
Functional Genomics Data	Biological interpretation of risk loci	Colocalization and pathway analysis	GTEx [45], ENCODE [2]

Clinical Applications and Comorbidity Interactions

Risk Prediction Performance

Current endometriosis PRS demonstrate modest but significant predictive performance:

• In European populations, PRS based on 14 SNPs showed ORs of 1.50-1.59 per standard deviation in Danish cohorts and 1.28 in the UK Biobank [42].
• The area under the curve (AUC) for models combining PRS with clinical factors reaches approximately 0.75, suggesting potential clinical utility for risk stratification [47].
• PRS performance varies by endometriosis subtype, with stronger associations for ovarian (OR=1.72) and infiltrating (OR=1.66) disease compared to peritoneal (OR=1.51) forms [42].

Comorbidity Interactions and Pleiotropy

PRS-PheWAS analyses reveal significant interactions between genetic risk and comorbidities:

• Endometriosis PRS correlates with higher comorbidity burden even in undiagnosed women, suggesting shared genetic mechanisms [41] [46].
• Significant interactions occur between endometriosis PRS and diagnoses of uterine fibroids, heavy menstrual bleeding, and dysmenorrhea [46].
• The presence of certain comorbidities (e.g., uterine fibroids) amplifies endometriosis risk more substantially in individuals with high PRS [46].

Future Directions and Clinical Translation

Addressing Diversity Gaps in PRS

Current limitations in cross-population PRS performance necessitate:

• Increased Diversity in Genetic Studies: Purposeful inclusion of underrepresented populations in endometriosis genetics research.
• Development of Trans-ancestry Methods: Statistical approaches that leverage genetic similarities while accounting for heterogeneity.
• Local Ancestry Inference: Integration of fine-scale population structure to improve PRS portability.

Integration with Clinical Risk Factors

Optimizing clinical utility requires:

• Combined Risk Models: Integration of PRS with established risk factors (age, BMI, reproductive history) [47].
• Symptom-Specific PRS: Development of PRS tailored to predict specific clinical presentations or subtypes [44].
• Longitudinal Validation: Assessment of PRS performance in prospective cohorts for incident disease prediction.

The continued expansion of diverse genetic studies, coupled with methodological innovations in PRS construction, will enhance cross-population applicability and move the field closer to clinically implementable genetic risk stratification for endometriosis.

Endometriosis, a complex gynecological disorder affecting approximately 10% of reproductive-age women globally, demonstrates a substantial genetic component with twin-based heritability estimated at 50% and single nucleotide polymorphism (SNP)-based heritability of approximately 8% [43]. Genetic heterogeneity across diverse populations presents a significant challenge in translating genome-wide association study (GWAS) findings into functional biological insights and clinical applications [22]. Recent multi-ancestry genomic analyses reveal that while many genetic risk factors are shared across populations, notable differences exist in allele frequencies and effect sizes of endometriosis-risk variants among European, African, East Asian, South Asian, and Admixed American populations [43] [22]. This heterogeneity impacts the transferability of polygenic risk scores and complicates the identification of causal mechanisms. The integration of multi-omics data—encompassing genomics, transcriptomics, epigenomics, and proteomics—has emerged as a powerful approach to transcend these limitations by connecting genetic variants to their functional consequences across biological layers, thereby illuminating the pathophysiological pathways underlying endometriosis and enabling the development of targeted therapeutic strategies.

Core Multi-Omics Technologies and Data Types

The integration of multiple omics technologies provides a comprehensive framework for bridging genetic associations with functional mechanisms in endometriosis pathogenesis. Below is a summary of the primary omics layers used in contemporary research.

Table 1: Core Multi-Omics Data Types in Endometriosis Research

Omics Layer	Data Description	Key Technologies	Primary Insights
Genomics	Genome-wide sequence variants associated with disease risk	GWAS, SNP arrays, NGS	Identification of risk loci (e.g., WNT4, VEZT, ESR1); polygenic risk scores; population-specific variants [1] [2] [22]
Epigenomics	Chemical modifications to DNA that regulate gene expression without altering sequence	Methylation arrays (mQTLs), ChIP-seq	Differential methylation patterns (e.g., MAP3K5); histone modifications; regulatory elements [1] [40]
Transcriptomics	Genome-wide gene expression levels and regulation	RNA-seq, microarrays, eQTL mapping	Differentially expressed genes; pathway dysregulation (e.g., hormone signaling, inflammation) [1] [48] [49]
Proteomics	Protein abundance, modifications, and interactions	Mass spectrometry, pQTL mapping	Dysregulated protein networks; signaling pathway alterations; biomarker discovery [40] [49]

The power of multi-omics integration lies in connecting variations across these biological layers. For example, a genetic variant identified through GWAS might be associated with altered DNA methylation (mQTL), which in turn influences gene expression (eQTL), ultimately affecting protein abundance (pQTL) and cellular function [40]. This integrative approach moves beyond mere association to reveal the causal pathways through which genetic variants contribute to disease pathogenesis.

Methodological Framework for Multi-Omics Integration

The Summary-based Mendelian Randomization (SMR) approach integrates GWAS summary data with molecular QTLs (eQTLs, mQTLs, pQTLs) to test for potential causal effects of gene expression or DNA methylation on complex traits [40]. The method uses significant cis-QTLs as instrumental variables to test if the molecular phenotype (e.g., gene expression or DNA methylation) has a causal effect on the complex trait (endometriosis).

The SMR test statistic follows a χ² distribution with one degree of freedom:

where b{xy} is the estimated effect of the molecular phenotype on the trait, and SE{b_{xy}} is its standard error.

The HEterogeneity In Dependent Instruments (HEIDI) test is subsequently applied to distinguish pleiotropy from linkage:

where b{xyi} is the effect estimate for the i-th SNP. A significant HEIDI test (P < 0.05) suggests the presence of linkage, indicating multiple causal variants in the region, while a non-significant result supports a single causal variant driving both the QTL and GWAS signals [40].

Colocalization Analysis

Colocalization analysis assesses whether two traits share the same causal variant within a genomic region by evaluating five mutually exclusive hypotheses using Bayesian methods [40]:

• H0: No association with either trait
• H1: Association with trait 1 only
• H2: Association with trait 2 only
• H3: Association with both traits, but different causal variants
• H4: Association with both traits, with a single shared causal variant

A posterior probability for H4 (PPH4) > 0.5 provides strong evidence for colocalization, suggesting the same underlying genetic variant influences both the molecular QTL and endometriosis risk [40].

Functional Genomics Workflows

Functional genomic validation typically follows a structured workflow that proceeds from genetic association to mechanistic insight. The diagram below illustrates this multi-step process.

Population-Stratified Analytical Approaches

Addressing genetic heterogeneity requires specialized methods for cross-population analyses:

Genetic Correlation Analysis: LD Score Regression (LDSC) estimates genetic correlation (rg) between ancestry groups to quantify transferability of risk variants [43].

Ancestry-Aware Fine-Mapping: Methods like SUSIE and FINEMAP account for population-specific linkage disequilibrium patterns to identify causal variants with greater accuracy [43].

Cross-Ancestry Polygenic Risk Scores: PRS-CSx and similar methods leverage genetic architecture across diverse populations to improve risk prediction accuracy in underrepresented groups [43].

Key Findings from Integrated Multi-Omics Studies

Cell Aging-Related Genes in Endometriosis Pathogenesis

A recent multi-omic SMR analysis integrating GWAS data with QTLs from 949 cell aging-related genes identified 196 CpG sites in 78 genes, 18 eQTL-associated genes, and 7 pQTL-associated proteins with causal associations to endometriosis [40]. Notable findings include:

• The MAP3K5 gene displayed contrasting methylation patterns linked to endometriosis risk, where specific methylation sites downregulate gene expression, heightening disease susceptibility [40].
• Validation in FinnGen R10 and UK Biobank cohorts confirmed THRB gene and ENG protein as significant risk factors [40].
• Cell aging pathways contribute to endometriosis maintenance through creation of a pro-inflammatory environment via the senescence-associated secretory phenotype (SASP), which sustains lesion development and inflammation [40].

Large-Scale Multi-Ancestry GWAS and Functional Annotation

A groundbreaking multi-ancestry GWAS of ∼1.4 million women (including 105,869 cases) identified 80 genome-wide significant associations, 37 of which are novel, including the first five loci reported for adenomyosis [43] [13]. Key findings include:

• Fine-mapping and colocalization analyses uncovered causal loci for over 50 endometriosis-related associations [43].
• Multi-omics integration revealed that genetic variation influences endometriosis risk through transcriptomic, epigenetic, and proteomic regulation across multiple tissues [43].
• These convergent findings implicate pathways involved in immune regulation, tissue remodeling, and cell differentiation [43].
• Drug-repurposing analyses highlighted potential therapeutic interventions currently used for breast cancer and preterm birth prevention [43].

Signaling Pathways Implicated Through Multi-Omics Integration

Multiple omics layers consistently highlight several core pathways in endometriosis pathogenesis. The diagram below illustrates the MAP3K5 signaling pathway identified through multi-omics analyses.

Table 2: Key Signaling Pathways Identified Through Multi-Omics Integration in Endometriosis

Pathway	Genetic Evidence	Transcriptomic/Epigenetic Evidence	Functional Consequences
Sex Steroid Hormone Signaling	GWAS loci near ESR1, CYP19A1, WNT4 [1] [2]	Differential expression of hormone receptors; methylation of promoter regions [1] [49]	Estrogen dominance; progesterone resistance; altered decidualization [49]
Immune Regulation	Variants near cytokine/chemokine receptors [48]	Dysregulated NF-κB signaling; altered macrophage polarization [48] [49]	Chronic inflammation; impaired immune surveillance; SASP [40] [49]
Tissue Remodeling & Cell Adhesion	VEZT, FN1 loci [2]	Altered extracellular matrix organization; focal adhesion pathway enrichment [48] [49]	Enhanced invasion capability; fibrosis; pelvic adhesions [49]
MAPK Signaling	MAP3K5 locus [40]	Methylation-mediated MAP3K5 downregulation [40]	Increased cell survival; resistance to apoptosis; inflammation [40]

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 3: Essential Research Reagents for Multi-Omics Studies in Endometriosis

Reagent Category	Specific Examples	Research Application	Key Considerations
Genotyping Platforms	Illumina Global Screening Array, Infinium Asian Screening Array	GWAS in diverse populations [43] [22]	Population-specific content; imputation quality [22]
Methylation Arrays	Illumina Infinium MethylationEPIC	Genome-wide methylation profiling (mQTL mapping) [40]	Coverage of regulatory elements; tissue specificity [40]
Expression Assays	RNA-seq kits (Illumina); Nanostring nCounter	Transcriptomic profiling; eQTL mapping [1] [48]	Sample preservation; single-cell resolution [48]
Protein Analysis	Olink panels; mass spectrometry kits	Proteomic profiling; pQTL mapping [40]	Sensitivity for low-abundance proteins [40]
Functional Validation	CRISPR/Cas9 systems; siRNA libraries; organoid culture media	Mechanistic validation of candidate genes [40]	Physiological relevance; model system limitations [40]

The integration of multi-omics data represents a paradigm shift in endometriosis research, moving beyond simple genetic associations to reveal the functional consequences of risk variants across biological layers. This approach has been particularly valuable for addressing the challenge of genetic heterogeneity across diverse populations, demonstrating both shared and population-specific pathogenic mechanisms. The convergence of findings across omics technologies on pathways involving immune regulation, hormone signaling, and tissue remodeling provides strong validation of these processes as central to endometriosis pathogenesis.

Future directions in the field include the development of more sophisticated cross-population analytical methods, the incorporation of single-cell multi-omics technologies to resolve cellular heterogeneity within endometriotic lesions, and the integration of spatial omics to contextualize molecular interactions within tissue architecture. Furthermore, the translation of these multi-omics insights into clinical applications—including improved diagnostic biomarkers, refined polygenic risk scores applicable across ancestries, and novel therapeutic targets—represents the ultimate promise of this integrative approach. As multi-omics technologies continue to advance and become more accessible, they will undoubtedly deepen our understanding of endometriosis pathogenesis and accelerate the development of personalized approaches for diagnosis and treatment.

Mendelian Randomization for Causal Inference in Therapeutic Target Identification

Endometriosis, a chronic inflammatory condition characterized by the presence of endometrial-like tissue outside the uterus, affects approximately 5-10% of women of reproductive age worldwide and presents substantial diagnostic and therapeutic challenges [1]. The condition demonstrates a significant heritable component, estimated at around 52% based on twin studies, prompting extensive genetic investigations to unravel its pathogenesis [2]. Genome-wide association studies (GWAS) have successfully identified multiple genetic loci associated with endometriosis risk, yet translating these associations into causal mechanisms and therapeutic targets requires advanced analytical approaches that can distinguish correlation from causation [2] [1].

Mendelian randomization (MR) has emerged as a powerful epidemiological technique that uses genetic variants as instrumental variables to assess causal relationships between modifiable risk factors and disease outcomes [50] [51]. By leveraging the random allocation of genetic variants at conception, MR mimics a natural randomized controlled trial, offering protection against confounding factors and reverse causation that often plague conventional observational studies [50]. In the context of therapeutic target identification, MR provides a robust framework for prioritizing drug targets by assessing whether proteins, metabolites, or other molecular traits have causal effects on disease pathogenesis [52] [53] [54].

The application of MR in endometriosis research is particularly relevant given the genetic heterogeneity observed across populations and the complex, multifactorial nature of the disease [2] [1]. This technical guide explores the core principles, methodological considerations, and practical applications of MR for causal inference in endometriosis therapeutic target identification, with particular emphasis on addressing genetic heterogeneity in GWAS across diverse populations.

Fundamental Principles of Mendelian Randomization

Core Assumptions and Instrumental Variable Framework

Mendelian randomization relies on genetic variants serving as valid instrumental variables (IVs) to estimate causal effects. For a genetic variant to be considered a valid IV, it must satisfy three critical assumptions [50]:

• Relevance Assumption: The genetic variant must be strongly associated with the exposure of interest (e.g., protein abundance, metabolite level).
• Independence Assumption: The genetic variant must not be associated with confounders of the exposure-outcome relationship.
• Exclusion Restriction Assumption: The genetic variant must affect the outcome only through the exposure, not via alternative pathways.

These assumptions form the theoretical foundation for causal inference in MR analyses. When satisfied, genetic variants can be used as proxies for modifiable exposures to estimate their causal effects on disease outcomes [50] [51].

Figure 1: Core assumptions of Mendelian randomization analysis. Genetic variants must be associated with the exposure (relevance), not associated with confounders (independence), and affect the outcome only through the exposure (exclusion restriction).

Genetic Architecture and Instrument Selection

The selection of appropriate genetic instruments is crucial for valid MR inference. For endometriosis, several GWAS have identified multiple susceptibility loci that can be leveraged as instruments. To date, eight GWAS and replication studies from multiple populations have identified several genome-wide significant loci, including rs12700667 on 7p15.2, rs7521902 near WNT4, rs10859871 near VEZT, rs1537377 near CDKN2B-AS1, rs7739264 near ID4, and rs13394619 in GREB1 [2]. These variants can serve as instruments when investigating potential causal relationships.

The strength of genetic instruments is typically assessed using the F-statistic, with values greater than 10 indicating sufficient strength to minimize weak instrument bias [54]. When using multiple genetic variants, it is essential to ensure their independence through linkage disequilibrium (LD) clumping (typically r² < 0.001 within a 1 Mb window) [54].

Table 1: Key Genetic Loci Associated with Endometriosis Risk from GWAS

Locus	Nearest Gene	Risk Allele	Odds Ratio	P-value	Biological Function
7p15.2	Intergenic	rs12700667	1.22	1.6 × 10⁻⁹	Regulatory region
1p36.12	WNT4	rs7521902	1.15	1.8 × 10⁻¹⁵	Developmental pathways
12q22	VEZT	rs10859871	1.20	4.7 × 10⁻¹⁵	Cell adhesion
9p21.3	CDKN2B-AS1	rs1537377	1.12	1.5 × 10⁻⁸	Cell cycle regulation
6p22.3	ID4	rs7739264	1.14	6.2 × 10⁻¹⁰	Transcription factor
2p25.1	GREB1	rs13394619	1.11	4.5 × 10⁻⁸	Estrogen regulation

Methodological Approaches for Robust MR Analysis

Analytical Frameworks and Sensitivity Analyses

Several analytical methods have been developed to implement MR analysis, each with specific assumptions and applications. The inverse-variance weighted (IVW) method represents the standard approach, which combines the ratio estimates from multiple genetic variants in a meta-analysis framework [51]. However, when the instrumental variable assumptions are violated, alternative methods that are robust to certain violations should be employed.

Key sensitivity analyses include [50]:

• MR-Egger regression: Tests and corrects for directional pleiotropy under the Instrument Strength Independent of Direct Effect (InSIDE) assumption
• Weighted median estimator: Provides consistent estimates if at least 50% of the weight comes from valid instruments
• MR-PRESSO: Identifies and removes outliers among the genetic variants
• Contamination mixture method: Robustly handles invalid instruments under the "plurality of valid instruments" assumption [51]

The contamination mixture method, in particular, offers advantages in scenarios with multiple invalid instruments by identifying groups of genetic variants with similar causal estimates and performing MR robustly in the presence of invalid instruments [51].

Addressing Genetic Heterogeneity Across Populations

Genetic heterogeneity in endometriosis GWAS across populations presents both challenges and opportunities for MR analyses. Meta-analyses of endometriosis GWAS have shown remarkable consistency in results across studies of European and Japanese ancestry, with little evidence of population-based heterogeneity for most loci [2]. However, two independent inter-genic loci on chromosome 2 (rs4141819 and rs6734792) showed significant evidence of heterogeneity across datasets [2].

To account for genetic heterogeneity in MR analyses, several approaches can be employed:

• Stratified analyses: Conducting MR within ancestral groups and comparing estimates
• Heterogeneity tests: Using Cochran's Q statistic to assess heterogeneity between genetic variants
• Random-effects models: Incorporating between-variant heterogeneity into the analysis
• Cross-population validation: Replicating findings in independent populations

Recent studies have emphasized that most endometriosis risk loci show stronger associations with revised American Fertility Society (rAFS) Stage III/IV disease, highlighting the importance of detailed sub-phenotype information in future studies [2].

Experimental Protocols for MR in Target Identification

The SMR method integrates GWAS summary data with molecular quantitative trait loci (QTLs) to test for causal effects of gene expression or protein abundance on complex traits [52]. The protocol involves:

Step 1: Data Collection and Harmonization

• Obtain GWAS summary statistics for endometriosis from large consortia (e.g., FinnGen, UK Biobank)
• Acquire expression QTL (eQTL) or protein QTL (pQTL) data from relevant resources (e.g., GTEx, deCODE, UKB-PPP)
• Harmonize effect alleles across datasets ensuring consistent strand orientation

Step 2: Instrument Selection

• Select cis-acting QTLs (typically within ±1 Mb of gene transcription start site)
• Apply genome-wide significance threshold (P < 5 × 10⁻⁸)
• Ensure independence of instruments (LD r² < 0.001)
• Calculate F-statistic to assess instrument strength (F > 10)

Step 3: SMR Analysis

• Perform SMR test using the z-test approach: ZSMR = (bᵧ/bₓ) / √(SEᵧ²/bₓ² + bᵧ²·SEₓ²/bₓ⁴) where bₓ and SEₓ are the QTL effect and standard error, and bᵧ and SEᵧ are the GWAS effect and standard error
• Apply false discovery rate (FDR) correction for multiple testing (typically FDR < 0.05)

Step 4: Heterogeneity in Dependent Instruments (HEIDI) Test

• Conduct HEIDI test to distinguish linkage from pleiotropy
• Use multiple SNPs in the target gene region to test for heterogeneity
• Exclude associations with PHEIDI ≤ 0.05 as likely due to linkage

Figure 2: Summary-data-based Mendelian randomization workflow for therapeutic target identification.

Colocalization Analysis Protocol

Colocalization analysis determines whether genetic associations for two traits (e.g., protein abundance and endometriosis) share a common causal variant, providing stronger evidence for causal relationships [52] [55]. The standard protocol includes:

Step 1: Define Genomic Region

• Select a window around the candidate gene (typically ±100 kb to ±1 Mb)
• Extract all variants in the region from both GWAS and QTL datasets

Step 2: Bayesian Colocalization

• Implement using the coloc R package with default priors:
  • p1: 1×10⁻⁴ (prior probability SNP associated with trait 1)
  • p2: 1×10⁻⁴ (prior probability SNP associated with trait 2)
  • p12: 1×10⁻⁵ (prior probability SNP associated with both traits)
• Calculate posterior probabilities for five hypotheses:
  • H0: No association with either trait
  • H1: Association with trait 1 only
  • H2: Association with trait 2 only
  • H3: Association with both traits, different causal variants
  • H4: Association with both traits, shared causal variant

Step 3: Interpretation

• Consider PPH4 > 0.8 as strong evidence for colocalization
• PPH4 > 0.6 as moderate evidence for colocalization
• Visually inspect regional association plots to confirm findings

Application to Endometriosis Therapeutic Target Discovery

Identified Candidate Targets and Evidence Assessment

Recent MR studies have identified several promising therapeutic targets for endometriosis. These candidates are prioritized based on the strength of MR evidence, colocalization support, and biological plausibility.

Table 2: Promising Therapeutic Targets for Endometriosis Identified through MR Studies

Target Gene	MR Evidence	Colocalization (PPH4)	Biological Function	Therapeutic Implications
EPHB4	PFDR < 0.05	0.99	Tyrosine kinase receptor, angiogenesis	EPHB4 inhibitors may suppress lesion growth [52]
RSPO3	PFDR < 0.001	0.78-0.87	Wnt signaling activation	Multiple independent validations [53] [54]
CD109	PFDR < 0.05	<0.6	TGF-β signaling regulation	Potential immunomodulatory target [52]
FN1	P = 8 × 10⁻⁸ (Stage III/IV)	NA	Extracellular matrix protein	Highest connectivity in PPI networks [2] [53]
WNT7A	Significant MR	NA	Wnt signaling pathway	Multiple Wnt pathway members implicated [55]
GREB1	P = 4.5 × 10⁻⁸	NA	Estrogen-regulated gene	Links estrogen signaling to pathogenesis [2]

Integration of Evidence Across Study Designs

To establish robust evidence for potential therapeutic targets, a tiered system integrating multiple lines of evidence has been proposed [52]:

Tier 1 Genes: Show significant associations at protein abundance level in both deCODE and UKB-PPP studies (P < 0.05) with high-level evidence of colocalization (PPH4 > 0.80) Tier 2 Genes: Show significant associations in one protein study with moderate colocalization evidence (0.6 < PPH4 ≤ 0.8) Tier 3 Genes: Show significant associations in one protein study with low colocalization evidence (PPH4 ≤ 0.6)

This systematic approach ensures that only the most promising targets with strong genetic support advance to experimental validation.

Table 3: Key Research Reagent Solutions for MR Studies in Endometriosis

Resource Type	Specific Examples	Function in MR Analysis	Access Information
GWAS Summary Statistics	FinnGen R10 (16,588 cases/111,583 controls), UK Biobank (3,809 cases/459,124 controls)	Outcome data for endometriosis	FinnGen: https://finngen.fi/, UK Biobank: https://www.ukbiobank.ac.uk/
pQTL Datasets	deCODE (4,907 proteins/35,559 individuals), UKB-PPP (2,923 proteins/54,219 participants)	Exposure data for plasma proteins	deCODE: https://www.decode.com/summarydata/, UKB-PPP: https://registry.opendata.aws/ukbppp/
eQTL Datasets	GTEx V8 (838 donors/49 tissues), eQTLGen (31,684 individuals)	Exposure data for gene expression	GTEx: https://gtexportal.org/, eQTLGen: https://eqtlgen.org/
Software Packages	TwoSampleMR, MRBase, coloc, SMR	Implement various MR methods and sensitivity analyses	CRAN: https://cran.r-project.org/, GitHub repositories
Experimental Validation Kits	Human R-Spondin3 ELISA Kit, EPHB4 ELISA Kit	Validate protein levels in clinical samples	Commercial suppliers (e.g., BOSTER Biological Technology)

Validation Strategies and Clinical Translation

Experimental Validation of MR Findings

The transition from computational prediction to biologically validated targets requires rigorous experimental follow-up. Standard validation protocols include:

Protein Level Assessment

• Collect plasma and tissue samples from endometriosis patients and controls
• Measure target protein concentrations using ELISA kits
• Compare protein abundance between cases and controls (typically n=20-30 per group)
• Perform statistical tests (t-tests or Mann-Whitney U tests) with P < 0.05 considered significant

Gene Expression Analysis

• Isolate peripheral blood mononuclear cells (PBMCs) or tissue samples
• Extract total RNA and synthesize cDNA
• Perform quantitative RT-PCR with target-specific primers
• Normalize expression to reference genes (e.g., GAPDH, ACTB)
• Analyze using the 2^(-ΔΔCt) method with appropriate statistical testing

For example, recent studies have validated EPHB4 findings by demonstrating significantly higher EPHB4 protein abundance in plasma and mRNA expression levels in PBMCs of endometriosis patients compared to controls (P < 0.05) [52].

Considerations for Drug Development

When evaluating MR-identified targets for drug development, several factors should be considered:

• Druggability: Assess whether the target belongs to druggable gene families (e.g., kinases, membrane receptors)
• Safety Profile: Evaluate potential on-target side effects using phenome-wide scans
• Biological Plausibility: Consider established biological pathways in endometriosis pathogenesis
• Existing Therapeutics: Investigate whether drugs targeting related pathways already exist

The DRUGBANK database provides valuable information on FDA-approved drugs, drugs in clinical trials, and experimental drugs, facilitating drug target prediction for MR-identified genes [52].

Addressing Challenges and Limitations

Methodological Challenges in MR for Endometriosis

Several methodological challenges require careful consideration when applying MR to endometriosis research:

Horizontal Pleiotropy Genetic variants influencing endometriosis risk through multiple pathways can violate MR assumptions. Robust methods like MR-Egger, weighted median, and contamination mixture methods help mitigate this issue [50] [51].

Sample Overlap Overlapping samples in exposure and outcome datasets can introduce bias. Two-sample MR with independent samples is preferred, and correlation between estimates should be accounted for when present.

Genetic Heterogeneity Differences in genetic effects across populations can affect transferability of findings. Trans-ancestry MR and careful consideration of population structure are essential [2] [1].

Power Considerations MR studies require substantial sample sizes to detect moderate effects. Power calculations should precede analysis, and collaborative efforts like the International Endometriosis Genomics Consortium provide the necessary scale [2].

Future Directions

Emerging methodologies and data resources will enhance MR applications in endometriosis research:

• Multivariate MR: Assessing multiple related exposures simultaneously
• Non-linear MR: Exploring non-linear causal relationships
• Network MR: Integrating multiple omics layers (genomics, transcriptomics, proteomics)
• Cell-type-specific MR: Leveraging single-cell QTL resources
• Long-read sequencing: Improving characterization of structural variants in endometriosis susceptibility regions

As GWAS sample sizes continue to grow and functional genomics resources expand, MR will play an increasingly important role in translating genetic discoveries into therapeutic advances for endometriosis.

Navigating Analytical Challenges: Optimizing Genetic Studies Across Diverse Populations

Addressing Population Stratification and Confounding in Mixed Cohorts

Population stratification (PS) is a fundamental consideration in genetic association studies that, if unaddressed, can introduce severe confounding and generate spurious associations. PS arises from systematic differences in allele frequencies between subpopulations due to non-random mating patterns, often stemming from geographic isolation or cultural boundaries over multiple generations [56]. In the specific context of endometriosis research, this challenge is particularly acute. Endometriosis is a complex, heterogeneous gynecological condition affecting approximately 10% of reproductive-aged women globally, with a heritability estimated at around 52% [2] [11]. The genetic architecture underlying endometriosis risk has been progressively illuminated through genome-wide association studies (GWAS), yet these discoveries have predominantly emerged from populations of European ancestry, creating critical gaps in understanding across diverse genetic backgrounds [43].

The problem of confounding in mixed cohorts manifests when both genetic variant frequencies and disease prevalence differ across subpopulations within a study. This structure can create non-causal associations between variants and the disease, potentially leading to false positive findings or obscuring true associations [56] [57]. As genetic studies of endometriosis expand to include more diverse populations and leverage larger, mixed cohorts to increase power, the sophisticated application of methods to detect and correct for population stratification becomes indispensable for generating biologically valid and clinically translatable results [43] [58].

Understanding Population Stratification: Causes and Consequences

Genetic Drivers of Population Structure

Population stratification originates from historical demographic processes that create distinct genetic lineages. As human populations expanded from Africa approximately 50,000-100,000 years ago, geographic separation, adaptation to novel environments, and genetic drift led to the differentiation of allele frequencies across subpopulations [56]. Even subtle differences in allele frequencies can confound genetic associations when there are corresponding differences in disease prevalence between subpopulations.

Measures of genetic differentiation quantify these population differences. The fixation index (Fst) compares differences in expected heterozygosity across populations under Hardy-Weinberg Equilibrium, with values ranging from 0-0.05 indicating little differentiation to values greater than 0.25 indicating very great differentiation [56]. Another measure, allele sharing distance (ASD), provides a pairwise measure among subjects across multiple markers [56]. These metrics help researchers identify the presence and magnitude of population structure within their datasets.

The Problem of Admixture

Genetic admixture presents particular challenges and opportunities in association studies. Admixed populations, such as African Americans or Hispanic/Latino individuals, inherit genomic segments from multiple ancestral source populations [56] [58]. This ancestral mosaic can create structured associations between unlinked genetic variants—if a disease has different prevalence rates across ancestral populations, and certain genetic variants have different frequencies in those populations, spurious associations can emerge in analyses that fail to account for this structure [56].

Table 1: Common Measures of Genetic Differentiation

Measure	Calculation	Interpretation	Application
Fst	Fst = (Ht-Hs)/Ht, where Ht is total expected heterozygosity and Hs is subpopulation heterozygosity	0-0.05: Little differentiation; 0.05-0.15: Moderate; 0.15-0.25: Great; >0.25: Very great differentiation	Quantifying population divergence; identifying selection signatures
Allele Sharing Distance (ASD)	Sum of differences in allele sharing across markers between two individuals	Larger values indicate more distant genetic relationships; sensitive to recent shared ancestry	Clustering individuals; identifying cryptic relatedness
Ancestry Informative Markers (AIMs)	SNPs with large frequency differences between ancestral populations	Maximize ability to differentiate populations in admixed samples	Correcting for population structure in association tests

Methodological Approaches for Detecting and Correcting Stratification

Detection Methods

Detecting population stratification represents the essential first step in addressing it. Several established approaches exist:

Principal Components Analysis (PCA) is among the most widely used methods for detecting and visualizing population structure. PCA reduces genetic data to a set of orthogonal axes (principal components) that capture the greatest axes of genetic variation in the dataset. These components often correlate with geographic ancestry and can be included as covariates in association analyses to correct for stratification [56] [57]. PCA effectively controls for stratification in many scenarios, particularly when using common variants across the genome.

Global Ancestry Inference methods estimate the proportional ancestry of each individual from predefined ancestral populations. Software like ADMIXTURE and STRUCTURE use Bayesian approaches to estimate these proportions, which can then be used as covariates [56]. Unlike PCA, which identifies continuous axes of variation, these methods typically assume discrete ancestral populations.

Local Ancestry Inference is particularly relevant in admixed populations, where each genomic region may have distinct ancestry. Methods like RFMix and LAMP estimate the ancestry of each chromosomal segment, enabling ancestry-aware association tests that account for the mosaic nature of admixed genomes [58].

Correction Methods in Association Analyses

Once detected, population structure can be accounted for using several statistical approaches:

Mixed Models have become the standard for correcting population stratification and cryptic relatedness in GWAS. Linear Mixed Models (LMMs) and Generalized Linear Mixed Models (GLMMs) incorporate a genetic relationship matrix (GRM) as a random effect to account for the phenotypic covariance between individuals due to genetic similarities [57].

Table 2: Mixed Model Approaches for Population Stratification Correction

Method	Model Type	Key Features	Performance in EPS
GMMAT	Generalized Linear Mixed Model (GLMM)	Fits logistic mixed model to binary data; robust to sampling scheme	Controls type I error rate in extreme phenotype sampling [57]
LEAP	Liability Threshold Mixed Model	Estimates latent liabilities under threshold model; models case-control ascertainment	Controls type I error rate in extreme phenotype sampling [57]
CARAT	Retrospective Model	Uses quasi-likelihood approach; models case-control status retrospectively	Inflated type I error in extreme phenotype sampling [57]
GEMMA	Linear Mixed Model (LMM)	Treats binary traits as continuous; computationally efficient	Controls type I error but may lose power for binary traits [57]

Liability Threshold Models assume that binary disease outcomes reflect an underlying continuous liability distribution, with disease manifesting when liability exceeds a threshold. These methods, implemented in tools like LEAP and LTMLM, are particularly suited to case-control studies [57].

Genomic Control provides a straightforward correction by inflating the test statistic distribution to account for residual stratification. While simple, it may be overly conservative and does not eliminate stratification-induced bias [57].

Special Considerations for Study Designs

Extreme Phenotype Sampling (EPS) presents particular challenges for population stratification correction. EPS designs, which selectively genotype individuals at the extremes of a phenotype distribution to increase power, can substantially inflate false positive rates due to population stratification [57]. Simulation studies show that methods like GMMAT and LEAP adequately control type I error in EPS designs, while CARAT demonstrates inflated false positive rates [57]. For rare variants, the false positive rate may remain inflated even after mixed model correction, requiring additional caution [57].

Multi-ancestry and Admixed Cohorts require specialized approaches. Recent methods have been developed specifically for the informed analysis of admixed populations, leveraging local ancestry to improve association mapping while controlling for confounding [58]. Cross-ancestry meta-analysis approaches also help integrate results across diverse populations while accounting for heterogeneity.

Diagram 1: Methodological Framework for Addressing Population Stratification. This workflow illustrates the progression from detection to correction methods and their specific applications in genetic studies.

Endometriosis-Specific Applications and Considerations

Genetic Architecture Informs Analytical Approach

The genetic architecture of endometriosis presents specific considerations for addressing population stratification. Endometriosis is a complex condition influenced by numerous genetic variants of small to moderate effect, with SNP-based heritability estimated at approximately 8% [43]. Early GWAS identified several susceptibility loci, with stronger genetic effects observed for moderate-to-severe (rAFS Stage III/IV) disease [2]. This heterogeneity in genetic effects across disease subtypes necessitates careful phenotype definition when correcting for population structure.

Recent large-scale efforts have substantially expanded our understanding of endometriosis genetics. A multi-ancestry GWAS comprising approximately 1.4 million women (including 105,869 cases) identified 80 genome-wide significant associations, 37 of which are novel [43]. This study implemented a cross-ancestry polygenic risk score framework across six ancestry groups (African, Admixed American, Central/South Asian, East Asian, European, and Middle Eastern), demonstrating both the challenges and opportunities of trans-ancestry genetic analysis [43].

Functional Genomics Provides Biological Validation

Integration of functional genomic data helps validate genetic associations and provides mechanistic insights that complement stratification correction. A recent study characterized 465 endometriosis-associated variants by exploring their regulatory effects as expression quantitative trait loci (eQTLs) across six physiologically relevant tissues: peripheral blood, sigmoid colon, ileum, ovary, uterus, and vagina [19]. This analysis revealed tissue-specific regulatory patterns, with immune and epithelial signaling genes predominating in colon, ileum, and blood, while reproductive tissues showed enrichment for genes involved in hormonal response, tissue remodeling, and adhesion [19].

This functional characterization provides an important validation step for GWAS findings. When genetic associations are mediated through specific regulatory effects on gene expression across relevant tissues, it strengthens the biological plausibility of these associations and provides evidence against spurious findings due to population stratification.

Gene-Environment Interplay

The intersection of genetic susceptibility and environmental exposures represents another dimension of complexity in endometriosis. Recent evidence suggests that ancient regulatory variants introgressed from Neandertal and Denisovan genomes may interact with modern environmental pollutants, particularly endocrine-disrupting chemicals (EDCs), to modulate endometriosis risk [11]. One study identified six regulatory variants in genes including IL-6, CNR1, and IDO1 that were significantly enriched in an endometriosis cohort and overlapped with EDC-responsive regulatory regions [11]. This gene-environment interplay may contribute to the heterogeneity of endometriosis presentation across populations with different genetic backgrounds and environmental exposures.

Table 3: Endometriosis-Associated Genetic Loci with Cross-Population Validation

Locus	Gene	Population(s)	Function/Pathway	Heterogeneity
7p15.2	Intergenic	European, Japanese	Developmental regulation	Consistent effects [2]
1p36.12	WNT4	European, Japanese	Hormone signaling, development	Consistent effects [2] [20]
12q22	VEZT	European, Japanese	Cell adhesion	Consistent effects [2] [20]
9p21.3	CDKN2B-AS1	Japanese, European	Cell cycle regulation	Consistent effects [2]
2p14	Intergenic	European	Unknown	Significant heterogeneity [2]

Practical Implementation and Research Protocols

Quality Control and Preprocessing

Robust quality control procedures are essential before conducting stratification correction:

• Variant Filtering: Remove variants with high missingness (>5%), significant deviation from Hardy-Weinberg equilibrium (P < 1×10^-6 in controls), or low minor allele frequency (MAF < 0.01) [57].

• Sample Quality Control: Exclude samples with high missingness (>5%), sex discrepancies, or outlier heterozygosity rates (±3 SD from mean).

• Relatedness Assessment: Calculate identity-by-descent (IBD) to identify related individuals (PI_HAT > 0.1875) and retain one individual from each pair.

• Ancestry PCA: Project study samples onto reference panels (e.g., 1000 Genomes) to identify ancestry outliers (>6 SD from population centroid).

Recommended Analytical Workflow for Endometriosis GWAS

Based on current evidence, the following workflow provides robust protection against population stratification:

• Initial PCA: Perform PCA on LD-pruned autosomal variants to capture major axes of genetic variation.

• Mixed Model Association Testing: Implement a mixed model approach (GMMAT or LEAP recommended for case-control data) including top PCs as fixed effects and a genetic relationship matrix as a random effect [57].

• Sensitivity Analysis: Conduct stratified analyses by disease stage (Stage I/II vs. III/IV) given the evidence for differential genetic effects [2].

• Cross-ancestry Replication: When possible, seek replication of associations in independent datasets from diverse ancestral backgrounds [43].

• Functional Annotation: Integrate eQTL and epigenomic data to prioritize putative causal genes and validate associations [19].

Diagram 2: Recommended Analytical Workflow for Endometriosis Genetic Studies. This protocol outlines key steps from quality control through validation, with special considerations for different study designs.

Table 4: Essential Resources for Stratification Analysis in Endometriosis Research

Resource	Type	Function	Application in Endometriosis
PLINK	Software Toolset	Whole-genome association analysis; basic QC and PCA	Preprocessing; initial stratification detection [57]
GMMAT	R Package	Generalized linear mixed models for binary traits	Primary association testing in case-control studies [57]
GTEx Database	Functional Annotation	Tissue-specific eQTL reference	Validating regulatory potential of endometriosis loci [19]
ADMIXTURE	Software	Maximum-likelihood estimation of individual ancestries	Estimating global ancestry proportions [56]
LDAK	Software	Heritability and association analysis	Modeling genetic architecture in power calculations [43]
GWAS Catalog	Database	Curated collection of published GWAS results	Comparing endometriosis loci across studies [19] [20]

Addressing population stratification remains an essential component of rigorous genetic study design, particularly for complex conditions like endometriosis that exhibit heterogeneity across populations and clinical presentations. The integration of sophisticated mixed model approaches, combined with functional validation and cross-population replication, provides a robust framework for distinguishing true biological signals from artifacts of population structure.

Future directions in this field will likely include the development of more powerful methods for multi-ancestry meta-analysis, improved integration of functional genomic data to prioritize causal variants, and enhanced approaches for modeling gene-environment interactions in diverse populations [43] [11] [58]. As endometriosis genetic studies continue to expand across diverse global populations, the thoughtful application of stratification correction methods will be paramount for translating genetic discoveries into biological insights and ultimately, improved clinical management for this complex condition.

The remarkable consistency of several endometriosis risk loci across studies and populations [2] [20], coupled with the identification of population-specific effects [12], highlights both the shared and distinct genetic underpinnings of this condition across human diversity. Carefully addressing population stratification ensures that we can accurately map both the commonalities and differences in endometriosis genetic architecture, advancing toward more personalized approaches to diagnosis and treatment.

Overcoming Limited Representation in Non-European Populations

Endometriosis, a chronic inflammatory gynecological disorder characterized by the presence of endometrial-like tissue outside the uterus, affects approximately 10% of women of reproductive age worldwide, representing over 190 million individuals [59] [60]. Despite its high prevalence, the disease faces significant diagnostic delays averaging 7-9 years, partly due to limited understanding of its complex etiology [7]. Genome-wide association studies (GWAS) have emerged as powerful tools for unraveling the genetic architecture of complex diseases like endometriosis, with heritability estimated at around 51% [2]. However, the overwhelming focus on European-ancestry populations in these studies has created critical gaps in our understanding of how genetic risk factors operate across diverse human populations, ultimately limiting the global applicability of findings and the development of universally effective diagnostics and therapeutics.

The current landscape of endometriosis genetics reveals both the promise and limitations of existing research. While multiple GWAS have identified numerous risk loci, including WNT4, GREB1, VEZT, and CDKN2B-AS1, these findings predominantly stem from studies of European, Japanese, and Taiwanese-Han descent [2] [34]. This limited representation creates substantial challenges for translating genetic discoveries into clinical benefits for underrepresented populations, particularly as genetic risk prediction models and therapeutic targets derived from European populations may have reduced accuracy or applicability in other groups [34]. This whitepaper examines the current state of endometriosis GWAS across populations, outlines methodological frameworks for enhancing diversity, and provides technical guidance for implementing inclusive research practices that can overcome existing representation limitations.

Current Landscape of Endometriosis GWAS Across Populations

Established Genetic Risk Loci and Population-Specific Patterns

Large-scale GWAS meta-analyses have successfully identified multiple genomic loci associated with endometriosis risk, though these discoveries remain concentrated in specific populations. A comprehensive meta-analysis of four GWAS and four replication studies including 11,506 cases and 32,678 controls of European and Japanese ancestry confirmed six genome-wide significant loci: rs12700667 on 7p15.2, rs7521902 near WNT4, rs10859871 near VEZT, rs1537377 near CDKN2B-AS1, rs7739264 near ID4, and rs13394619 in GREB1 [2]. Notably, this analysis demonstrated remarkable consistency in results across studies and populations, with seven out of nine loci showing consistent directions of effect, suggesting some shared genetic architecture across populations [2].

However, closer examination reveals important population-specific patterns in endometriosis genetics. Research has identified that while three genetic loci (WNT4, CDC42, and CCDC170) are shared across European, Japanese, and Taiwanese-Han descent, many other loci show population-specific effects [34]. For instance, European and Japanese populations share associations with VEZT, GREB1, and genes in the sex hormone pathway (FN1, ESR1, STNE1, and FSHB), while studies focused on women of Taiwanese-Han descent have identified two novel significant loci (C5orf66/C5orf66-AS2 and STN1) not observed in other populations [34]. This pattern highlights both conserved and population-specific elements in endometriosis genetic architecture.

Table 1: Established Endometriosis Risk Loci Across Populations

Genetic Locus	Location	European	Japanese	Taiwanese-Han	Proposed Function
WNT4	1p36.12	✓	✓	✓	Development of female reproductive organs [34]
CDC42	1p36.12	✓	✓	✓	Molecular switch for cellular signaling [34]
CCDC170	6q25.1	✓	✓	✓	Sex hormone pathway [34]
VEZT	-	✓	✓	✗	Cellular adhesion [2]
GREB1	2p25.1	✓	✓	✗	Estrogen regulation [2]
FN1	-	✓	✓	✗	Extracellular matrix organization [2]
C5orf66/C5orf66-AS2	-	✗	✗	✓	Novel population-specific locus [34]
STN1	-	✗	✗	✓	Novel population-specific locus [34]

Limitations of Current Representation and Clinical Implications

The concentration of endometriosis genetic studies in specific populations has created significant limitations in clinical translation and understanding of global disease biology. Currently, no GWAS of endometriosis including other women of color exists that can be used to further identify common risk loci, creating a substantial knowledge gap for clinical application in diverse healthcare settings [34]. This underrepresentation may stem from the historical view of endometriosis as a condition primarily affecting white women, which has shifted research focus to this particular group [34].

The clinical consequences of these representation gaps are profound. Women of color experience higher rates of misdiagnosis, more invasive surgical procedures (open abdominal laparoscopies versus minimally invasive approaches), and higher rates of complications including cardiopulmonary arrest, sepsis, and renal failure [34]. These disparities persist even after adjusting for variables such as age, body mass index, and comorbidities, suggesting that factors like access to care and systemic biases in diagnostic approaches may contribute to these unequal outcomes [34]. Developing genetic risk prediction models that work effectively across populations requires addressing these representation gaps in fundamental research.

Methodological Framework for Inclusive Study Design

Population Diversity and Sample Collection Strategies

Implementing methodological frameworks that prioritize inclusive study design is essential for overcoming current limitations in endometriosis genetics research. The foundation of any diverse genetic study begins with intentional sample collection strategies that explicitly include underrepresented populations. Researchers should establish collaborative networks with healthcare institutions serving diverse patient populations and develop ethical frameworks for sample and data sharing that respect cultural sensitivities and provide appropriate benefits to participating communities.

Specific considerations for endometriosis research include:

• Intentional Cohort Recruitment: Target specific underrepresented populations (African, Indigenous, Hispanic, South Asian) with sufficient sample sizes for meaningful analysis
• Standardized Phenotyping: Implement consistent, detailed sub-phenotype characterization across all populations, including rAFS stage, lesion location, and symptom profiles [2]
• Cultural Competence: Develop recruitment materials and protocols that address potential distrust of medical research in historically marginalized communities
• Geographic Diversity: Establish collection sites across different regions to capture within-population genetic diversity

Advanced Analytical Approaches for Diverse Datasets

Overcoming representation challenges requires not only diverse samples but also analytical methods capable of handling genetic heterogeneity across populations. Recent methodological advances offer promising approaches for extracting more information from diverse datasets:

Combinatorial Analytics: Traditional GWAS approaches examine single variants independently, potentially missing multi-variant interactions that contribute to disease risk. Combinatorial analytics platforms like PrecisionLife can identify multi-SNP disease signatures in smaller datasets, making efficient use of limited samples from underrepresented populations. This approach has demonstrated success in identifying 1,709 disease signatures comprising 2,957 unique SNPs in combinations of 2-5 SNPs associated with endometriosis prevalence, with 58-88% of these signatures replicating across diverse ancestry groups in the All of Us cohort [7].

Multi-Ancestry Meta-Analysis: Conducting meta-analyses that incorporate data from diverse populations while accounting for genetic ancestry can increase power to detect trans-ancestry risk variants. Methods that explicitly model population-specific effects and incorporate local ancestry information can improve risk prediction across populations.

Functional Annotation Integration: Combining GWAS findings with functional genomic data from diverse populations, including eQTL mapping across multiple tissues, helps prioritize candidate genes and understand regulatory mechanisms. A multi-tissue eQTL analysis of endometriosis-associated variants across six physiologically relevant tissues (uterus, ovary, vagina, sigmoid colon, ileum, and peripheral blood) revealed substantial tissue specificity in regulatory profiles, with immune and epithelial signaling genes predominating in colon, ileum, and blood, while reproductive tissues showed enrichment of genes involved in hormonal response, tissue remodeling, and adhesion [8].

Technical Protocols for Cross-Population Genetic Studies

Genotyping, Quality Control, and Imputation in Diverse Cohorts

Robust technical protocols are essential for generating high-quality genetic data from diverse populations. The following workflow outlines key steps for processing diverse samples in endometriosis genetic studies:

Genotyping Platform Selection:

• Utilize arrays with comprehensive coverage of genetic variation across multiple populations (e.g., Illumina Global Screening Array, Infinium H3A-MEGA)
• Consider custom content to include population-specific variants based on reference panels
• Maintain consistency across studies to facilitate future meta-analyses

Quality Control Procedures:

• Implement stringent QC criteria: sample call rate >98%, variant call rate >95%, remove outliers for heterozygosity and ancestry [61]
• Account for population structure in QC metrics rather than applying uniform thresholds
• Cryptic relatedness analysis with ancestry-informed relatedness matrices

Population Structure Assessment:

• Perform principal component analysis (PCA) with reference populations (1000 Genomes, HapMap)
• Use ADMIXTURE or similar tools to estimate ancestry proportions
• Stratify analyses by genetic ancestry rather than self-reported race

Imputation in Diverse Cohorts:

• Use population-specific reference panels or combined panels (TOPMed, 1000 Genomes Phase 3)
• Assess imputation quality (R²) within each ancestral group
• Consider pre-phasing with SHAPEIT or Eagle for improved accuracy

Table 2: Essential Research Reagents and Analytical Tools

Category	Specific Tools/Reagents	Function	Considerations for Diverse Populations
Genotyping Arrays	Illumina Global Screening Array, Infinium H3A-MEGA	Genome-wide variant detection	Includes content tailored for multiple populations
Reference Panels	1000 Genomes, TOPMed, gnomAD	Imputation and frequency reference	Combined panels improve imputation in diverse groups
QC Tools	PLINK, SNPTEST, QCTOOL	Quality control and basic association	Implement ancestry-stratified QC thresholds
Population Genetics	ADMIXTURE, EIGENSOFT, RFMix	Ancestry inference and local ancestry	Essential for admixed population analysis
Association Testing	REGENIE, SAIGE, GEMMA	GWAS accounting for relatedness and structure	Mixed models handle population structure
Functional Annotation	ANNOVAR, VEP, FUMA	Functional consequence prediction	Integrate population-specific functional data

Functional Validation and Experimental Follow-up

Following genetic discovery, functional validation is crucial for understanding the biological mechanisms underlying population-specific risk variants. A multi-tissue eQTL analysis approach provides a powerful framework for functional characterization:

Tissue Selection and Processing:

• Prioritize biologically relevant tissues: uterus, ovary, vagina, sigmoid colon, ileum, and peripheral blood [8]
• Ensure diverse representation in tissue sources when possible
• Process samples using standardized protocols to minimize technical artifacts

eQTL Mapping Protocol:

• Extract RNA and genotype from same individuals
• Perform RNA sequencing with sufficient depth (≥30 million reads)
• Conduct eQTL analysis using Matrix eQTL or FastQTL
• Adjust for relevant covariates (ancestry, sex, batch effects)

Functional Prioritization:

• Identify genes regulated by endometriosis-associated variants
• Calculate slope values indicating direction and magnitude of regulatory effects
• Analyze tissue-specific patterns of regulation
• Integrate with pathway databases (MSigDB Hallmark, Cancer Hallmarks)

This approach has demonstrated that endometriosis-associated variants show tissue-specific regulatory profiles, with key regulators such as MICB, CLDN23, and GATA4 consistently linked to immune evasion, angiogenesis, and proliferative signaling pathways [8].

Implementation Roadmap and Future Directions

Strategic Priorities for Building Inclusive Research Programs

Building a more inclusive future for endometriosis genetics research requires coordinated effort across multiple domains. The following strategic priorities provide a roadmap for researchers and institutions:

Short-Term Priorities (0-2 years):

• Establish diverse research cohorts through community engagement and partnerships with healthcare institutions serving diverse populations
• Develop standardized protocols for cross-population data generation and analysis
• Create shared resources for population-specific imputation reference panels and analysis tools

Medium-Term Initiatives (2-5 years):

• Conduct large-scale endometriosis GWAS in currently underrepresented populations (African, Indigenous, Hispanic)
• Develop and validate polygenic risk scores that work effectively across multiple populations
• Establish functional genomics resources from diverse tissues and populations

Long-Term Vision (5+ years):

• Implement clinical genetic tools that work equitably across all populations
• Develop therapeutic approaches targeting pathways relevant across diverse genetic backgrounds
• Establish continuous feedback between discovery and clinical application to refine understanding of population-specific factors

Emerging Technologies and Methodological Innovations

Several emerging technologies and methodological approaches show particular promise for advancing cross-population endometriosis research:

DNA-Encoded Chemistry Technology (DEC-Tec): This transformative tool in drug discovery offers unprecedented efficiency, diversity and scalability in identifying potential drug-like compounds [59]. DEC-Tec enables rapid screening of compound libraries against targets identified through genetic studies, potentially leading to new non-hormonal treatment options relevant across populations.

Single-Cell Multi-omics: Applying single-cell technologies to endometriosis lesions from diverse populations can reveal cell-type-specific regulatory mechanisms and identify novel therapeutic targets with cross-population relevance.

Mendelian Randomization for Target Validation: Using genetic variants as instrumental variables, Mendelian randomization can provide evidence for causal relationships between potential drug targets and endometriosis risk, helping prioritize targets for therapeutic development [62]. This approach has identified several potential drug targets for endometrial cancer subtypes that may inform endometriosis drug discovery.

Overcoming limited representation in non-European populations is not merely an ethical imperative but a scientific necessity for advancing our understanding of endometriosis genetics and developing effective, universally applicable diagnostics and therapeutics. The current concentration of genetic studies in European and East Asian populations leaves critical gaps in our knowledge that limit clinical translation for underrepresented groups. By implementing intentional sampling strategies, employing advanced analytical methods capable of handling genetic heterogeneity, and building collaborative networks that prioritize diversity, researchers can transform endometriosis genetics into a more inclusive and clinically relevant field. The path forward requires sustained commitment to methodological rigor, community engagement, and interdisciplinary collaboration to ensure that the benefits of genetic research in endometriosis are realized equitably across all populations.

Improving Polygenic Risk Prediction Accuracy Across Ancestries

Polygenic risk scores (PRS) have emerged as powerful tools for quantifying an individual's genetic predisposition to complex diseases, yet their translation into clinical practice faces a significant challenge: limited transferability across diverse ancestral populations. This disparity stems largely from the overwhelming Eurocentric bias in genome-wide association studies (GWAS), with approximately 79% of participants being of European ancestry [63]. This bias creates substantial limitations for PRS applications in global populations, as genetic variants, their effect sizes, and linkage disequilibrium (LD) patterns differ across ancestries. When PRS derived from European populations are applied to non-European groups, performance degradation is commonly observed, potentially exacerbating health disparities [64] [63]. Within the specific context of endometriosis—a heritable gynecological condition with estimated heritability of 47-51%—understanding and addressing these ancestral disparities is crucial for developing equitable genetic risk prediction tools applicable to all populations [65]. This technical guide examines the methodological advances and strategic approaches for improving cross-ancestry PRS performance, with particular emphasis on implications for endometriosis research and clinical application.

Methodological Advances in Cross-Ancestry PRS

Statistical Methods for Enhancing PRS Portability

Several sophisticated statistical approaches have been developed to improve PRS performance across diverse populations. These methods can be broadly categorized into single-ancestry methods that optimize portability and multi-ancestry methods that directly incorporate diverse genetic data.

Single-ancestry methods focus on improving the genetic signal from primarily European GWAS for application in other populations. SBayesR and PRS-CS employ Bayesian regression frameworks with continuous shrinkage priors, which have demonstrated superior performance in both European and East Asian populations [66]. These methods assume a priori that all SNPs have some effect, with effects drawn from mixtures of normal distributions, allowing for more accurate effect size estimation [67].

Multi-ancestry methods represent a paradigm shift by directly incorporating genetic data from multiple populations:

• PRS-CSx extends the PRS-CS framework by integrating GWAS summary statistics from multiple populations simultaneously. This approach allows the model to share information across ancestries while accommodating population-specific genetic architectures, significantly improving portability compared to single-ancestry methods [64] [66].
• LDpred-funct and SBayesRC incorporate functional annotations to upweight or downweight variants based on their biological relevance, which can improve cross-population prediction when functional elements are conserved across ancestries [67] [66].

Table 1: Comparison of PRS Methods for Cross-Ancestry Application

Method	Architecture	Ancestry Approach	Key Advantages	Performance Evidence
SBayesR	Bayesian mixture model	Single-ancestry optimization	Excellent performance in East Asian populations; handles sparse effects well	Superior R² and AUC for most diseases in East Asian cohorts [66]
PRS-CS	Bayesian continuous shrinkage	Single-ancestry optimization	Robust performance across varying genetic architectures; does not require tuning sample	Outperforms lassosum and LDpred-funct in simulations [66]
PRS-CSx	Bayesian continuous shrinkage	Multi-ancestry integration	Leverages data from multiple populations; improves portability	Better performance than single-ancestry methods in three AoU populations [64]
LDpred-funct	Functional annotation-informed	Single-ancestry optimization	Incorporates functional genomic data	Performs well when proportion of causal variants is 0.01 [66]

Performance Benchmarking Across Methods

Recent large-scale benchmarking studies provide critical insights into the relative performance of these methods across ancestries. In a comprehensive evaluation using the Korean HEXA cohort, SBayesRC (which incorporates functional annotations) and PRS-CS demonstrated superior prediction accuracy compared to other methods including lassosum, LDpred-funct, and PRSice, particularly at higher heritability levels (0.3 and 0.7) [66]. The performance advantage of these methods became more pronounced as heritability increased.

When specifically comparing ancestry approaches, multi-ancestry methods consistently outperform when diverse data is available. A pivotal analysis leveraging the Million Veterans Program and All of Us cohorts demonstrated that "approaches that combine GWAS data from multiple populations produce PGSs that perform better than approaches that utilize smaller single-population GWAS results matched to the target population" [64]. Specifically, PRS-CSx outperformed other methods across African, Admixed American, and European target populations in the AoU cohort [64].

Table 2: Relative Performance of GWAS Data Sources for East Asian PRS Development

Disease	BBJ GWAS Performance	UKB GWAS Performance	Superior Approach
Breast Cancer	Higher R² and AUC	Lower performance	East Asian GWAS
Cataract	Higher R² and AUC	Non-significant association	East Asian GWAS
Gastric Cancer	Higher R² and AUC	Non-significant association	East Asian GWAS
Type 2 Diabetes	Higher R² and AUC	Lower performance	East Asian GWAS
Asthma	Moderate performance	Moderate performance	Comparable
Coronary Artery Disease	Moderate performance	Moderate performance	Comparable
Hypothyroidism	Moderate performance	Moderate performance	Comparable

Application to Endometriosis Genetics

Current Status of Endometriosis PRS

Endometriosis genetics has made significant strides through large-scale GWAS efforts, with the largest meta-analysis identifying 42 risk loci explaining up to 5.01% of disease variance [65]. The heritable nature of endometriosis (approximately 52% based on twin studies) makes it a promising candidate for PRS applications [2]. Initial PRS development for endometriosis utilized a relatively simple 14-variant score based on early GWAS discoveries, which demonstrated significant association with surgically confirmed endometriosis (OR = 1.59, p = 2.57×10^−7) and differentiated endometriosis from adenomyosis, suggesting specificity of the genetic signal [42].

More recent applications of PRS in endometriosis research have revealed compelling pleiotropic effects. A PRS-phenome-wide association study (PheWAS) in the UK Biobank identified associations between genetic liability to endometriosis and multiple health conditions, biomarkers, and reproductive factors, notably suggesting a causal relationship with lower testosterone levels through Mendelian randomization analysis [65]. This finding highlights how cross-ancestry PRS applications can reveal novel biological insights beyond risk prediction.

Genetic Heterogeneity and Ancestral Considerations

Endometriosis demonstrates both genetic homogeneity and heterogeneity across populations. Early meta-analyses found remarkable consistency in endometriosis GWAS results across studies of European and Japanese ancestry, with little evidence of population-based heterogeneity for most loci [2]. However, some loci, such as rs4141819 on chromosome 2, showed significant heterogeneity across datasets, indicating population-specific genetic influences [2].

This mixed pattern suggests that while many core genetic risk factors are shared across populations, optimal PRS for diverse populations will need to account for both shared and population-specific variants. The continued expansion of endometriosis GWAS in diverse populations is essential to fully elucidate the genetic architecture across ancestries.

Implementation Protocols for Cross-Ancestry PRS

Technical Workflow for Cross-Ancestry PRS Development

The development of optimized cross-ancestry PRS follows a structured workflow that integrates diverse datasets and validation approaches. Below is a diagram illustrating the key stages in this process:

Stage 1: Multi-Ancestry GWAS Data Collection

• Collect largest possible GWAS summary statistics from diverse populations
• For endometriosis, leverage datasets from BioBank Japan, FinnGen, and diverse cohorts from large biobanks
• Ensure consistent phenotype definitions across cohorts (surgical confirmation vs. ICD codes)

Stage 2: Data Harmonization

• Implement rigorous quality control across all datasets
• Use ancestry-specific LD reference panels from 1000 Genomes or population-specific references
• Perform careful allele alignment and strand orientation across datasets

Stage 3: Method Selection and Training

• Begin with SBayesR or PRS-CSx as baseline methods based on current evidence
• For PRS-CSx, integrate summary statistics from European and East Asian ancestries simultaneously
• For SBayesR, utilize functional annotations to improve cross-ancestry portability

Stage 4: Ancestry-Specific Tuning

• Use independent tuning samples from target ancestry populations
• Optimize parameters for each ancestry group separately
• For endometriosis, consider subtype-specific tuning for ovarian, infiltrating, and peritoneal forms

Stage 5: Cross-Ancestry Validation

• Validate performance in completely independent cohorts from multiple ancestries
• Report both relative (OR per SD) and absolute risk metrics
• Compare performance with ancestry-matched PRS when available

Stage 6: Clinical Model Integration

• Combine PRS with clinical risk factors (age, BMI, reproductive history)
• Develop ancestry-specific risk thresholds based on population prevalence
• For endometriosis, integrate with symptoms, imaging findings, and biomarker data

Table 3: Research Reagent Solutions for Cross-Ancestry Endometriosis PRS

Resource Category	Specific Tools/Datasets	Function in PRS Development	Application Notes
GWAS Summary Statistics	UK Biobank, FinnGen, BioBank Japan, Biobank Japan Project [42] [66]	Discovery data for variant effect sizes	Prefer diverse ancestry datasets; ensure consistent endometriosis phenotyping
LD Reference Panels	1000 Genomes Project, population-specific reference panels	Account for linkage disequilibrium patterns	Use ancestry-matched references; HRC panel for European populations
PRS Methods Software	PRS-CSx, SBayesR, LDpred2, MegaPRS [67] [64] [66]	Calculate optimized SNP weights	SBayesR and PRS-CSx recommended based on current evidence
Validation Cohorts	All of Us, Million Veteran Program, diverse population biobanks	Independent performance assessment	Ensure no sample overlap with discovery GWAS
Functional Annotation Data	ENCODE, Roadmap Epigenomics, tissue-specific chromatin marks	Inform functional PRS methods	Particularly valuable for LDpred-funct and SBayesRC

Future Directions and Implementation Challenges

Addressing Remaining Barriers

Despite significant methodological progress, substantial challenges remain in achieving equitable PRS performance across ancestries. The limited sample sizes of non-European GWAS continues to be the primary bottleneck, particularly for endometriosis where large-scale diverse datasets are still emerging. Recent initiatives like the All of Us Research Program and Our Future Health aim to address this disparity by actively recruiting diverse participants [63].

Additional challenges include:

• Phenotypic heterogeneity: Endometriosis diagnosis varies from surgical confirmation to ICD code-based definitions, introducing noise [42]
• Subtype-specific effects: Genetic effects differ across endometriosis subtypes (ovarian, infiltrating, peritoneal), requiring stratified approaches [42]
• Gene-environment interactions: Environmental factors may modulate genetic effects differently across populations

Clinical Translation Pathway

For eventual clinical implementation of endometriosis PRS across diverse populations, a structured translation pathway is essential:

• Technical validation: Establish analytical validity across genotyping platforms and ancestries
• Clinical validation: Demonstrate improved risk stratification beyond current clinical factors across diverse populations
• Clinical utility: Show that PRS-guided decisions improve outcomes (earlier diagnosis, better treatment selection)
• Implementation research: Develop clinical guidelines, physician education, and patient resources
• Continuous refinement: Update PRS as more diverse genetic data becomes available

The integration of PRS with other clinical risk factors is particularly important for endometriosis, where the combination of genetic risk with symptoms, imaging findings, and demographic factors may create sufficiently robust prediction models for clinical use [42] [63].

Improving polygenic risk prediction across ancestries represents both a technical challenge and an ethical imperative in genomic medicine. For endometriosis research and clinical application, the strategic integration of diverse datasets, advanced statistical methods like SBayesR and PRS-CSx, and careful attention to population-specific genetic architectures will be essential for developing equitable PRS tools. The remarkable genetic consistency observed across endometriosis studies of different ancestries provides a promising foundation for these efforts, though continued expansion of diverse genomic datasets remains crucial. As these tools evolve, their integration with clinical risk factors and biomarkers will ultimately enable more personalized risk stratification and preventive strategies for endometriosis across all ancestral backgrounds.

Statistical Power Considerations in Understudied Populations

Endometriosis, a chronic inflammatory condition affecting approximately 10% of reproductive-aged women globally, demonstrates substantial heritability estimated at around 52% [2]. While genome-wide association studies (GWAS) have successfully identified multiple genetic loci associated with endometriosis risk, the majority of these discoveries originate from populations of European and Japanese ancestry, creating significant knowledge gaps for other populations [2] [1]. This disparity introduces critical challenges in understanding the complete genetic architecture of endometriosis across diverse human populations.

Genetic effect heterogeneity—the phenomenon where genetic effects on disease risk vary across subpopulations due to differences in ancestry, environmental exposures, or lifestyle factors—represents a fundamental challenge in endometriosis genetics [68]. When unaccounted for, this heterogeneity substantially reduces statistical power in GWAS and impedes the discovery of population-specific risk variants. The development of analytical frameworks that explicitly model this heterogeneity is therefore essential for advancing endometriosis genetics in understudied populations [68]. This technical guide examines the methodological considerations, experimental approaches, and analytical frameworks required to enhance statistical power in genetic studies of endometriosis across diverse populations.

Statistical Foundations of Power Limitations in Diverse Populations

Fundamental Concepts of Statistical Power in Genetic Studies

Statistical power in GWAS refers to the probability of detecting a true genetic association when one exists. Power is primarily influenced by allele frequency, effect size, sample size, significance threshold, and genetic architecture [69]. In understudied populations, additional factors exacerbate power limitations, including minor allele frequency differences, linkage disequilibrium (LD) heterogeneity, and population-specific environmental interactions.

The basic relationship determining statistical power for a case-control GWAS can be expressed as:

[ \text{Power} = \Phi\left(\frac{|\beta|\sqrt{2Np(1-p)}}{\sigma} - Z_{\alpha/2}\right) ]

Where:

• (\Phi) = cumulative standard normal distribution
• (\beta) = true effect size
• (N) = total sample size
• (p) = risk allele frequency
• (\sigma) = phenotypic standard deviation
• (Z_{\alpha/2}) = quantile of standard normal distribution at significance threshold (\alpha)

Allele Frequency Disparities: Genetic variants exhibit considerable frequency differences across populations. A variant with minor allele frequency (MAF) of 20% in Europeans might be rare (MAF < 1%) in African or Asian populations, dramatically reducing power to detect associations in the latter groups.

LD Structure Heterogeneity: Patterns of linkage disequilibrium vary substantially across populations, affecting how well tag SNPs represent causal variants. In populations with more complex LD structures (e.g., African ancestry), greater genomic coverage is required to capture the same proportion of causal variants [69].

Gene-Environment Interactions: Environmental factors prevalent in specific geographic regions (e.g., pathogens, dietary patterns) may modify genetic effects, creating population-specific associations that are not transferable across groups [68].

Table 1: Factors Reducing Statistical Power in Understudied Populations

Factor	Impact on Power	Potential Magnitude of Effect
Allele Frequency Differences	Reduces effective variant count	2-5x power reduction for low-frequency variants
LD Structure Heterogeneity	Increases required marker density	1.5-3x more SNPs needed for equivalent coverage
Sample Size Disparities	Directly reduces power according to √N	Understudied populations often have 10-100x smaller sample sizes
Gene-Environment Interactions	Effect size heterogeneity	Can completely mask associations in cross-population analyses
Population Stratification	Increases false positive rate	Requires stringent correction, reducing effective sample size

Methodological Frameworks for Power Enhancement

Accounting for Effect Heterogeneity in Fine-Mapping

Novel computational approaches such as SharePro have been developed specifically to address effect heterogeneity in genetic association studies [68]. This method improves both fine-mapping accuracy and power for gene-environment interaction (GxE) analysis by integrating exposure-stratified GWAS summary statistics.

The SharePro framework utilizes a Bayesian probabilistic model that represents causal configurations across exposure categories:

[ ye \sim \mathcal{N}\left(Xe\sumk sk \beta{ke} c{ke}, \tau_y^{-1}I\right) ]

Where:

• (y_e) = phenotype in exposure group (e)
• (X_e) = genotype matrix for group (e)
• (s_k) = effect group indicator for causal signal (k)
• (\beta_{ke}) = effect size of group (k) in exposure category (e)
• (c_{ke}) = causal status of group (k) in category (e)

This approach enables simultaneous fine-mapping across multiple subpopulations while accounting for heterogeneity, significantly improving power compared to traditional methods [68].

Figure 1: SharePro Analytical Workflow for Heterogeneity-Aware Fine-Mapping

Variance-Heterogeneity GWAS (vGWAS) Approaches

Traditional GWAS focuses exclusively on mean differences in phenotype across genotypes. Variance-heterogeneity GWAS (vGWAS) represents an alternative approach that detects genetic loci involved in gene-gene and gene-environment interactions by testing for variance differences across genotypes [70].

The vGWAS model extends the standard GWAS equation:

[ y = \mu + g\alpha + \epsilon, \quad \epsilon \sim \mathcal{N}(0, \sigma_E^2) ]

Where the residual variance (\sigma_E) is modeled as:

[ \sigma_E = \sigma + g\phi ]

Here, (\phi) represents the variance shift due to the minor allele, capturing GxG and GxE interactions that manifest as variance heterogeneity [70]. This approach is particularly valuable in understudied populations where environmental exposures may differ substantially from well-studied populations.

Multi-Trait and Cross-Population Analysis Methods

Integrating data across multiple traits and populations can significantly enhance power in understudied groups. Mendelian randomization (MR) and colocalization analyses allow researchers to leverage genetic information from better-characterized populations while accounting for heterogeneity.

Two-sample MR analysis uses genetic variants as instrumental variables to infer causal relationships, relying on three core assumptions:

• Genetic variants are strongly associated with the exposure
• Variants are independent of confounders
• Variants affect the outcome only through the exposure [71]

When applied across populations, MR can identify stable causal effects while highlighting population-specific differences in genetic architecture [29] [71].

Experimental Design Considerations for Understudied Populations

Sample Size and Cohort Collection Strategies

Achieving sufficient sample size remains the most significant challenge in understudied populations. Strategic approaches include:

Consortium-Based Data Generation: Large-scale international collaborations such as the International Endogene Study have demonstrated the feasibility of collecting multi-ancestry samples, with one meta-analysis including 11,506 cases and 32,678 controls of European and Japanese ancestry [2].

Phenotypic Harmonization: Standardized phenotyping is critical for cross-population analyses. The use of revised American Fertility Society (rAFS) Stage III/IV classifications in endometriosis studies enables more precise comparison across cohorts [2].

Biobank Integration: Leveraging diverse biobanks (e.g., UK Biobank, BioBank Japan) provides access to larger sample sizes, though careful attention to population stratification is required [69].

Table 2: Minimum Sample Size Requirements for 80% Power in Endometriosis GWAS

Population Group	Minor Allele Frequency	Odds Ratio	Required Cases	Required Controls
European (Reference)	0.15	1.2	3,194	7,060
African Ancestry	0.15	1.2	3,800-4,500	8,500-10,000
East Asian	0.15	1.2	3,300-3,800	7,500-8,500
Admixed Populations	0.15	1.2	4,200-5,000	9,500-11,500

Note: Requirements for African and admixed populations are higher due to greater genetic diversity and more complex LD patterns. Calculations assume α = 5×10⁻⁸, 80% power, and 1:2 case-control ratio based on established power calculation methods [69].

Genotyping and Imputation Strategies

Genotyping Array Selection: Population-specific arrays optimized for local variation improve coverage in understudied groups. For example, the African Genome Resource array provides enhanced coverage for African populations.

Reference Panel Development: Creating population-specific reference panels significantly improves imputation accuracy. The inclusion of 53,831 diverse genomes in the NHLBI TOPMed program has dramatically improved variant imputation in non-European groups [69].

Quality Control Procedures: Stringent QC must account for population-specific factors, including:

• Different patterns of LD for relatedness inference
• Population-specific technical artifacts
• Differential missingness patterns across ancestry groups

Analytical Protocols for Enhanced Power

Tissue-Specific eQTL Mapping Across Populations

Expression quantitative trait locus (eQTL) analysis helps interpret GWAS findings by identifying genetic variants that influence gene expression. Multi-tissue eQTL analysis across diverse populations reveals both shared and population-specific regulatory mechanisms [19].

Protocol: Cross-Population eQTL Analysis

• Variant Selection: Curate endometriosis-associated variants from GWAS Catalog (EFO_0001065) with p < 5×10⁻⁸ [19]
• Tissue Selection: Include biologically relevant tissues (uterus, ovary, vagina, colon, ileum, blood)
• eQTL Identification: Cross-reference variants with tissue-specific eQTL data from GTEx v8 (FDR < 0.05)
• Effect Size Comparison: Calculate slope values (effect direction and magnitude) for each variant-tissue pair
• Functional Annotation: Map regulated genes to biological pathways using MSigDB Hallmark gene sets

This approach has revealed tissue-specific regulatory profiles, with immune and epithelial signaling genes predominating in colon, ileum, and blood, while reproductive tissues show enrichment for hormonal response and tissue remodeling genes [19].

Figure 2: Cross-Population eQTL Analysis Workflow

Polygenic Risk Score (PRS) Construction in Diverse Populations

PRS aggregate effects across multiple variants to predict disease risk. Standard PRS developed in European populations typically show reduced performance in other groups due to differences in LD and allele frequencies [1].

Protocol: Trans-Ancestry PRS Development

• Variant Selection: Include all genome-wide significant variants from multi-ancestry meta-analysis
• Effect Size Estimation: Use fixed-effects or random-effects models accounting for heterogeneity
• LD Reference Panel: Employ ancestry-appropriate LD panels for clumping
• Validation: Assess performance in independent cohorts from target population
• Calibration: Adjust for ancestry-specific baseline risk and prevalence

Recent studies suggest that PRS could become useful tools for identifying high-risk individuals in diverse populations, potentially enabling earlier diagnosis and intervention [1].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for Cross-Population Endometriosis Genetics

Reagent/Resource	Function	Application in Understudied Populations
GTEx v8 Database	Tissue-specific gene expression and eQTL reference	Identify population-specific regulatory mechanisms [19]
GWAS Catalog (EFO_0001065)	Repository of published GWAS associations	Curate endometriosis-associated variants for cross-population analysis [19]
SharePro Software	Fine-mapping accounting for effect heterogeneity	Identify causal variants in presence of GxE interactions [68]
PLINK Toolset	Whole-genome association analysis	Quality control, stratification adjustment, association testing [69]
METAL Software	GWAS meta-analysis	Combine results across diverse cohorts with heterogeneity testing [2]
TwoSampleMR R Package	Mendelian randomization analysis	Test causal relationships in multi-ancestry data [71]
LD Score Regression	Genetic correlation and heritability estimation	Quantify trans-ancestry genetic correlations [69]
GTeX Portal	Tissue-specific regulatory element annotation	Functional interpretation of non-coding variants [19]

Enhancing statistical power in genetic studies of understudied populations requires multifaceted approaches addressing study design, genotyping strategies, and analytical methods. Methodological innovations that explicitly model effect heterogeneity, such as SharePro, combined with larger diverse cohorts and improved functional annotation, are rapidly closing the discovery gap in endometriosis genetics. The continued development and application of these methods will not only advance our understanding of endometriosis pathophysiology across human diversity but also ensure equitable benefits from genetic discoveries in diagnosis, risk prediction, and therapeutic development.

Future directions should prioritize: (1) substantial expansion of diverse biobank resources, (2) development of ancestry-aware analytical methods, (3) deep functional characterization of population-specific variants, and (4) integration of multi-omics data across diverse populations. Through these coordinated efforts, the field can overcome current power limitations and deliver transformative insights into endometriosis genetics that benefit all global populations.

Ethical Considerations in Global Genomics Research

Genomic research holds transformative potential for understanding complex diseases like endometriosis, a heritable gynecological condition affecting approximately 10% of reproductive-aged women globally [11]. Despite estimated heritability of 47-52% [2] [4], research progress has been hampered by significant ethical challenges in international data sharing and population representation. The World Health Organization emphasizes that genomic technologies "are advancing at a remarkable pace, offering unprecedented insights into health and disease" but acknowledges that "as genomic data use expands, so too do the ethical and logistical challenges surrounding privacy, equitable access and responsible data management" [72]. These challenges are particularly acute in endometriosis research, where genetic heterogeneity across populations remains inadequately characterized, potentially limiting the benefits of discoveries for non-European populations. This technical guide examines the ethical frameworks, methodological considerations, and practical implementations required to advance equitable endometriosis genomics while protecting individual rights and promoting global equity.

Ethical Frameworks for Genomic Data Sharing

Foundational Principles and Global Standards

International organizations have established comprehensive frameworks to guide ethical genomic research. The WHO's 2024 principles emphasize that "the potential of genomics to revolutionize health and disease understanding can only be realized if human genomic data are collected, accessed and shared responsibly" [72]. These principles are anchored in several foundational elements:

• Human Rights Foundation: Both the WHO framework and Global Alliance for Genomics and Health (GA4GH) code of conduct are guided by Article 27 of the Universal Declaration of Human Rights, which guarantees the rights "to share in scientific advancement and its benefits" and "to the protection of the moral and material interests" from scientific productions [73] [74].

• Core Ethical Pillars: Established frameworks prioritize transparency, accountability, data security, privacy protection, and minimizing harm while maximizing benefits across diverse populations [74]. The WHO specifically emphasizes informed consent, privacy, equity, and international collaboration as foundational to ethical genomic data practices [72].

• Progressive Implementation: Effective frameworks "serve as dynamic instruments that can respond to future developments in the science, technology, and practices of genomic and health-related data sharing" [73], allowing adaptation to evolving technological and ethical landscapes.

Applications to Endometriosis Genomics

The practical application of these ethical frameworks to endometriosis research requires specialized considerations:

• Equity in Representation: Current endometriosis genome-wide association studies (GWAS) display significant population biases, with approximately 93% of participants in major studies being of European ancestry [4]. This limited diversity raises ethical concerns regarding the equitable distribution of research benefits and the applicability of findings across populations.

• Data Sharing Governance: Responsible data sharing for endometriosis research requires "robust governance structures" [72] that facilitate international collaboration while protecting participant privacy. This is particularly important given the sensitive nature of gynecological health information.

• Capacity Building: Ethical endometriosis genomics requires "targeted efforts to address disparities in genomic research, especially in low- and middle-income countries (LMICs)" [72] through investment in local expertise and resources to ensure sustainable and inclusive research participation.

Table 1: Core Ethical Principles in Genomic Research and Their Endometriosis Applications

Ethical Principle	WHO Definition	Endometriosis Research Application
Informed Consent	"Foundational... ensuring individuals understand and agree to how their genomic data will be used" [72]	Dynamic consent processes for longitudinal studies of disease progression
Equity	"Targeted efforts to address disparities in genomic research, especially in LMICs" [72]	Intentional inclusion of diverse populations in GWAS studies to reduce European bias
Privacy and Security	"Clear guidelines to ensure... data collection processes are openly communicated and safeguarded against misuse" [72]	Special protections for sensitive reproductive health information in database sharing
Benefit Sharing	"Ensuring that genomic research benefits populations in all their diversity" [72]	Ensuring diagnostics and therapies derived from genetics research are accessible globally

Genetic Heterogeneity in Endometriosis Across Populations

Current Landscape of Endometriosis GWAS

Endometriosis GWAS have identified numerous susceptibility loci, yet significant gaps remain in understanding population-specific genetic factors:

• Identified Loci: To date, multiple GWAS have identified genome-wide significant loci for endometriosis, including signals near WNT4, GREB1, VEZT, CDKN2B-AS1, and ID4 [2]. Larger meta-analyses have expanded these findings to include additional loci in FN1, CCDC170, ESR1, SYNE1, and FSHB [4], implicating genes involved in sex steroid hormone pathways.

• Population-Specific Effects: The first endometriosis GWAS in Japanese populations identified CDKN2B-AS1 (rs10965235) as a significant locus [2], while subsequent studies in European ancestry populations revealed different association patterns. Cross-population comparisons show that "seven out of nine loci had consistent directions of effect across studies and populations" [2], suggesting both shared and population-specific genetic architectures.

• Stratification by Disease Severity: Stronger genetic effects are observed for moderate-to-severe (rAFS Stage III/IV) endometriosis, with most loci showing "stronger effect sizes among Stage III/IV cases" [2]. This heterogeneity underscores the need for precise phenotyping in diverse populations to fully understand genetic influences on disease progression.

Functional Annotation of Variants Across Tissues

Understanding the functional impact of endometriosis-associated variants across diverse populations requires sophisticated analytical approaches:

• Tissue-Specific Regulatory Effects: Integration of GWAS findings with expression quantitative trait loci (eQTL) data from multiple tissues reveals how genetic variants differentially regulate gene expression. One recent study analyzed "465 endometriosis-associated variants" across six physiologically relevant tissues (uterus, ovary, vagina, colon, ileum, and blood) [19], finding distinct regulatory patterns in reproductive versus intestinal tissues and peripheral blood.

• Ancestral Variation in Regulatory Elements: Emerging evidence suggests that ancient regulatory variants, including "Neandertal-derived methylation sites" and "Denisovan origin" variants, may contribute to endometriosis susceptibility [11]. These ancestral variations may have different frequencies across populations, contributing to heterogeneous disease risk.

• Environmental Interactions: Regulatory variants may interact with modern environmental exposures, as "several of these variants overlapped EDC-responsive regulatory regions, suggesting gene-environment interactions may exacerbate risk" [11]. These interactions may manifest differently across populations with varying environmental exposures.

Table 2: Methodologies for Evaluating Population Genetic Heterogeneity in Endometriosis Research

Methodological Approach	Technical Implementation	Ethical Considerations
Cross-Population GWAS Meta-analysis	Combining datasets from diverse ancestries using standardized imputation and quality control [4]	Equitable data sharing agreements; recognition of contributions from all participating populations
eQTL Mapping in Multiple Tissues	Using GTEx and population-specific datasets to identify tissue-specific regulatory effects [19]	Appropriate consent for tissue collection across diverse populations; respectful handling of biological samples
Linkage Disequilibrium and Population Branch Statistics	Analyzing LD patterns and population differentiation using 1000 Genomes data [11]	Protection against misinterpretation of population differences; avoidance of genetic determinism
Functional Validation Studies	Experimental follow-up of putative causal variants using CRISPR and other molecular techniques	Consideration of how functional insights will benefit all participating populations

Diagram Title: Ethical Genomic Research Workflow

Methodological Protocols for Ethical Cross-Population Genomics

GWAS and Meta-Analysis Protocols

Comprehensive GWAS protocols enable robust identification of genetic associations while addressing population heterogeneity:

• Study Design and Cohort Development: Largest endometriosis GWAS meta-analyses have included "17,045 endometriosis cases and 191,596 controls" from multiple populations [4]. Case definitions should prioritize surgical confirmation with standardized staging using the revised American Fertility Society (rAFS) classification system [4]. Stratified analyses by disease severity (minimal/mild versus moderate/severe) are essential, as most loci show "stronger associations with Stage III/IV disease" [2].

• Genotyping and Quality Control: Standardized genotyping using genome-wide SNP arrays followed by imputation with 1000 Genomes Project or population-specific reference panels provides comprehensive variant coverage [4]. Quality control should include exclusion based on call rate, heterozygosity, sex inconsistencies, and relatedness. Population structure should be assessed using principal component analysis.

• Statistical Analysis and Meta-Analysis: Association testing should employ logistic regression adjusted for principal components. Fixed-effects meta-analysis combines results across studies, with random-effects models (e.g., RE2) applied when heterogeneity is detected [4]. Genome-wide significance threshold is standardly set at P < 5 × 10⁻⁸. Conditional analysis identifies independent association signals at loci.

Functional Validation Experimental Designs

Understanding the molecular mechanisms of endometriosis-associated variants requires functional validation:

• Regulatory Element Characterization: Investigation of endometriosis-associated variants in regulatory regions should include "variant effect predictor consequence categories corresponding to regulatory sequence" [11]. Analysis should prioritize "non-coding regulation (introns, untranslated regions, promoter-flanking, ±1 kb Transcription Start Site/Transcription End Site)" [11] given that environmental pollutants more often affect gene expression than protein structure.

• eQTL Integration and Pathway Analysis: Integration with eQTL data from GTEx and other resources identifies genes whose expression is regulated by endometriosis-associated variants. Functional interpretation using MSigDB Hallmark gene sets and similar resources reveals enriched biological pathways [19]. Tissue-specific patterns should be noted, as reproductive tissues typically show enrichment of "genes involved in hormonal response, tissue remodeling, and adhesion" while blood and intestinal tissues show immune and epithelial signaling enrichment [19].

• Gene-Environment Interaction Studies: Experimental designs should account for potential interactions between genetic variants and environmental exposures, particularly endocrine-disrupting chemicals (EDCs). Studies should examine whether regulatory variants "overlapped EDC-responsive regulatory regions" [11], as these interactions may contribute to disease risk heterogeneity across populations with different environmental exposures.

Research Reagent Solutions for Endometriosis Genomics

Table 3: Essential Research Reagents and Platforms for Endometriosis Genomics

Reagent/Platform	Specific Function	Application in Endometriosis Research
GWAS SNP Arrays	Genome-wide genotyping of common variants	Initial genotyping in case-control studies; identifies associated genomic regions [75]
1000 Genomes Imputation Reference	Provides reference haplotypes for imputation	Increases variant coverage beyond directly genotyped SNPs; enables cross-study comparisons [4]
GTEx eQTL Database	Tissue-specific gene expression and QTL data	Mapping regulatory consequences of endometriosis-associated variants [19]
Ensembl VEP (Variant Effect Predictor)	Functional annotation of genetic variants	Characterizing potential impact of associated variants [19]
LDlink Tools	Linkage disequilibrium and population genetics analysis	Evaluating LD patterns across populations [11]
Genomics England Research Environment	Secure analytical platform for genomic data	Large-scale analysis of whole genome sequencing data [11]

Implementation Pathways for Ethical Global Research

Data Sharing and Collaborative Frameworks

Responsible data sharing requires balancing scientific progress with ethical protections:

• GA4GH Framework Implementation: The Global Alliance for Genomics and Health framework provides practical guidance for international data sharing, emphasizing "trust, integrity, and reciprocity" [74]. Implementation requires "developing clearly defined and accessible information on the purposes, processes, procedures and governance frameworks for data sharing" [74].

• Federated Analysis Models: As an alternative to raw data sharing, federated analysis approaches allow algorithms to be brought to data rather than transferring sensitive data across jurisdictions. This approach can help address privacy concerns while enabling cross-border research collaboration.

• Data Access Committees (DACs): Establishment of diverse, multidisciplinary DACs ensures appropriate oversight of data access requests. DACs should include "representatives from research ethics, legal, clinical, and community perspectives" to evaluate proposed uses of genomic data [73].

Capacity Building and Equity Initiatives

Addressing global disparities in genomics research requires intentional investment:

• Technical Training and Infrastructure: The WHO principles specifically encourage "investment in local expertise and resources" in regions with limited genomic infrastructure [72]. This includes supporting bioinformatics training, computational resources, and laboratory capabilities in underrepresented regions.

• Equitable Research Partnerships: Collaborative research should ensure that "populations in all their diversity" benefit from genomic advances [72]. This includes fair intellectual property agreements, co-leadership opportunities for researchers from LMICs, and ensuring that research priorities reflect global health needs rather than solely commercial interests.

• Community Engagement and Benefit Sharing: Ethical genomics requires ongoing engagement with participant communities, particularly regarding "return of results, commercial involvement, and proprietary claims" [74]. Benefit-sharing arrangements should consider how diagnostics and therapies developed from genomic research will be accessible to all populations, including those who participated in research.

Advancing ethical global genomics research for complex conditions like endometriosis requires integrating robust scientific methods with thoughtful ethical frameworks. As genomic technologies continue to evolve, maintaining focus on equity, diversity, and responsible data sharing will be essential to ensuring that the benefits of research reach all global populations. The remarkable consistency observed in some endometriosis genetic associations across populations [2] provides encouraging evidence that carefully conducted genomic research can yield insights with broad applicability, while the identification of population-specific effects highlights the continued importance of diverse representation in research. By implementing comprehensive ethical frameworks alongside rigorous scientific methods, the research community can advance our understanding of endometriosis genetics while building trust and promoting equity in global health research.

Bridging Discovery and Translation: Validating Genetic Insights Across Populations

Cross-Population Replication of Endometriosis Risk Loci

Endometriosis, a complex gynecological disorder affecting approximately 10% of reproductive-aged women globally, demonstrates a significant genetic component with an estimated heritability of 47-52% based on twin studies [2] [11]. While genome-wide association studies (GWAS) have successfully identified multiple susceptibility loci for endometriosis, a critical challenge emerges when examining the transferability of these findings across diverse ethnic populations. The replication of GWAS-identified risk loci across different ancestral groups remains inconsistent, complicating efforts to develop universal genetic risk models and targeted therapies [12] [1]. This technical review examines the current landscape of cross-population replication for endometriosis risk loci, analyzing the underlying causes of heterogeneity and proposing methodological frameworks to enhance the portability of genetic findings across diverse human populations.

Table 1: Key Endometriosis Risk Loci and Their Replication Status Across Populations

Locus/SNP	Gene	Chromosome	Initial Discovery Population	European Replication	East Asian Replication	Functional Pathway
rs7521902	WNT4	1p36.12	European [2]	Confirmed [76]	Confirmed [2]	Hormone regulation
rs13394619	GREB1	2p25.1	European [2]	Confirmed[ccitation:1] [76]	Partial [2]	Estrogen response
rs6542095	IL1A	2q13	Japanese [76]	Confirmed [76]	Confirmed [76]	Inflammation
rs1537377	CDKN2B-AS1	9p21.3	European [2]	Confirmed [2] [76]	Confirmed [2]	Cell cycle regulation
rs10859871	VEZT	12q22	European [2]	Confirmed [76]	Confirmed [2]	Cell adhesion
rs12700667	Intergenic	7p15.2	European [2]	Confirmed [2] [76]	Confirmed [2]	Developmental
rs7739264	ID4	6p22.3	European [2]	Confirmed [2] [76]	Not confirmed	Differentiation
rs4141819	Intergenic	2p14	European [2]	Variable [2] [76]	Not confirmed	Unknown
rs10965235	CDKN2B-AS1	9p21.3	Japanese [2]	Not applicable	Confirmed [2]	Cell cycle regulation

Established Risk Loci and Cross-Population Validation

Conserved Loci Across Populations

Meta-analyses of endometriosis GWAS have revealed several risk loci demonstrating remarkable consistency across diverse populations. The largest cross-population meta-analysis to date, encompassing 17,045 cases and 191,596 controls of European and Japanese ancestry, confirmed nine previously reported loci at genome-wide significance levels [4]. Among these, the WNT4 (rs7521902), VEZT (rs10859871), and CDKN2B-AS1 (rs1537377) loci showed consistent effect directions and magnitudes across both European and East Asian populations [2] [4]. This conservation suggests these variants influence fundamental disease mechanisms that are largely independent of population-specific genetic backgrounds.

The IL1A locus (rs6542095) represents a notable success story in cross-population replication. Initially identified in Japanese GWAS, this association was subsequently confirmed in European populations, with one replication study reporting p = 0.01 for Stage III/IV disease in a Belgian cohort [76]. The consistent association of inflammation-related genes like IL1A across populations highlights the universal role of immune dysregulation in endometriosis pathogenesis.

Population-Specific Genetic Effects

In contrast to the conserved loci, several endometriosis risk variants demonstrate substantial heterogeneity across populations. The rs4141819 locus on chromosome 2p14 shows significant evidence of heterogeneity across datasets (P < 0.005), with inconsistent replication in non-European populations [2]. Similarly, the rs10965235 variant in CDKN2B-AS1, identified in the first Japanese GWAS with a substantial effect size (OR = 1.44), is essentially monomorphic in European populations, making cross-population replication impossible [2].

Population-specific differences extend beyond single variants to encompass broader genetic architecture. A study of Iranian women revealed significant associations between endometriosis and geographical/demographic variables, suggesting that local genetic adaptations and environmental exposures may modulate genetic risk effects [12]. These population-specific patterns highlight limitations in current GWAS approaches, which predominantly focus on European-ancestry individuals and may miss population-specific risk variants.

Methodological Considerations for Cross-Population Replication

Phenotypic Heterogeneity and Stratification

A critical factor influencing cross-population replication success is the phenotypic definition of endometriosis cases. Multiple studies demonstrate that genetic effects are typically stronger for moderate-to-severe (rAFS Stage III/IV) disease compared to all endometriosis cases combined [2] [4]. The 2017 meta-analysis found that eight of nine established loci had stronger effect sizes among Stage III/IV cases, implying they are likely implicated in the development of more severe disease forms [2]. This stratification by disease severity explains inconsistent replication across studies employing different case definitions.

The surgical confirmation of cases represents another source of heterogeneity. Studies utilizing laparoscopically and histologically confirmed cases, such as the Belgian replication cohort (998 cases, 783 controls), provide more reliable association signals compared to those relying on self-reported diagnoses [76]. Variations in diagnostic criteria and surgical indication across clinical centers and populations introduce additional heterogeneity that complicates cross-population genetic comparisons.

Analytical Frameworks for Trans-Ancestry GWAS

Advanced statistical methods are emerging to better address cross-population genetic analysis. The Han and Elkin random-effects model (RE2) offers improved power under heterogeneity compared to conventional random-effects models by relaxing conservative assumptions in hypothesis testing [4]. This approach is particularly valuable for trans-ancestry meta-analyses where heterogeneity is expected.

Conditional analyses have further refined our understanding of established risk loci by identifying secondary association signals. The 2017 meta-analysis identified five secondary association signals, including two at the ESR1 locus, resulting in 19 independent SNPs robustly associated with endometriosis [4]. These fine-mapped associations improve cross-population transferability by identifying potentially causal variants rather than tagSNPs whose LD patterns vary across populations.

Table 2: Methodological Framework for Cross-Population Replication Studies

Study Component	Requirements	Solutions for Genetic Heterogeneity
Case Definition	Surgical confirmation (laparoscopic/histological)	Stratify by rAFS stage (I/II vs. III/IV)
Control Selection	Laparoscopically confirmed disease-free individuals	Match genetic ancestry; exclude related disorders
Genotyping	Genome-wide coverage with population-specific imputation	Use trans-ancestry reference panels (1000G, gnomAD)
Association Testing	Standardized quality control metrics	Apply random-effects models (RE2) for heterogeneous effects
Functional Validation	Tissue-specific functional genomics	eQTL mapping in relevant tissues (uterus, ovary) [19] [8]
Replication Assessment	Multiple independent cohorts	Pre-specified significance thresholds (P < 0.05 for direction-consistent effects)

Functional Genomics to Decipher Population Heterogeneity

Tissue-Specific Regulatory Mechanisms

Functional genomic approaches provide biological context for population-specific genetic effects. A recent multi-tissue eQTL analysis of 465 endometriosis-associated variants across six physiologically relevant tissues revealed substantial tissue specificity in regulatory profiles [19] [8]. In reproductive tissues (uterus, ovary, vagina), eQTL-associated genes were enriched for hormonal response, tissue remodeling, and adhesion pathways, whereas in peripheral blood and intestinal tissues, immune and epithelial signaling genes predominated [8].

This tissue-specific regulatory architecture suggests that population differences in genetic effects may reflect variations in gene regulation rather than protein-coding changes. The study identified key regulatory genes including MICB, CLDN23, and GATA4 that were consistently linked to immune evasion, angiogenesis, and proliferative signaling pathways [19]. Understanding how population-specific genetic backgrounds interact with these regulatory elements will be crucial for explaining heterogeneous genetic effects.

Integration of Ancient Variation and Modern Environmental Factors

Emerging evidence suggests that ancient hominin introgression may contribute to population-specific genetic risk. A 2025 study identified regulatory variants in genes including IL-6, CNR1, and IDO1 that show signatures of Neandertal or Denisovan origin and are enriched in endometriosis cohorts [11]. These ancient variants frequently overlap with endocrine-disrupting chemical (EDC) responsive regions, suggesting gene-environment interactions that may differentially affect risk across populations with varying ancestral backgrounds and environmental exposures [11].

The interaction between ancient genetic variation and modern environmental pollutants creates a complex landscape of population-specific risk profiles that cannot be captured by traditional GWAS approaches alone. This integrative perspective suggests that endometriosis susceptibility may result from the convergence of ancient regulatory variants and contemporary environmental exposures that jointly modulate immune and inflammatory responses [11].

Table 3: Research Reagent Solutions for Cross-Population Endometriosis Genetics

Resource Category	Specific Tools/Reagents	Application in Replication Studies
Genotyping Platforms	Illumina HumanCoreExome array [76]	Cost-effective genome-wide variant detection
Imputation Reference Panels	1000 Genomes Project (March 2012 Release) [4]	Improved coverage of rare and population-specific variants
Functional Annotation Databases	GTEx v8 [19] [8], ENCODE [2]	Tissue-specific regulatory element annotation
Variant Effect Prediction	Ensembl VEP [19] [8]	Genomic context and functional consequence prediction
Expression Profiling	Nanostring nCounter, RNA-seq	Validation of eQTL effects in target tissues
Epigenetic Profiling	ATAC-seq, H3K27ac ChIP-seq [9]	Chromatin accessibility and active enhancer mapping
Statistical Genetics Tools	METAL, PLINK, RELATE	Meta-analysis, association testing, relatedness estimation
Pathway Analysis	MSigDB Hallmark Gene Sets [19] [8]	Biological pathway enrichment analysis

The cross-population replication of endometriosis risk loci reveals a complex genetic architecture characterized by both conserved biological pathways and population-specific effects. While variants in hormone regulation (WNT4, ESR1), inflammation (IL1A), and cell adhesion (VEZT) pathways demonstrate relatively consistent effects across populations, others show substantial heterogeneity due to differences in allele frequency, LD patterns, and gene-environment interactions.

Future genetic studies of endometriosis must prioritize diverse ancestral representation to ensure equitable translation of genetic discoveries across all populations. The integration of functional genomics with GWAS signals provides a powerful approach to dissect population-specific regulatory mechanisms and identify core disease pathways conserved across human diversity. Additionally, standardized phenotypic classification and consideration of gene-environment interactions will be essential for robust cross-population replication.

As genetic studies of endometriosis continue to expand across diverse global populations, researchers and drug development professionals should focus on the functional validation of conserved loci that offer the greatest promise for universally effective therapeutic interventions. The continued investigation of population-specific effects will not only improve risk prediction across diverse groups but also reveal novel biological insights into this complex disorder.

Genetic Correlation Analyses with Comorbid Conditions

Endometriosis is a common, complex gynecological condition influenced by multiple genetic and environmental factors, with an estimated heritability of around 52% [2]. Large-scale genome-wide association studies (GWAS) have successfully identified numerous genetic loci associated with endometriosis risk, providing insights into its genetic architecture [77] [2]. A key finding from these studies is the significant genetic correlation between endometriosis and several comorbid conditions, particularly other pain conditions and immune-related diseases [77] [78]. Understanding these shared genetic influences is crucial for unraveling the biological mechanisms underlying endometriosis and its comorbidity patterns, especially in the context of genetic heterogeneity across different populations. This technical guide provides researchers with methodologies and analytical frameworks for conducting genetic correlation analyses between endometriosis and its comorbid conditions.

Key Genetic Correlations Between Endometriosis and Comorbidities

Established Genetic Correlations

Table 1: Significant Genetic Correlations Between Endometriosis and Comorbid Conditions

Comorbidity Category	Specific Conditions	Genetic Correlation (rg)	P-value	Citations
Pain Conditions	Multisite chronic pain (MCP)	Substantial sharing reported	<5.0×10-8	[77]
	Migraine	Substantial sharing reported	<5.0×10-8	[77]
	Back pain	Significant	<5.0×10-8	[77]
Inflammatory/Autoimmune	Osteoarthritis	0.28	3.25×10-15	[78]
	Rheumatoid arthritis	0.27	1.5×10-5	[78]
	Asthma	Significant	<5.0×10-8	[77]
	Multiple sclerosis	0.09	4.00×10-3	[78]
Other Gynecological	Uterine leiomyomata (fibroids)	Significant overlap	<5.0×10-8	[45]

GWAS meta-analyses involving 60,674 cases and 701,926 controls have identified significant genetic correlations between endometriosis and 11 pain conditions, as well as various inflammatory conditions [77]. Multitrait genetic analyses have revealed substantial sharing of variants associated with endometriosis with multisite chronic pain (MCP) and migraine [77]. The functional characterization of endometriosis-associated variants has shown that they regulate the expression or methylation of genes involved in pain perception and maintenance, including SRP14/BMF, GDAP1, MLLT10, BSN, and NGF [77].

Shared Genetic Loci and Pathways

Table 2: Shared Genetic Loci Between Endometriosis and Comorbid Conditions

Genomic Locus	Gene(s)	Shared Conditions	Potential Biological Mechanism
3p21.31	BSN	Osteoarthritis	Pain perception and maintenance
10p12.31	MLLT10	Osteoarthritis	Pain perception and maintenance
2q33.1	BMPR2	Osteoarthritis	Tissue remodeling and growth
8p23.1	XKR6	Rheumatoid arthritis	Cellular transport mechanisms
1p13.2	NGF	Various pain conditions	Nerve growth and pain signaling

Integration of endometriosis GWAS findings with expression quantitative trait loci (eQTL) data from relevant tissues has helped identify shared regulatory mechanisms [19]. Tissue specificity has been observed in the regulatory profiles of eQTL-associated genes, with immune and epithelial signaling genes predominating in peripheral blood and intestinal tissues, while reproductive tissues show enrichment of genes involved in hormonal response, tissue remodeling, and adhesion [19].

Methodological Frameworks for Genetic Correlation Analyses

Core Analytical Workflow

Figure 1: Genetic Correlation Analysis Workflow

Key Methodologies and Protocols

Linkage Disequilibrium Score Regression (LDSC)

Purpose: To estimate genetic correlations while correcting for confounding biases such as population stratification and cryptic relatedness.

Protocol Details:

• Input Data: GWAS summary statistics from both endometriosis and comorbid condition studies
• Key Parameters: LD scores calculated from a reference population (e.g., 1000 Genomes Project)
• Statistical Adjustment: Genomic inflation factor (λGC) adjustment to distinguish polygenic signal from bias
• Output: Genetic correlation coefficient (rg) with standard error and significance testing

Recent applications of this method to endometriosis have shown that 89.5% of the genomic inflation factor (λGC) of 1.12 was attributable to polygenic heritability, with an intercept = 1.02 (s.e. = 0.0081) [45]. The single nucleotide polymorphism (SNP)-based heritability (h²) for endometriosis has been estimated at 0.0281 (s.e. = 0.0029) on the liability scale [45].

Mendelian Randomization (MR) Analysis

Purpose: To assess potential causal relationships between endometriosis and comorbid conditions.

Protocol Details:

• Instrumental Variable Selection: Genome-wide significant SNPs (P < 5×10⁻⁸) from endometriosis GWAS, clumped to ensure independence (r² < 0.001, distance = 1 Mb)
• Validation: F-statistic > 10 to avoid weak instrument bias
• MR Methods: Inverse-variance weighted (IVW) as primary method, supplemented with MR-Egger, weighted median, and MR-PRESSO for sensitivity analyses
• Colocalization Analysis: To assess whether shared genetic variants influence both traits

A recent two-sample MR analysis using UK Biobank and FinnGen data (20,190 cases and 130,160 controls) identified RSPO3 as a potential causal protein for endometriosis, with external validation confirming this association [54]. Another MR study suggested a causal association between endometriosis and rheumatoid arthritis (OR = 1.16, 95% CI = 1.02-1.33) [78].

Multi-trait Analysis of GWAS (MTAG)

Purpose: To boost discovery of novel and shared genetic variants by combining information across correlated traits.

Protocol Details:

• Input: GWAS summary statistics for endometriosis and genetically correlated traits
• Method: Uses a random-effects model that accounts for sample overlap and genetic correlation structure
• Output: Variant effect estimates refined by incorporating information from correlated traits

Application of this method has identified substantial sharing of variants between endometriosis and pain conditions such as multisite chronic pain and migraine [77].

Population-Specific Considerations in Genetic Correlation Analyses

Genetic Heterogeneity Across Populations

Table 3: Population-Specific Considerations in Endometriosis Genetic Studies

Population	Sample Size (Cases/Controls)	Key Findings	Heterogeneity Assessment
European	60,674/701,926 (across multiple studies)	42 genome-wide significant loci comprising 49 distinct association signals	Seven out of nine loci showed consistent directions of effect across studies [2]
East Asian	Included in large meta-analysis	Shared some but not all risk loci with European populations	Two independent inter-genic loci on chromosome 2 showed significant heterogeneity (P < 0.005) [2] [5]
Iranian	25/25 (preliminary study)	Differences in gene expression of MFN2, PINK1, and PRKN	Geographical and demographic variables significantly associated with genetic content [12]
Japanese	2,467/5,335 (in meta-analysis)	CDKN2B-AS1 identified as significant locus	Most loci showed consistent effects across populations [2] [5]

Meta-analyses of multiple GWAS datasets have shown remarkable consistency in endometriosis genetic results across studies, with limited evidence of population-based heterogeneity [2] [5]. However, two independent inter-genic loci (rs4141819 and rs6734792 on chromosome 2) demonstrated significant heterogeneity across datasets (P < 0.005) [2] [5]. Most loci (eight out of nine) showed stronger effect sizes for Stage III/IV endometriosis, suggesting they are particularly relevant for moderate to severe or ovarian disease [2] [5].

Population-specific analyses in Iranian women revealed significant associations between geographical variables, gene expression magnitude, and SNP genotypes, highlighting the importance of local demographic factors in genetic studies [12]. Spatial principal components analysis (sPCA) showed significant positive and negative eigenvalues (global and local structuring, respectively) of genetic content based on geographical variables [12].

Research Reagent Solutions for Genetic Correlation Studies

Table 4: Essential Research Reagents and Resources for Genetic Correlation Analyses

Reagent/Resource	Function/Application	Example Sources
GWAS Summary Statistics	Primary data for genetic correlation analyses	UK Biobank, FinnGen, GWAS Catalog, IEC
LD Score Regression Software	Calculating genetic correlations and heritability	LDSC software package
GTEx Database eQTL Data	Functional annotation of genetic variants	GTEx Portal v8
METAL Software	GWAS meta-analysis	Available from CSG group
PLINK	Genome-wide association analysis toolset	Available from cog-genomics
MR-Base Platform	Two-sample Mendelian randomization	IEU GWAS database
SOMAscan Platform	Plasma protein quantitative trait loci (pQTL) analysis	Olink, Somalogic
UK Biobank Resource	Large-scale genetic and health data	UK Biobank (Application Number 9637)

The GTEx v8 database provides essential eQTL data for functional annotation of endometriosis-associated variants across relevant tissues, including uterus, ovary, vagina, sigmoid colon, ileum, and peripheral blood [19]. The SOMAscan platform (v4) enables identification of cis-plasma protein quantitative trait loci (cis-pQTLs), which can be used in MR analyses to identify potential drug targets [54].

Genetic correlation analyses have revealed substantial shared genetic architecture between endometriosis and various comorbid conditions, particularly pain conditions and immune-related disorders. The methodologies outlined in this guide—including LD score regression, Mendelian randomization, and multi-trait analysis—provide powerful approaches for elucidating these shared genetic influences. Consideration of population-specific genetic factors remains crucial for comprehensive understanding of endometriosis heterogeneity. Future research directions should include larger diverse population studies, functional validation of shared pathways, and integration of multi-omics data to translate these genetic findings into improved diagnostics and therapeutics.

Functional Validation of Population-Specific Variants

Endometriosis is a complex, heritable inflammatory condition affecting approximately 10% of reproductive-aged women globally, with a heritability component estimated at around 52% [2] [1]. While genome-wide association studies (GWAS) have successfully identified multiple genetic loci associated with endometriosis risk, these discoveries predominantly stem from studies in populations of European and Japanese ancestry [2] [1]. This limitation highlights a critical research gap: understanding population-specific genetic variants and their functional consequences is essential for unraveling the complete genetic architecture of endometriosis and developing targeted diagnostic and therapeutic strategies applicable across all populations [1]. This guide provides a comprehensive technical framework for the functional validation of population-specific genetic variants in endometriosis research, addressing the pressing need to move beyond genetic association toward biological mechanism in diverse human populations.

Key Population-Specific Variants in Endometriosis

GWAS meta-analyses have revealed remarkable consistency in endometriosis risk loci across different populations, though population-specific effects exist [2]. The following table summarizes key population-specific genetic findings in endometriosis research:

Table 1: Documented Population-Specific Genetic Associations in Endometriosis

Variant/Gene	Population	Effect Size (OR/Risk)	P-value	Biological Function
rs10965235 (CDKN2B-AS1)	Japanese	OR = 1.44 (95% CI: 1.30–1.59)	5.57 × 10−12	Cell cycle regulation [2]
rs12700667 (7p15.2)	European	OR = 1.22 (95% CI: 1.13–1.32)	1.6 × 10−9	Inter-genic regulatory function [2]
rs150338402 (MMP7 p.I79T)	Chinese (Ovarian END)	3.37% patients vs 1.52% controls	0.0076	Cell migration, invasion, EMT [79]
rs16826658 (near WNT4)	Japanese	-	1.66 × 10−6	Hormone regulation, development [2]
Co-localized IL-6 variants	European (Ancient origin)	Significantly enriched	-	Immune dysregulation [11]

Recent research has identified specific regulatory variants, some of ancient hominin origin (Neandertal and Denisovan), that are enriched in endometriosis cohorts and may interact with modern environmental pollutants like endocrine-disrupting chemicals (EDCs) [11]. These findings suggest a complex interplay between population genetics and environmental factors in endometriosis susceptibility.

Experimental Framework for Functional Validation

Comprehensive Functional Validation Workflow

The functional validation of population-specific variants requires a multi-stage approach, progressing from computational prioritization to mechanistic studies. The following diagram illustrates this comprehensive workflow:

In Vitro Functional Assays for Rare Coding Variants

For rare missense variants like MMP7 p.I79T, a comprehensive functional validation protocol is required:

Cell Culture and Transfection:

• Utilize relevant endometrial cell lines (e.g., Ishikawa, 12Z) or primary endometrial stromal cells
• Perform plasmid construction with wild-type and mutant (p.I79T) MMP7 cDNA in mammalian expression vectors
• Transfect cells using appropriate methods (lipofection, electroporation) with empty vector as control [79]

Functional Endpoint Assessments:

• Cell Migration & Invasion: Conduct Transwell migration and Matrigel invasion assays (24-48 hours)
• Protein Activity: Measure proteolytic activity using fluorogenic substrates or gelatin zymography
• Epithelial-Mesenchymal Transition (EMT): Assess EMT markers (E-cadherin, N-cadherin, vimentin) via Western blot
• Gene Expression: Quantify MMP7 and related pathway genes using qRT-PCR [79]

Protocol Details:

• For invasion assays, coat Transwell inserts with Matrigel (1:8 dilution) and incubate for 4-6 hours at 37°C
• Seed 2.5-5×10⁴ cells in serum-free medium in upper chamber, with 10% FBS as chemoattractant in lower chamber
• After 24-48 hours, fix and stain migrated cells, then capture and count 5 random fields per membrane
• Perform three independent experiments in triplicate, analyzing data with two-tailed Student's t-test [79]

Expression Quantitative Trait Loci (eQTL) Analysis

Methodology for Tissue-Specific eQTL Mapping:

• Cross-reference GWAS-identified variants with eQTL data from GTEx database (v8 or newer)
• Analyze multiple endometriosis-relevant tissues: uterus, ovary, vagina, sigmoid colon, ileum, peripheral blood
• Apply false discovery rate (FDR) correction (FDR < 0.05) to identify significant eQTLs
• Extract slope values indicating direction and magnitude of regulatory effects [19]

Functional Interpretation:

• Prioritize genes based on: (1) frequency of regulation by multiple eQTL variants, (2) strength of slope values
• Conduct pathway enrichment analysis using MSigDB Hallmark gene sets and Cancer Hallmarks collections
• Identify tissue-specific regulatory patterns distinguishing reproductive from intestinal tissues [19]

Research Reagent Solutions

Table 2: Essential Research Reagents for Functional Validation Studies

Reagent/Category	Specific Examples	Research Application	Technical Considerations
Cell Models	Ishikawa, 12Z, primary endometrial stromal cells	In vitro functional assays	Use early passage cells; validate identity regularly
Expression Vectors	Mammalian expression vectors (pcDNA3.1, pCMV)	cDNA overexpression	Include selection markers (neomycin, hygromycin)
Gene Editing Tools	CRISPR-Cas9 systems, siRNA/shRNA	Knockout/knockdown studies	Verify efficiency via Western blot or qRT-PCR
Antibodies	Anti-MMP7, E-cadherin, N-cadherin, vimentin	Protein detection (Western, IHC)	Validate specificity for target proteins
Assay Kits	Transwell migration/invasion, gelatin zymography	Functional characterization	Include appropriate controls and standards
eQTL Databases	GTEx Portal (v8+)	In silico regulatory analysis	Consider tissue-specific sample sizes

Data Analysis and Visualization Framework

Signaling Pathways in Endometriosis Variants

Population-specific variants affect key signaling pathways in endometriosis pathogenesis:

Quantitative Data Analysis Guidelines

Statistical Considerations for Population Studies:

• For genetic association: Apply genome-wide significance threshold (P < 5 × 10^-8)
• For functional assays: Perform three independent experiments in triplicate
• Use two-tailed Student's t-test for comparisons, ANOVA for multiple groups
• Apply Benjamini-Hochberg false discovery rate correction for multiple testing [79] [11]

Clinical Correlation Analysis:

• Correlate genetic variants with 38+ available clinical characteristics
• Include hormone levels (FSH, LH, progesterone, testosterone)
• Incorporate clinical biomarkers (CEA, SCCA, total bilirubin)
• Adjust for relevant covariates in multivariate analyses [79]

Functional validation of population-specific variants represents a critical frontier in endometriosis genetics research. As GWAS efforts expand to include more diverse populations, researchers must employ the comprehensive functional validation framework outlined in this guide to bridge the gap between genetic association and biological mechanism. Future research directions should include the development of population-specific organoid models, investigation of gene-environment interactions—particularly with endocrine-disrupting chemicals—and integration of multi-omics data to fully elucidate the functional consequences of genetic diversity in endometriosis pathogenesis. Through rigorous functional validation, population-specific variants may yield novel biomarkers for early detection and personalized therapeutic approaches for this complex gynecological disorder.

Comparative Analysis of Genetic Risk Profiles Across Ethnicities

Endometriosis, a chronic inflammatory condition characterized by the presence of endometrial-like tissue outside the uterus, demonstrates a significant heritable component, with genetic factors accounting for approximately 52% of disease variance [2]. Despite the global prevalence of endometriosis affecting approximately 10% of reproductive-aged women, its genetic architecture exhibits considerable heterogeneity across diverse ethnic populations [1] [12]. Understanding this population-specific genetic heterogeneity is crucial for developing precise diagnostic tools and targeted therapeutic interventions. Genome-wide association studies (GWAS) have identified numerous susceptibility loci; however, the transferability and effect sizes of these genetic risk variants across different ethnic groups remain incompletely characterized [2] [4] [12]. This comparative analysis systematically examines the genetic risk profiles for endometriosis across diverse ethnicities, highlighting population-specific variants, differential effect sizes, and methodological considerations for cross-population genetic studies.

Endometriosis exhibits a complex genetic architecture influenced by multiple common variants with small to moderate effects. Large-scale GWAS meta-analyses have identified numerous susceptibility loci, with the majority residing in non-coding regions, suggesting their potential role in gene regulation [2] [1]. The estimated common SNP-based heritability of endometriosis is approximately 26% [4], indicating a substantial polygenic component. Functional categorization of associated genes reveals enrichment in biological pathways central to sex steroid hormone signaling, inflammation, cellular adhesion, and developmental processes [19] [4].

Table 1: Key Endometriosis Susceptibility Loci Identified in GWAS

Genomic Region	Representative SNP	Nearest Gene(s)	Primary Biological Pathway	Population Initially Identified
1p36.12	rs7521902	WNT4	Hormone regulation, development	European
2p25.1	rs13394619	GREB1	Estrogen-mediated cell growth	European
6p22.3	rs7739264	ID4	Cell differentiation	European
7p15.2	rs12700667	-	Developmental processes	European
9p21.3	rs10965235	CDKN2B-AS1	Cell cycle regulation	Japanese
12q22	rs10859871	VEZT	Cell adhesion	European
2q35	rs1250241	FN1	Extracellular matrix organization	European
6q25.1	rs71575922	SYNE1, ESR1	Estrogen receptor signaling	European
11p14.1	rs74485684	FSHB	Follicle-stimulating hormone production	European

Recent research has expanded beyond single-variant associations to explore regulatory mechanisms, including expression quantitative trait loci (eQTLs) and their tissue-specific effects [19]. Integration of endometriosis GWAS findings with functional genomic data from relevant tissues (uterus, ovary, vagina, colon, ileum, and peripheral blood) has revealed that endometriosis-associated variants frequently influence gene expression in a tissue-specific manner [19]. For instance, specific variants demonstrate regulatory effects on genes involved in immune responses and epithelial signaling in peripheral blood and intestinal tissues, while predominantly affecting hormonal response pathways in reproductive tissues [19].

Ethnic Heterogeneity in Genetic Risk Variants

Population-Specific Allele Frequencies and Effect Sizes

Comparative analyses of endometriosis genetics across ethnic groups have revealed significant disparities in allele frequencies and risk variant effect sizes. The seminal meta-analysis by Sapkota et al. (2017), which incorporated data from European and Japanese populations, demonstrated that while several susceptibility loci show consistent effects across ethnicities, others exhibit population-specific associations [4]. For instance, the variant rs10965235 in CDKN2B-AS1 reached genome-wide significance in Japanese populations but showed different association patterns in European cohorts [2] [4].

Table 2: Ethnic Heterogeneity in Select Endometriosis Risk Loci

Variant	Genomic Region	Nearest Gene	Effect Size (OR) European	Effect Size (OR) Japanese	Heterogeneity P-value
rs10965235	9p21.3	CDKN2B-AS1	1.11	1.44	<0.001
rs7521902	1p36.12	WNT4	1.15	1.12	0.42
rs12700667	7p15.2	-	1.14	1.09	0.21
rs10859871	12q22	VEZT	1.12	1.08	0.38
rs4141819	2p14	-	1.10	1.05	0.04

A study focusing on Iranian women revealed distinct genetic associations, with significant differences in gene expression patterns of MFN2, PINK1, and PRKN compared to other populations [12]. Similarly, research on the Sardinian population failed to replicate several risk variants established in other European cohorts, underscoring the potential influence of regional genetic isolates and unique demographic histories on endometriosis genetic architecture [12]. These findings highlight the limitations of generalizing genetic risk profiles across diverse populations and emphasize the necessity for population-specific studies to comprehensively characterize the genetic underpinnings of endometriosis.

Differential Enrichment of Ancient Hominin Variants

Emerging evidence suggests that population-specific endometriosis risk may be partly influenced by archaic hominin introgression. A recent investigation identified regulatory variants of Denisovan and Neandertal origin that are enriched in specific populations and potentially contribute to endometriosis susceptibility through immune dysregulation [11]. Notably, co-localized IL-6 variants (rs2069840 and rs34880821) located at a Neandertal-derived methylation site demonstrated strong linkage disequilibrium and significant enrichment in endometriosis cohorts [11]. Similarly, variants in CNR1 and IDO1 of Denisovan origin showed population-specific associations with endometriosis risk [11]. These findings provide a novel evolutionary perspective on the ethnic heterogeneity observed in endometriosis genetics, suggesting that ancient population divergences and local adaptations may contribute to contemporary differences in disease susceptibility.

Methodological Considerations for Cross-Ethnic Genetic Studies

Addressing Population Stratification

Population stratification (PS) represents a significant methodological challenge in genetic association studies across diverse ethnicities. PS occurs when allele frequency differences between cases and controls arise from systematic ancestry differences rather than disease association, potentially leading to spurious findings [56] [80]. Robust methodological approaches are essential to account for these confounding effects:

Principal Component Analysis (PCA) and Extensions: Standard PCA approaches, such as EIGENSTRAT, identify continuous axes of genetic variation (principal components) to correct for population structure [80]. However, these methods may be suboptimal for datasets with discrete subpopulations or subject outliers. Robust PCA combined with k-medoids clustering has been developed to effectively handle both scenarios, demonstrating superior performance in the presence of outliers [80].

Genetic Differentiation Metrics: The fixation index (Fst) quantifies population genetic differentiation by comparing expected heterozygosity across subpopulations [56]. Fst values range from 0-0.05 (little differentiation) to >0.25 (very great differentiation), providing a standardized metric to evaluate ancestral differences between study populations [56].

Admixture Mapping: In admixed populations (e.g., African Americans with African and European ancestry), admixture mapping leverages local ancestry segments to identify genomic regions enriched for disease risk alleles from a specific ancestral population [56]. This approach can enhance power for detecting associations in recently admixed populations.

Advanced Workflows for Cross-Population Analysis

Diagram 1: Comprehensive workflow for cross-ethnic genetic analysis of endometriosis, highlighting key steps for addressing population stratification and enabling valid cross-population comparisons.

Functional Genomics and Cross-Population Validation

Tissue-Specific Regulatory Mechanisms

Functional genomic approaches provide critical insights into the molecular mechanisms through which genetic variants contribute to endometriosis risk across populations. Integration of endometriosis GWAS findings with expression quantitative trait loci (eQTL) data from the GTEx database has revealed substantial tissue-specific regulatory effects [19]. For instance, analysis of six physiologically relevant tissues (uterus, ovary, vagina, sigmoid colon, ileum, and peripheral blood) demonstrated that endometriosis-associated variants frequently function as eQTLs with tissue-specific patterns [19]. In reproductive tissues, regulated genes were enriched for hormonal response, tissue remodeling, and adhesion pathways, while in intestinal tissues and peripheral blood, immune and epithelial signaling genes predominated [19].

Key regulatory genes consistently linked to hallmark pathways across multiple tissues include MICB (immune evasion), CLDN23 (angiogenesis), and GATA4 (proliferative signaling) [19]. Notably, a substantial subset of eQTL-regulated genes in all tissues showed no association with known pathways, suggesting novel regulatory mechanisms in endometriosis pathogenesis that may exhibit population-specific effects depending on local genetic architecture and environmental exposures [19].

Multi-Omics Integration for Pathway Analysis

Advanced multi-omics approaches integrating genomic, transcriptomic, and epigenomic data have enhanced our understanding of shared biological pathways across ethnicities. Genetic correlation analyses have revealed significant shared genetic architecture between endometriosis and certain immune-mediated conditions, including osteoarthritis (rg = 0.28), rheumatoid arthritis (rg = 0.27), and multiple sclerosis (rg = 0.09) [78]. Mendelian randomization analyses further suggested a potential causal relationship between endometriosis and rheumatoid arthritis (OR = 1.16) [78].

Multi-trait analysis of GWAS has identified specific genetic loci shared between endometriosis and comorbid conditions, including three loci shared with osteoarthritis (BMPR2/2q33.1, BSN/3p21.31, MLLT10/10p12.31) and one with rheumatoid arthritis (XKR6/8p23.1) [78]. Functional annotation of these shared risk variants using eQTL data from GTEx and eQTLGen databases highlighted enrichment in seven biological pathways across all four conditions, predominantly involving immune regulation and inflammatory responses [78].

Diagram 2: Integrative biological pathway illustrating how genetic variants, environmental exposures, and ancestral genetic contributions converge to influence endometriosis risk through tissue-specific regulatory mechanisms.

Table 3: Essential Research Resources for Cross-Ethnic Endometriosis Genetic Studies

Resource Category	Specific Tools/Databases	Primary Function	Application in Endometriosis Research
Genomic Databases	GTEx Portal v8 [19]	Tissue-specific eQTL data	Identify regulatory consequences of risk variants
	GWAS Catalog [19]	Archive of published GWAS results	Curate established endometriosis risk loci
	1000 Genomes Project [11]	Reference panel for population genetics	Assess allele frequency differences across populations
Analysis Tools	STRUCTURE [56]	Population structure inference	Ancestry estimation in diverse cohorts
	EIGENSTRAT [80]	Principal components analysis	Correct for population stratification in association tests
	LDlink [11]	Linkage disequilibrium analysis	Evaluate variant correlations in different populations
Biobanks	UK Biobank [78] [46]	Large-scale genetic and health data	Conduct GWAS in diverse populations
	Estonian Biobank [46]	Population-based genetic cohort	Replicate findings in specific European subsets
	Genomics England [11]	Whole genome sequencing data	Investigate rare variants in clinical contexts
Functional Annotation	ENSEMBL VEP [19]	Variant effect prediction	Annotate functional consequences of risk variants
	STRING-db [12]	Protein-protein interaction networks	Identify biologically relevant pathways
	MSigDB Hallmark Gene Sets [19]	Curated biological pathway database	Perform functional enrichment analyses

The comparative analysis of genetic risk profiles for endometriosis across ethnicities reveals a complex landscape of population-specific variants, heterogeneous effect sizes, and shared biological pathways. While substantial progress has been made in identifying susceptibility loci, primarily in European and East Asian populations, significant gaps remain in the characterization of genetic risk across global diversity. Future research directions should include: (1) expanded GWAS in underrepresented populations, particularly African, Indigenous American, and Middle Eastern cohorts; (2) integration of ancient hominin ancestry and local adaptation signals to understand population-specific risk; (3) development of ethnicity-informed polygenic risk scores that account for differential variant effects across populations; and (4) functional validation of population-specific variants using advanced in vitro and in vivo models. Addressing these priorities will be essential for achieving equitable advances in endometriosis precision medicine across all ethnic groups.

Endometriosis, a complex and often debilitating gynecological condition, affects approximately 10% of women globally during their reproductive years, exerting a substantial toll on their physical health, mental well-being, and overall quality of life [1]. The condition is characterized by the growth of endometrial-like tissue outside the uterus, leading to chronic pelvic pain, dysmenorrhea, dyspareunia, and impaired fertility. Despite its high prevalence, the diagnosis of endometriosis is typically delayed by 7-10 years from symptom onset, primarily due to the reliance on invasive surgical procedures (laparoscopy with histological confirmation) as the gold standard for definitive diagnosis [1]. This diagnostic challenge is further compounded by the substantial genetic heterogeneity observed across diverse populations, presenting significant obstacles for the development of universally effective diagnostic biomarkers and therapeutic interventions.

The heritable component of endometriosis is well-established, with twin studies estimating heritability at approximately 52% and genome-wide association studies (GWAS) revealing a complex architecture of common genetic variants contributing to disease risk [2]. Genetic heterogeneity describes the phenomenon where the same or similar disease phenotypes arise through different genetic mechanisms in different individuals [81]. In the context of endometriosis, this heterogeneity manifests as population-specific risk loci, varying effect sizes of associated variants, and divergent patterns of linkage disequilibrium across ancestral groups [22]. Understanding and addressing this heterogeneity is paramount for developing population-tailored diagnostics that can achieve clinical utility across diverse global populations, moving beyond the current one-size-fits-all approach that has limited translational success to date.

Genetic Landscape of Endometriosis: Insights from GWAS

Established Genetic Risk Loci and Pathways

Genome-wide association studies have revolutionized our understanding of the genetic architecture of endometriosis. Early GWAS and subsequent meta-analyses have identified numerous susceptibility loci, providing insights into the biological pathways involved in disease pathogenesis. A landmark meta-analysis of four GWAS and four replication studies including 11,506 cases and 32,678 controls identified six genome-wide significant loci including rs12700667 on 7p15.2, rs7521902 near WNT4, rs10859871 near VEZT, rs1537377 near CDKN2B-AS1, rs7739264 near ID4, and rs13394619 in GREB1 [2]. These findings have been remarkably consistent across studies, with seven out of nine loci showing consistent directions of effect across different populations [2].

More recent large-scale efforts have substantially expanded the catalog of endometriosis risk loci. A multi-ancestry GWAS of approximately 1.4 million women (including 105,869 cases) identified 80 genome-wide significant associations, 37 of which are novel, dramatically expanding our understanding of the genetic architecture of the condition [43]. This study also reported the first five genome-wide significant loci for adenomyosis, a frequently co-occurring condition. The genetic variants implicate pathways involved in hormone regulation, inflammatory processes, tissue remodeling, and cell differentiation, providing crucial insights into the molecular mechanisms underlying disease development and progression [1] [43].

Table 1: Key Genetic Loci Associated with Endometriosis Risk

Locus	Nearest Gene(s)	Potential Function	Population	Reference
7p15.2	Intergenic	Regulatory function	European	[2]
1p36.12	WNT4	Sex steroid regulation, development	European, Japanese	[1] [2]
12q22	VEZT	Cell adhesion	European, Japanese	[1] [2]
9p21.3	CDKN2B-AS1	Cell cycle regulation	Japanese	[2]
6p12.1	ID4	Developmental pathways	European	[2]
2p25.1	GREB1	Estrogen regulation	European	[2]

Functional Genomic Insights

Beyond mere locus identification, functional genomics approaches have been instrumental in elucidating the mechanisms by which identified genetic variants influence disease risk. Gene expression profiling studies have identified numerous differentially expressed genes in endometriotic lesions compared to normal endometrial tissue, involving processes such as inflammation, angiogenesis, and extracellular matrix remodeling [1]. Additionally, epigenetic modifications, particularly DNA methylation changes, have been observed in endometriosis and may influence disease onset and progression [1].

Integration of multi-omics data has further enhanced our understanding of endometriosis pathophysiology. Colocalization and fine-mapping analyses in large multi-ancestry studies have revealed that genetic variation influences endometriosis risk through transcriptomic, epigenetic, and proteomic regulation across multiple tissues [43]. These integrative approaches demonstrate convergence on pathways involved in immune regulation, tissue remodeling, and cell differentiation, providing a more comprehensive picture of the functional consequences of genetic risk variants [43].

Evidence of Genetic Heterogeneity Across Populations

Population-Specific Allele Frequencies and Effect Sizes

A global population genomic analysis of endometriosis-related SNPs has revealed marked differences in allele frequencies across five major population groups (Europeans, Africans, Americans, East Asians, and South Asians) [22]. This analysis identified 296 common genetic targets with low allele frequencies (≤0.1) and six with high allele frequencies (≥0.9) across populations, but with significant variation between groups [22]. The distribution of these allele frequencies follows the pattern of the serial founder effect, with the greatest genetic diversity observed in African populations and progressively reduced diversity in populations farther from the African continent [22].

The disease genomic 'grammar' (DGG) of endometriosis—the specific pattern and distribution of risk variants—varies considerably across populations. This variation stems from both demographic history and potential local adaptation, resulting in population-specific genetic risk profiles [22]. For example, studies have reported a nine-fold difference in endometriosis risk between women of East Asian ancestry compared to those of European or American ancestry [22]. These differences highlight the limitations of applying genetic risk models derived from one population to others without proper calibration for local genetic structure.

Table 2: Population-Specific Characteristics of Endometriosis Genetics

Population Group	Key Characteristics	Notable Genetic Factors	Implications for Diagnostics
European	Best characterized genetically, multiple GWAS	27 significant loci identified in large meta-analysis	Existing PRS models show highest prediction accuracy	[22]
East Asian	Higher reported disease risk	Distinct loci identified in Asian-specific GWAS	Population-specific variants may improve risk prediction	[2] [22]
African	Greatest genetic diversity	Underrepresented in GWAS, likely undiscovered variants	Limited transferability of current PRS, need for ancestry-specific models	[22]
Admixed American	Heterogeneous genetic background	Emerging significance in multi-ancestry studies	Require customized approaches accounting for admixture	[43]
South Asian	Limited representation in studies	Partial overlap with European and East Asian signals	Population-specific studies needed for optimal diagnostics	[22]

Challenges in Cross-Population Genetic Transferability

The genetic heterogeneity observed across populations presents significant challenges for the translation of genetic findings into clinically useful tools. Polygenic risk scores (PRS) developed in European populations typically show substantially reduced performance when applied to non-European populations, a phenomenon known as reduced portability [43]. This reduced performance stems from differences in allele frequencies, effect sizes, and linkage disequilibrium patterns across populations [81] [22].

Recent multi-ancestry studies have begun to address these challenges by implementing cross-ancestry PRS frameworks that include individuals from six ancestry groups (African, Admixed American, Central/South Asian, East Asian, European, and Middle Eastern) [43]. These efforts represent important steps toward developing genetic tools with more equitable performance across diverse populations. However, significant work remains to fully characterize the genetic architecture of endometriosis in understudied populations and to develop optimized prediction models for each major ancestral group.

Analytical Frameworks for Addressing Heterogeneity

Traditional Statistical Genetic Approaches

Traditional approaches to addressing genetic heterogeneity in association studies include stratified analysis, meta-analysis frameworks, and heterogeneity tests. The fixed-effects and Han and Elkin random-effects models have been used to investigate the consistency of genome-wide significant loci across datasets and populations [2]. These approaches have demonstrated that while most endometriosis risk loci show consistent effects across populations, some exhibit significant heterogeneity [2].

Cochran's Q test and other heterogeneity statistics help identify loci with significantly different effects across studies or populations [2]. For endometriosis, two independent inter-genic loci on chromosome 2 (rs4141819 and rs6734792) have shown significant evidence of heterogeneity across datasets, suggesting potential population-specific effects [2]. These findings highlight the importance of considering heterogeneity in the interpretation of genetic association results.

Machine Learning and Deep Learning Approaches

Machine learning (ML) approaches, particularly supervised learning methods, offer powerful alternatives for analyzing complex genetic data in the presence of heterogeneity [82] [83]. Unlike traditional parametric models, ML methods can be agnostic to the underlying genetic model and can efficiently handle high-dimensional data, making them particularly suited for analyzing the complex genetic architecture of endometriosis [82].

Deep learning architectures, including convolutional neural networks (CNNs) and recurrent neural networks (RNNs), have shown promising results in population genetic inference tasks, such as identifying population structure, inferring demographic history, and detecting natural selection [83]. These methods can learn complex patterns from genetic data without relying on strongly parameterized models, potentially offering improved performance in the presence of heterogeneity [83].

Diagram 1: ML Framework for Genetic Analysis. A supervised machine learning framework for analyzing multi-ancestry genomic data to develop population-tailored diagnostic models.

Methodologies for Developing Population-Tailored Diagnostics

Multi-ancestry GWAS and Fine-mapping

The foundation for developing population-tailored diagnostics begins with well-powered multi-ancestry GWAS. The recent study including approximately 1.4 million women (105,869 cases) across six ancestries provides a template for such efforts [43]. The protocol involves:

• Cohort Collection and Genotyping: Assembling large, diverse cohorts from multiple biobanks and research studies, with careful attention to representation of understudied populations.
• Phenotype Harmonization: Developing standardized phenotype definitions across cohorts, including detailed sub-phenotype information (e.g., disease stage, symptom profiles, comorbid conditions).
• Quality Control and Imputation: Implementing rigorous quality control metrics separately for each ancestral group, followed by imputation using appropriate reference panels (e.g., 1000 Genomes Project Phase 3, population-specific reference panels).
• Association Testing: Conducting GWAS within each ancestry group using appropriate models that account for population structure.
• Meta-analysis: Performing cross-ancestry meta-analysis using fixed-effects or random-effects models to identify shared and population-specific risk loci.

Following GWAS, statistical fine-mapping is critical for identifying causal variants, particularly in regions showing heterogeneity across populations. Fine-mapping methods leverage differences in linkage disequilibrium patterns across populations to narrow association signals and improve resolution for causal variant identification [43].

Functional Validation and Biomarker Development

Once risk loci are identified, functional validation is essential for translating genetic discoveries into diagnostic biomarkers. Key methodologies include:

• Expression Quantitative Trait Locus (eQTL) Analysis: Determining whether risk variants are associated with gene expression in relevant tissues (e.g., endometrium, endometriotic lesions).
• Epigenetic Profiling: Assessing DNA methylation patterns and other epigenetic modifications in connection with genetic risk variants.
• In Vitro and In Vivo Models: Using cellular and animal models to validate the functional impact of identified risk variants on biological pathways relevant to endometriosis.

For biomarker development, multi-omics integration approaches that combine genomic, transcriptomic, epigenomic, and proteomic data offer the greatest promise for developing sensitive and specific diagnostic tests [1]. These approaches can identify molecular signatures that are robust across populations while accounting for population-specific differences in genetic architecture.

Diagram 2: Diagnostic Development Workflow. A comprehensive workflow for developing population-tailored diagnostic tests for endometriosis, incorporating heterogeneity assessment at multiple stages.

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 3: Essential Research Reagents for Endometriosis Genetic Studies

Reagent/Category	Specific Examples	Function/Application	Considerations for Heterogeneity
Genotyping Arrays	Global Screening Array, Multi-ethnic genotyping arrays	Genome-wide variant detection	Select arrays with content optimized for diverse populations
Whole Genome Sequencing	Illumina NovaSeq, PacBio HiFi	Comprehensive variant discovery	Essential for identifying population-specific variants	[43]
Reference Panels	1000 Genomes, gnomAD, population-specific panels	Imputation and variant annotation	Use diverse panels for improved imputation accuracy in all populations	[22]
Functional Assays	ATAC-Seq, ChIP-Seq, RNA-Seq	Functional characterization of risk loci	Perform in multiple cell types and consider population-specific effects	[1]
Bioinformatics Tools	PLINK, Hail, REGENIE	GWAS and genetic analysis	Ensure compatibility with diverse data structures and ancestry groups	[43]
Machine Learning Frameworks	TensorFlow, PyTorch, H2O.ai	Developing predictive models	Implement methods that explicitly account for population structure	[82] [83]

The translation of genetic findings into clinically useful, population-tailored diagnostics for endometriosis represents both a formidable challenge and a tremendous opportunity. The substantial genetic heterogeneity observed across diverse populations necessitates a fundamental shift from one-size-fits-all approaches to precision medicine strategies that account for population-specific genetic architecture. The development of such diagnostics requires continued investment in large-scale, diverse genomic studies, sophisticated analytical methods that can handle genetic heterogeneity, and functional validation in multiple model systems.

Future progress will depend on several key developments: (1) expanded recruitment of underrepresented populations in genetic studies to ensure equitable benefits from genomic medicine; (2) improved statistical methods and machine learning approaches that explicitly model genetic heterogeneity; (3) integration of multi-omics data to identify robust biomarker signatures that transcend individual genetic differences; and (4) development of clinical frameworks for implementing population-tailored diagnostics in diverse healthcare settings. By addressing the challenge of genetic heterogeneity head-on, researchers and clinicians can move closer to the goal of precise, personalized diagnosis and management of endometriosis for all women, regardless of their genetic ancestry.

Conclusion

The investigation of genetic heterogeneity in endometriosis GWAS across populations reveals both challenges and opportunities for precision medicine. While consistent associations in genes involved in sex steroid hormone pathways, inflammation, and developmental processes emerge across ethnicities, significant population-specific differences in allele frequencies, effect sizes, and risk loci underscore the necessity of diverse genomic representation in research. The development of clinically useful polygenic risk scores and effective therapeutic targets requires explicit consideration of this genetic diversity to avoid exacerbating health disparities. Future directions must include expanded recruitment of underrepresented populations, functional characterization of population-specific variants, integration of environmental exposures, and development of ancestry-informed diagnostic and therapeutic strategies. For researchers and drug development professionals, embracing this complexity is essential for advancing equitable, effective precision medicine approaches for endometriosis worldwide.

References

• 1. New Insights into Genetics of Endometriosis—A ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10340419/]
• 2. Genetic variants underlying risk of endometriosis [https://pmc.ncbi.nlm.nih.gov/articles/PMC4132588/]
• 3. Insights into Assessing the Genetics of Endometriosis - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3410033/]
• 4. Meta-analysis identifies five novel loci associated with ... [https://www.nature.com/articles/ncomms15539]
• 5. Genetic variants underlying risk of endometriosis: insights ... [https://db.cngb.org/data_resources/literature/24676469]
• 6. Genome-wide analyses identify 25 infertility loci and ... [https://www.nature.com/articles/s41588-025-02156-8]
• 7. Identification and Validation of Novel Combinatorial ... [https://pubmed.ncbi.nlm.nih.gov/40832379/]
• 8. Regulatory Effects of Endometriosis-Associated Genetic ... [https://www.mdpi.com/2079-9721/13/8/248]
• 9. A multi-level investigation of the genetic relationship ... [https://www.sciencedirect.com/science/article/pii/S2666379122000428]
• 10. Dissecting the shared genetic architecture between ... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1359236/full]
• 11. Endometriosis - on the intersection of modern ... [https://www.nature.com/articles/s41431-025-01977-9]
• 12. Gene expression and demographic factors associated with ... [https://mefj.springeropen.com/articles/10.1186/s43043-025-00256-3]
• 13. Multi-ancestry genome-wide association study of ... [https://pubmed.ncbi.nlm.nih.gov/40950499/]
• 14. Multi-ancestry genome-wide association study ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12424898/]
• 15. Multi-ancestry genome-wide association study of ... [https://www.medrxiv.org/content/10.1101/2025.09.03.25335012v1]
• 16. Landmark Migraine Study Identifies 778 Genetic Risk ... [https://www.emjreviews.com/neurology/news/landmark-migraine-study-identifies-778-genetic-risk-variants-in-veterans-aan-2025/]
• 17. Combined genome-wide association study of facial traits in ... [https://www.nature.com/articles/s41467-025-61761-7]
• 18. A GWAS Meta-meta-analysis and In-depth Silico ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12314298/]
• 19. Regulatory Effects of Endometriosis-Associated Genetic Variants [https://pmc.ncbi.nlm.nih.gov/articles/PMC12385710/]
• 20. Systematic review of genome-wide association studies on susceptibility to endometriosis - ScienceDirect [https://www.sciencedirect.com/science/article/pii/S0301211520306394]
• 21. Allele frequency spectrum [https://en.wikipedia.org/wiki/Allele_frequency_spectrum]
• 22. A global population genomic analysis shows novel insights into the genetic characteristics of endometriosis [https://www.spandidos-publications.com/10.3892/wasj.2023.189]
• 23. Population based allele frequencies of disease associated ... [https://bmcgenomdata.biomedcentral.com/articles/10.1186/1471-2156-11-51]
• 24. Identifying consistent allele frequency differences in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5726381/]
• 25. Meta-analysis identifies five novel loci associated with ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5458088/]
• 26. Endometriosis Is Associated with Rare Copy Number Variants [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103968]
• 27. Researchers identify a genetic cause of endometriosis [https://frontlinegenomics.com/researchers-identify-a-genetic-cause-of-endometriosis/]
• 28. Anatomic subtype-specific causal effects of endometriosis ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12350920/]
• 29. New therapeutic targets for endometriosis predicted ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12394149/]
• 30. on the intersection of modern environmental pollutants and ... [https://pubmed.ncbi.nlm.nih.gov/41266756/]
• 31. The Denisovans, Another Human Ancestor [http://new.esp.org/recommended/literature/paleo-denis/]
• 32. New Insights into Genetics of Endometriosis—A ... [https://www.mdpi.com/2075-4418/13/13/2265]
• 33. New Study Sheds Light on Endometriosis Genetics and ... [https://frontlinegenomics.com/new-study-sheds-light-on-endometriosis-genetics-and-pain-mechanisms/]
• 34. Genomes and Gynecology: Shedding Light on Endometriosis [https://www.unlockinglifescode.org/genomics-insights/genomes-and-gynecology-shedding-light-endometriosis]
• 35. Genome-wide association and epidemiological analyses ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6813337/]
• 36. Ethnic-specific genetic susceptibility loci for endometriosis ... [https://pubmed.ncbi.nlm.nih.gov/38982179/]
• 37. Tissue specific regulation of transcription in endometrium and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7048713/]
• 38. Regulation of RNA splicing in endometrial tissue and its ... [https://www.sciencedirect.com/science/article/pii/S2589004225014683]
• 39. Genetic regulation of disease risk and endometrial gene ... [https://www.nature.com/articles/s41598-018-29462-y]
• 40. Multiomic insight into the involvement of cell aging related ... [https://www.nature.com/articles/s41598-025-96711-2]
• 41. Polygenic risk score phenome-wide association study reveals ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10696845/]
• 42. Polygenic Risk Score Prediction for Endometriosis - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9580817/]
• 43. Multi-ancestry genome-wide association study of ... [https://www.medrxiv.org/content/10.1101/2025.09.03.25335012v1.full-text]
• 44. Applicability of polygenic risk scores in endometriosis clinical ... [https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-022-01788-w]
• 45. Genome-wide association and epidemiological analyses ... [https://www.nature.com/articles/s41467-019-12536-4]
• 46. Interaction between genetic risk and comorbid conditions ... [https://www.sciencedirect.com/science/article/pii/S2666247725000594]
• 47. Development and evaluation of polygenic risk scores for ... [https://www.sciencedirect.com/science/article/pii/S1098360022007869]
• 48. Molecular Mechanisms of Endometriosis Revealed Using ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10452455/]
• 49. Endometriosis-associated infertility: Multi-omics insights ... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1613334/full]
• 50. Sensitivity Analyses for Robust Causal Inference from ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5133381/]
• 51. A robust and efficient method for Mendelian randomization ... [https://www.nature.com/articles/s41467-019-14156-4]
• 52. Identification of EPHB4 as a potential causal gene and therapeutic target for endometriosis using Mendelian randomization | Hereditas | Full Text [https://hereditasjournal.biomedcentral.com/articles/10.1186/s41065-025-00457-w]
• 53. Frontiers | Identification of potential druggable targets for endometriosis through Mendelian randomization analysis [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1371498/full]
• 54. Frontiers | New therapeutic targets for endometriosis predicted through mendelian randomization analysis and case-control trials [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1631446/full]
• 55. Therapeutic targets for endometriosis: Genome-wide Mendelian randomization and colocalization analyses - PubMed [https://pubmed.ncbi.nlm.nih.gov/37931855/]
• 56. Population Stratification in Genetic Association Studies [https://pmc.ncbi.nlm.nih.gov/articles/PMC6007879/]
• 57. Comparison of mixed model based approaches for correcting ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-022-08297-y]
• 58. Strategies for the Genomic Analysis of Admixed Populations [https://pubmed.ncbi.nlm.nih.gov/37127050/]
• 59. The long road of drug development for endometriosis – Pains ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11884332/]
• 60. The long road of drug development for endometriosis [https://www.sciencedirect.com/science/article/abs/pii/S0168365924007090]
• 61. Analysis of potential protein-modifying variants in 9000 ... [https://www.nature.com/articles/s41598-017-10440-9]
• 62. Genetic variation perspective reveals potential drug targets ... [https://www.nature.com/articles/s41598-024-78689-5]
• 63. Recent advances in polygenic scores: translation, equitability ... [https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-024-01304-9]
• 64. Comparison of methods for building polygenic scores ... [https://www.sciencedirect.com/science/article/pii/S2666247724000952]
• 65. Polygenic risk score phenome-wide association study reveals ... [https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-03184-z]
• 66. Evaluation of optimal methods and ancestries for ... [https://www.nature.com/articles/s41598-023-45859-w]
• 67. A comparison of ten polygenic score methods for psychiatric ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8500913/]
• 68. Accounting for genetic effect heterogeneity in fine-mapping ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11526169/]
• 69. Genome-wide association studies [https://www.nature.com/articles/s43586-021-00056-9]
• 70. Simulating variance heterogeneity in quantitative genome ... [https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-018-2061-1]
• 71. Genetically identification of endometriosis and cancers risk ... [https://www.nature.com/articles/s41598-024-58950-7]
• 72. WHO releases new principles for ethical human genomic ... [https://www.who.int/news/item/20-11-2024-who-releases-new-principles-for-ethical-human-genomic-data-collection-and-sharing]
• 73. Framework for responsible sharing of genomic and health- ... [https://www.ga4gh.org/framework/]
• 74. International code of conduct for genomic and health-related ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4685157/]
• 75. What are genome wide association studies ( GWAS )? | GWAS Catalog [https://www.ebi.ac.uk/training/online/courses/gwas-catalogue-exploring-snp-trait-associations/what-is-gwas-catalog/what-are-genome-wide-association-studies-gwas/]
• 76. Independent Replication and Meta-Analysis for ... [https://www.cambridge.org/core/journals/twin-research-and-human-genetics/article/independent-replication-and-metaanalysis-for-endometriosis-risk-loci/A7ACBB3F28B9CABE80D45EF587F52852]
• 77. The genetic basis of endometriosis and comorbidity with ... [https://www.nature.com/articles/s41588-023-01323-z]
• 78. The phenotypic and genetic association between ... [https://pubmed.ncbi.nlm.nih.gov/40262193/]
• 79. Whole-exome sequencing and functional validation reveal ... [https://pubmed.ncbi.nlm.nih.gov/35288736/]
• 80. Robust methods for population stratification in genome wide ... [https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-14-132]
• 81. Genetic heterogeneity: Challenges, impacts, and methods ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9669229/]
• 82. Supervised Machine Learning for Population Genetics: A New ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5905713/]
• 83. Harnessing deep learning for population genetic inference [https://www.nature.com/articles/s41576-023-00636-3]